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Abstract 
 
Helicobacter hepaticus infection of A/JCr mice is a model of liver cancer resulting from 
chronic active inflammation. We monitored hepatic global gene expression profiles and 
correlated them to histological liver lesions in H. hepaticus infected and control male 
A/JCr mice at 3 months, 6 months, and 1 year of age. We used an Affymetrix-based 
oligonucleotide microarray platform on the premise that a specific genetic expression 
signature at isolated time points would be indicative of disease status. Model based 
expression index comparisons generated by dChip yielded consistent profiles of 
differential gene expression for H. hepaticus infected male mice with progressive liver 
disease versus uninfected control mice within each age group. Linear discriminant 
analysis and principal component analysis allowed segregation of mice based on 
combined age and lesion status, or age alone. Up-regulated genes present throughout the 
12 month study involved inflammation, tissue repair, and host immune function. Up-
regulation of putative tumor and proliferation markers correlated with advancing 
hepatocellular dysplasia. Transcriptionally down-regulated genes in mice with liver 
lesions included those related to peroxisome proliferator, cholesterol, and steroid 
metabolism pathways.  Transcriptional profiling of hepatic genes documented gene 
expression signatures in the livers of H. hepaticus infected male A/JCr mice with chronic 
progressive hepatitis and preneoplastic liver lesions, complemented the histopathological 
diagnosis, and suggested molecular targets for the monitoring and intervention of disease 
progression prior to the onset of hepatocellular neoplasia. 
 
Our laboratory, in collaboration with Professors Suerbaum and Schauer, recently 
identified a 70kb genomic island in Helicobacter hepaticus strain ATCC 51488 as a 
putative pathogenicity island (HhPAI) (Suerbaum et al, PNAS, 2003).  This region within 
H. hepaticus contains genes HH0233-HH0302, a differential GC content, several long 
tandem repeats but no flanking repeats, and three components of a type IV secretion 
system (T4SS).  A/JCr mice were experimentally infected with three naturally occurring 
strains of H. hepaticus including the type strain H. hepaticus ATCC 51488 strain (Hh 
3B1) isolated from A/JCr mice, MIT 96-1809 (Hh NET) isolated from mice shipped from 
the Netherlands, and MIT-96-284 (HhG) isolated from mice acquired from Germany.  
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HhNET (missing most of the HhPAI) infected male A/JCR mice exhibited a significantly 
lower prevalence (p<.05) of hepatic lesions at 6 months post infection than Hh 3B1 with 
an intact HhPAI.  Hh G also has a large segment of the genomic island deleted, but not as 
many genes are deleted as compared to Hh NET.  Hh G also demonstrated a lower 
prevalence of hepatic lesions.  This variable pathological effect was evident in male mice 
only.  The severity of chronic active inflammation in the liver of the H. hepaticus 
infected A/JCr mice depended on H. hepaticus liver colonization levels.  The in vivo 
results support the presence of the HhPAI as a legitimate virulence determinant and 
predictor of severity of liver lesions in H. hepaticus infected A/JCr male mice. 
 
To further determine the differences in virulence of the H. hepaticus strains Hh 3B1, Hh 
NET, Hh G and an isogenic mutant H. hepaticus mutant lacking genes HH0250-HH0268 
(containing two of the vir homologues of a T4SS) of the HhPAI, in vitro experiments 
were performed.  Since the macrophage participates in the immune response to H. 
hepaticus infection in the liver as demonstrated by histopathology and microarray studies, 
a murine macrophage cell line, RAW264.7, was chosen for the in vitro experiments.  
RAW264.7 murine macrophage cell cultures were infected with three wild type strains 
(Hh3B1, HhG, HhNET) and a mutant strain (HhBac26) of H. hepaticus at a multiplicity 
of infection (MOI) of 0.1 for 24 hours.  Cytokine Cxcl4, Cxcl10, Cxcl1, Cxcl2, Ccl2, 
Ccl3, and Tnf expression levels were monitored by real time PCR.  These in vitro 
experiments demonstrated statistical significance (p<.05) of H. hepaticus strain 
differences (i.e. higher levels in Hh3B1 versus HhNET and HhBac26) compared to 
controls in the Cxcl2, Ccl2, Ccl3, and Tnf cytokine responses of a murine macrophage 
cell line, RAW 264.7.  These in vitro results generated additional evidence of virulence 
differences in H. hepaticus strains based on the pathogenicity island, HhPAI.  In 
conclusion, these studies provided further insight into the host-pathogen interaction of 
infectious liver cancer by identifying genes in both the murine host and the pathogenicity 
island in H. hepaticus, as well as the importance of macrophages in eliciting and profiling 
the hosts tissue responses that participate in chronic active inflammation-associated 
preneoplasia which ultimately progresses to hepatocellular carcinoma. 
 
 
Thesis Supervisor: James G. Fox 
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           Director, Division of Comparative Medicine 
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Helicobacter species 
 
History of Helicobacter species 
 
In 1982, gastroscopic antral biopsies revealed curved, gram negative, flagellate bacilli in 
patients with chronic gastritis, gastric ulceration, and duodenal ulceration (Marshall and 
Warren 1984).  Marshall and Warren identified the bacterium as a Campylobacter sp., a 
member of a genus noted for strains that cause enterocolitis and diarrhea in humans and 
animals.  The bacterium was initially named Campylobacter pyloridis but the 
nomenclature was later revised to Campylobacter pylori (Marshall and Goodwin 1987).  
Campylobacter pylori experimental infections satisfied Koch’s postulates when two 
human volunteers, with histologically normal gastric mucosa, were orally inoculated with 
the new bacterial species and exhibited gastritis within days (Marshall et al. 1985; Morris 
and Nicholson 1987).  Due to ultrastructural differences including sheathed flagella and 
16S rRNA sequence differences between this new species and existing Campylobacter 
spp. (Romaniuk et al. 1987), a new genus was formally created and Campylobacter 
pylori was renamed Helicobacter pylori in 1989 (Goodwin et al. 1989).   
 
The Helicobacter genus is expanding as different anatomical niches within numerous 
vertebrate hosts yield novel species.  There are 26 Helicobacter species at the date of this 
writing, with more proceeding through formal taxonomic classification (Fox and Lee 
1997; Whary and Fox 2004a).  Helicobacter spp. colonize the stomach, liver, cecum, 
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colon, and gall bladder in various animals species, and can be grouped as either gastric or 
enterohepatic.   
 
Gastric Helicobacter species 
Spiral-shaped bacteria occupying the gastrointestinal tract have been observed for over a 
century.  Gastric spiral-shaped bacteria were reported in animals by Rappin (1881), 
Bizzozero (1893), and Salomon (1898) and their association with gastric carcinoma by 
Krienitz (1906) and Celler and Thalheimer (1916) (Fox 1995; Fox and Lee 1989; 
Versalovic and Fox 2003).  In 1939, JL Doenges observed gastric spiral bacteria in 43% 
of 243 human samples and 100% of 43 rhesus macaque samples (Fox and Lee 1989).  
Ultrastructural studies in the 1970’s of duodenal ulceration and gastric metaplasia 
revealed spiral bacteria (Steer 1975, 1984).  The successful isolation of the gastric spiral 
bacteria from human patients with gastritis initiated intensive research into an infectious 
cause of gastric and duodenal disease (Marshall and Warren 1984).  Electron microscopy 
revealed various morphologies of the gastric spiral bacteria in humans and animals 
including the distribution of periplasmic fibrils, and the location, number, and sheathing 
of flagella (Fox and Lee 1989; Lockard and Boler 1970).  As mentioned earlier, the 
ultrastructure and 16S rRNA sequence differentiated the gastric spiral bacteria from 
Campylobacter, thus justifying the establishment of the Helicobacter genus (Goodwin et 
al, 1989).    
 
H. pylori usually colonizes people for life within the mucus layer of the gastric mucosa.  
The infection is often acquired in childhood and may be transient in childhood.  
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However, once the infection is re-established, the organism usually persists for life.  H. 
pylori demonstrates gastric tissue tropism and a narrow host range.  Natural H. pylori 
infection and gastritis also occurs in rhesus monkeys (Handt et al. 1997; Newell et al. 
1987; Suerbaum et al. 2002) and the domestic cat (Fox et al. 1995a).  The first successful 
experimental infections of H. pylori were established in neonatal gnotobiotic piglets 
(Krakowka et al. 1987) but the inflammatory infiltrate was distinctly different between 
humans and piglets (Bertram et al. 1991).  Subsequently, H. pylori also successfully 
colonized and produced gastritis in macaques (Fujioka et al. 1994; Shuto et al. 1993).  
Unfortunately, H. pylori would not colonize mice and other laboratory animals in early 
experimental infections despite numerous attempts.  Experimental infections of BALB/c 
nude and BALB/c euthymic mice with freshly isolated H. pylori strains from human 
patients colonized the gastric mucosa of the mice for 20 weeks and 2 weeks, respectively. 
However, the established H. pylori strain did not colonize these BALB/c nude and 
BALB/c euthymic mice (Karita et al. 1991).  The same group colonized athymic germ-
free mice with H. pylori (Karita et al. 1994).  A standardized mouse model of H. pylori 
infection, the Sydney strain SS1, was not attained until the late 1990’s (Lee et al. 1997; 
Marchetti et al. 1995).  A second H. pylori strain, B128, induces pangastritis, ulcerations, 
and gastric atrophy in the Mongolian gerbil and gastric adenocarcinoma in the INS-GAS 
mouse model (Fox et al. 2003b; Wang et al. 2000).  Recently, a third mouse-adapted 
strain of H. pylori was isolated and characterized, allowing comparative studies of both 
H. pylori strains and their effect on various rodent host strains (Thompson et al. 2004).  
In addition to H. pylori, another gastric Helicobacter sp. identified from humans in a 
small percentage of gastritis cases is  “H. heilmannii”.  H. heilmannii, although not yet 
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formally classified because it has been cultured only once, is more prevalent in animals.  
A homogenized human gastric biopsy infected with H.heilmannii was used as a inoculum 
and the organism colonized mice (Dick et al. 1989).    H. heilmannii has also been 
associated with human duodenal ulceration, gastric carcinoma, and gastric B-cell 
mucosa-associated lymphoid tissue (MALT) lymphoma (Heilmann and Borchard 1991; 
O'Rourke et al. 2004).   
 
H. mustelae in the ferret was the second gastric Helicobacter species to be isolated and 
characterized (Fox et al. 1988).  The ferret became the first natural infection animal 
model of Helicobacter-induced gastritis (Fox et al. 1990).  H. felis, isolated from the 
gastric mucosa of a cat, is another natural gastric Helicobacter species (Paster et al. 
1991).  H. felis exhibits a wider host range, with experimental infection colonizing many 
other animals, including the gnotobiotic rat (Fox et al. 1991), the mouse (Chen et al. 
1992; Lee et al. 1990), and the beagle dog (Lee et al. 1992a).   
 
Enterohepatic Helicobacter species 
 
Cecal and colonic colonization 
 
Historically, culturing the spiral shaped bacteria in the gastrointestinal tracts of animals 
was problematic.  Morphologically distinct spiral bacteria colonizing the mucus layer of 
the colon of a rat were first cultured in 1978 (Lee and Phillips 1978).  Later, these gram 
negative spiral bacteria were isolated from the ileum, cecum, and colon of mice and rats 
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and were cultured on Campylobacter medium in a microaerobic environment (Phillips 
and Lee 1983).  The bacterial morphology did not correspond to any known genus at the 
time, and this spiral bacterium with “9 to 11 helically coiled periplasmic fibers and 
bipolar tufts of flagellum-like appendages” would eventually be designated as belonging 
to a Helicobacter sp. and was subsequently named H. muridarum (Lee et al. 1992b; 
Phillips and Lee 1983).   
 
The first human enterohepatic Helicobacters, H. cinaedi and H. fennelliae, formerly 
classified as a Campylobacter spp., were first isolated from homosexual men with 
proctitis, protocolitis, and/or enteritis (Totten et al. 1985) and later from patients with 
Human Immunodeficiency Virus (HIV) exhibiting multifocal cellulitis and arthritis 
(Burman et al. 1995; Kiehlbauch et al. 1994).  H. cineadi has also been isolated from the 
feces and blood of clinically normal female adults and children (Vandamme et al. 1990) 
and the cerebrospinal fluid and blood of a neonate with meningitis and septicemia 
(Orlicek et al. 1993).  Molecular evidence of gastric colonization of H. cinaedi has been 
reported once (Pena et al. 2002).  Experimental infection of infant pig-tailed macaques 
(Macaca nemestrina) with H. cinaedi and H. fennelliae produced acute diarrhea and 
bacteremia, and gastrointestinal infection (Flores et al. 1990).  H. cinaedi has been 
isolated from other animal reservoirs (Kiehlbauch et al. 1994; Vandamme et al. 2000) 
including hamsters, presumed to be enzootically infected (Gebhart et al. 1989), and 
captive rhesus macaques with chronic hepatitis and colitis (Fox et al. 2001a; Fox et al. 
2001b).   
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Other enteroheptic Helicobacter spp. include H. canis, H. pullorum, H. marmotae, and H. 
canadensis. H. canis was isolated from healthy and diarrheic dogs and from humans with 
a history of gastroenteritis (Stanley et al. 1993).  H. canis has also been associated with 
hepatitis in a dog (Fox et al. 1996a) and colitis in Bengal cats (Foley et al. 1999).  The 
avian enterohepatic species, H. pullorum, has been cultured from chickens with and 
without gastrointestinal lesions, including hepatitis, and has been associated with human 
gastroenteritis (Burnens et al. 1994; Stanley et al. 1994).  H. canadensis was isolated 
from diarrheic humans (Fox et al. 2000b) and subsequently was isolated from geese in 
Europe (Waldenstrom et al. 2003).   
 
Hepatic colonization 
 
In 1992, the first enterohepatic Helicobacter sp. colonizing liver was discovered in the 
liver and cecal scrapings of of untreated control A/JCr mice s in a long term toxicology 
study at the National Cancer Institute (Fox et al. 1994; Ward et al. 1994).  The A/JCr 
mice with chronic, active hepatatis exhibited a high incidence of hepatic tumors.  This 
new species, Helicobacter hepaticus, was spiral-shaped and exhibited bipolar single 
sheathed flagella.  Helicobacter hepaticus is now associated with chronic hepatitis and 
hepatocellular carcinoma (HCC) in A/JCr and other susceptible mouse strains, including 
BALB/CAnNCr, SJL/NCr, C3H/HeNCr, SCID/NCr, AxB recombinant inbred mice, 
B6C3F1 mice, and B6AF1 mice (Fox et al. 1996b; Fox et al. 1996d; Garcia et al. 2004; 
Hailey et al. 1998; Ihrig et al. 1999).  H. hepaticus has since been isolated from mice 
housed in many other academic and commercial mouse colonies, and continues to be a 
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risk factor for compromising experimental enteric studies (Shames et al. 1995; Taylor et 
al. 2004). 
 
Eventually, more murine enterohepatic species were isolated, including ‘Flexispira 
rappini’ (now recognized as a Helicobacter sp. but not formally named) (Dewhirst et al. 
2000; Schauer et al. 1993), Helicobacter bilis in 1995 (Fox et al. 1995b), Helicobacter 
rodentium in 1997 (Shen et al. 1997), H. ganmani (Robertson et al. 2001), H. typhlonius 
(Franklin et al. 2001) as well as rat enterohepatic species, H. trogontum (Mendes et al. 
1996).  H. rodentium, however, appears to be part of the normal murine microbiota and is 
sometimes found in Helicobacter spp. co-infections of mouse colonies (Shen et al. 1997; 
Shomer et al. 1998).  H. bilis was found to colonize the liver, bile, and intestines of aged 
mice and is pathogenic in some murine strains (Fox et al. 2004b; Fox et al. 1995b; 
Shomer et al. 1998; Whary and Fox 2004a).  H. bilis colonizes several other laboratory 
animals, including a mouse, dog, rat, and gerbil, (Ge et al. 2001) and has been associated 
with biliary disease and biliary tract cancer in humans (Fox et al. 1998; Matsukura et al. 
2002; Murata et al. 2004).  Other Helicobacter spp. isolated from the liver of animals 
include H. marmotae from the woodchuck (Fox et al. 2002), H. cinaedi from rhesus 
macaques, and H. canis from dogs (Fox et al. 1996a; Fox et al. 2001a; Fox et al. 2001b).   
 
Infection, inflammation and cancer 
 
The link between inflammation and cancer has been recognized for some time, as has the 
relationship between infectious agents and cancer (Balkwill and Coussens 2004; Balkwill 
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and Mantovani 2001; Clevers 2004; Coussens and Werb 2002; Shacter and Weitzman 
2002; van Kempen et al. 2003).  Persistent infection initiates an estimated 15%-20% of 
cancer cases worldwide, amounting to 1.2 million cases per year (Kuper et al. 2000; 
Pisani et al. 1999).  H. pylori, Hepatitis B virus, Hepatitis C virus, Epstein-Barr virus, the 
liver fluke (Opisthorchis viverrini), human immunodeficiency virus, human herpes virus 
type 8, human papilloma virus, and Schistosoma spp.are some of the infectious agents 
associated with cancer (Coussens and Werb 2002; Giordano et al. 2004; Stewart et al. 
2003).   
 
Chronic inflammation results in persistent tissue injury and possible DNA damage due to 
reactive oxygen and nitrogen species from inflammatory cells (Dedon and Tannenbaum 
2004).  Continual cell proliferation in this inflammtory microenvironment increases the 
risk of neoplasia due to the possibility of DNA damage and tumor initiation.  The 
inflammatory mileu consists of cytokines, chemokines, and growth factors that are an 
integral part of tissue regeneration.  Thus, infectious agents not eliminated by the host 
produces a continual innate and acquired immune responses and chronic, active 
inflammation, thus establishing a putative causal link to cancer due to the promotion and 
progression of initiated cells (Coussens and Werb 2002). 
 
Helicobacter sp. infection causes chronic, active inflammation of varying severity in 
susceptible hosts.  Helicobacter spp. may cause chronic active gastritis, colitis, hepatitis, 
and cholecystitis.  The location of the infection and severity of the disease depends on the 
genetics of the host and the bacteria.  The inflammatory response is cell mediated and is 
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predominantly a Th1 phenotype.  Proinflammatory cytokines interferon gamma (IFN-γ), 
interleukin 2 (IL-2) and tumor necrosis factor beta (TNFβ) are secreted, and activation of 
macrophages and other phagocytes observed. (Hauer et al. 1997; Mohammadi et al. 
1996; Mohammadi et al. 1997; Whary et al. 1998).  Anti-inflammatory Th2 responses 
presumably areinhibited unless there is co-colonization with a pathogen that induces a 
Th2 response (Fox et al. 2000a; Whary and Fox 2004b) 
 
Persistent infection causes a large percentage of cancer cases, nearly 1 in 5.  H. pylori is 
the infectious agent responsible for the highest cancer mortality.  Estimates of the 
percentage of all cancer cases caused by H. pylori are just under 6% (Kuper et al. 2000; 
Parsonnet 1999; Pisani et al. 1999).  Therefore, a large number of gastric cancer cases 
can be avoided by the prevention of this infectious disease.  Recent studies report the 
association of Helicobacter spp. with cancer of other segments of the gastrointestinal 
tract, including the liver and the gall bladder.  We propose the paradigm of H. pylori and 
gastric cancer may extend to persisent enterohepatic Helicobacter spp. infection in other 
gastrointestinal organs. 
 
Helicobacter pylori 
 
Overview 
 
It is estimated that H. pylori infects around 50% of the world’s population.  H. pylori 
persistently colonizes the gastric mucosa, a unique niche for bacterial colonization.  The 
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gastric niche, as opposed to the enterohepatic niche, contains few bacterial species due to 
the pH of the environment.  A series of prospective case-control studies using stored 
serum from well-characterized populations yielded epidemiological evidence established 
a link between H. pylori infection and gastric cancer (Aromaa et al. 1996; Forman et al. 
1991; Ley and Parsonnet 2000; Lin et al. 1995; Nomura et al. 1991; Parsonnet et al. 
1991; Siman et al. 1997; Watanabe et al. 1997; Webb et al. 1996).   
 
Gastric cancer is the second leading cause of cancer-related mortality (Mathers et al. 
2002; Shibuya et al. 2002).  H. pylori is listed as a group I (definite) carcinogen by the 
World Health Organization due to its association with gastric adenocarcinoma.  The 
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER, 
http://seer.cancer.gov/) report of Estimated New Cancer Cases and Deaths for 2004 
approximates the number of deaths in the United States for the year 2004 from cancers of 
the digestive system to reach approximately 135,000 people, and the number of new 
digestive system cancers to approach 256,000 people.  In the year 2000, 7 million deaths 
was the estimated total mortality worldwide, and 13% of these deaths were cancer 
related.  Ten million new cancer cases were diagnosed (Mathers et al. 2002; Shibuya et 
al. 2002). In the year 2002, it is estimated 445,000 male and 254,000 female deaths per 
year worldwide due to gastric cancer (GLOBOCAN, 2002, Tables by cancer, 
http://www-depdb.iarc.fr/globocan/GLOBOframe.htm).  Gastric cancer is ranked second 
only to lung cancer (lung cancer deaths per year: 848,000 males, 330,000 females) as the 
leading cause of cancer mortality in the world.  Liver cancer accounts for 417,000 male 
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and 181,000 female deaths per year worldwide, and is the third leading cause of cancer 
mortality.   
 
The clinical outcome for the majority of H. pylori infected people is a mild gastritis.  
However, H. pylori is a risk factor for duodenal ulcers and gastric cancer, yet only a 
small percentage of those infected develop disease.  The reason for these disparate 
outcomes is unknown.  Antral-predominant gastritis increases the risk of hyperchloridia 
and duodenal ulcers.  Corpus predominant gastritis increases the risk of gastric atrophy, 
hypochloridia, and gastric cancer.  Experimental evidence suggests both host genetics, 
and bacterial genetics contribute to the development of lesions.  Human interleukin-1 (IL-
1), interleukin 1 receptor 1 (IL1-R1), interleukin 1 receptor antagonist (IL1-RN*2), and 
interleukin 8 (IL-8) polymorphisms correlate with the differences in host response (El-
Omar et al. 2000; Gyulai et al. 2004; Hartland et al. 2004; Hsu et al. 2004).  H. pylori 
strains possessing putative virulence factors are also associated with increased gastric 
cancer risk (Azuma et al. 2004; Blaser et al. 1995a; Blaser et al. 1995b; Covacci et al. 
1999; Parsonnet et al. 1997).    
 
H. pylori genome 
 
The extensive genetic diversity of H. pylori has been known for some time (Langenberg 
et al. 1986).  The genome of H. pylori is 1.6 Mb (Alm et al. 1999; Tomb et al. 1997).  
Genomic analysis suggests that specific DNA mismatch repair systems are not present in 
this species, suggesting that mutation may be responsible for the highly variable genome 
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of H. pylori (Alm et al. 1999; Alm and Trust 1999; Tomb et al. 1997).  Further, strain-
specific restriction and modification systems (R-M) comprise a significant percentage of 
H. pylori strain specific genes, contributing to the variability (Alm et al. 1999; Alm and 
Trust 1999; Tomb et al. 1997).  Suerbaum and Achtman state “the nucleotide sequence 
diversity of H. pylori exceeds that of many bacterial species” and that “almost every 
nucleotide sequence from unrelated isolates is unique, an unprecedented situation” 
(Achtman and Suerbaum 2000).  Thus, many studies propose a non-clonal population 
structure of H. pylori with frequent recombination (Achtman and Suerbaum 2000; Falush 
et al. 2001; Falush et al. 2003; Salaun et al. 1998; Suerbaum and Achtman 1999; 
Suerbaum et al. 1998).  Consequently, H. pylori virulence factors containing specific 
nucleotide sequences could explain the small percentage of the infected population 
developing disease from a bacterial genetics standpoint.   
 
Virulence factors 
 
Pathogenicity islands 
 
Evolution has given bacterial pathogens various mechanisms to survive against the host's 
immune system and commensal competition.  For example, strains of E. coli (Holden and 
Gally 2004; Kaper et al. 2004; Karmali 2004; Landraud et al. 2004), Legionella 
spp.(Bitar et al. 2004; Heuner and Steinert 2003), Brucella spp. (Delrue et al. 2004) 
invade host epithelial cells, Salmonella spp (Waterman and Holden 2003)and Yersinia 
spp.(Carniel 2001) target the antigen presenting M cells in the gastrointestinal tract, while 
 28
H. pylori remains extracellular, residing in the mucous layer coating the gastric 
epithelium and possessing a secretion system enabling protein injection into epithelial 
cells.  One aspect of pathogenicity common across many bacterial species is a 
pathogenicity island (PAI).  The term “pathogenicity island” was coined to denote a 
genomic island or a cluster of genes in close physical proximity on the bacterial 
chromosome correlated to virulence (Blum et al. 1995; Hacker et al. 1990).  It often 
includes a group of genes transferred from other species contributing to a different GC 
content than the rest of the genome.  The GC content of the PAI suggests the age of the 
island, implying increased similarity in GC content over time.  Other common attributes 
of a PAI are the lack of stability, the site of integration being near tRNA genes, and direct 
repeats at the flanking sequences. 
 
Type III and Type IV secretion systems 
 
Several species of bacteria export virulence factors into host cells using Type III (T3SS) 
or Type IV secretion systems (T4SS).  Bacteria possessing the T3SS include Salmonella 
spp., E. coli, Yersinia spp., and Shigella spp.  T3SS probably evolved from flagellar 
secretion systems.  Bacteria utilizing T4SS include Agrobacterium tumefasciens, 
Brucella spp., Wolbachia spp., Campylobacter jejeuni, Bordetella pertussis, and 
Helicobacter pylori with probable common ancestral functions of conjugation systems 
for transferring nucleoprotein complexes (Batchelor et al. 2004; Boschiroli et al. 2002; 
Celli and Gorvel 2004; Cheung et al. 2004; Christie 2001; den Hartigh et al. 2004; 
Hoppner et al. 2004; Larsen et al. 2004; Masui et al. 2000; McGraw and O'Neill 2004; 
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Poly et al. 2004; Rambow-Larsen and Weiss 2004).  Both types of secretion systems 
stabilize effector molecules via chaperones and utilize ATP-hydrolysis as a transport 
energy source.  H. pylori possesses two functional independent T4SS, cag and comB.  
The cag system involves protein translocation while the comB promotes uptake of DNA 
by natural transformation.   
 
Cag pathogenicity island of H. pylori 
 
The H. pylori PAI was named “cag” as an abbreviation for the cytotoxin associated gene 
(Sharma et al. 1995).  The PAI is 40kb, has 31 open reading frames, and is flanked by 
repeats.  Insertion element(s) are variably located on the ends or within the island.  (Alm 
et al. 1999; Alm and Trust 1999; Blomstergren et al. 2004; Tomb et al. 1997).  An 
important component of the PAI is the CagA protein, also variable in size due to the 
number of repeats.  Most H. pylori strains can be classified into two major types.  Type I 
strains possess the gene for CagA and express both the CagA protein and the vacuolating 
cytotoxin (see below).  Type II H. pylori strains do not possess cagA and do not express 
either the CagA protein or the vacuolating cytotoxin.  The H. pylori T4SS inserts CagA 
into AGS gastric epithelial cells producing a morphological transformation termed the 
“hummingbird” phenotype.  A model of H. pylori pathogenesis is depicted in Figure 1 
(Suerbaum and Michetti 2002).  CagA is tyrosine phosphorylated within the epithelium 
and deregulates the SHP2 oncoprotein (Higashi et al. 2002a; Higashi et al. 2002b; 
Higuchi et al. 2004).  CagA exhibits high sequence variability within H. pylori,  
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Figure 1 (Suerbaum and Michetti, 2002; with permission) 
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Figure 1  Pathogen-Host Interactions in the Pathogenesis of Helicobacter pylori 
Infection. 
 
The host response to H. pylori participates in the induction of damage to the gastric 
epithelium and therefore has an integral role in H. pylori pathogenesis.  During the early 
phase of the infection, binding of H. pylori to gastric epithelial cells, in particular through 
BabA and by strains harboring the cag pathogenicity island, results in the production of 
interleukin 8 and other chemokines, such as epithelial-cell-derived neutrophil-activating 
peptide 78 (ENA-78) and growth-related oncogene a (GRO-α), by epithelial cells.  
Nuclear factor-κB (NF-κB) and the erly-response transcription-factor activator protein 1 
(AP-1) are the intracellular messengers involved in this process.  The chemokines 
secreted by epithelial cells bind to the proteoglycan scaffolding, generating a gradient 
along which polymorphonuclear cells (PMN) are recruited.  The chronic phase of H. 
pylori gastritis associates an adaptive lymphocyte response with the initial innate 
response.  Lymphocyte recruitment is facilitated by chemokine mediated expression of 
vascular addressins such as vascular-cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule (ICAM-1) that are required for lymphocyte extravasation.  
Macrophages that participate in interleukin-8 production produce proinflammatory 
cytokines involved in the activation of the recruited cells, in particular T helper cells 
(Th0, Th1, Th2) that respond with a biased TH1 response to H. pylori.  In turn, Th1-type 
cytokines such as interferon-γ (INF-γ) induce the expression of class II major 
histocompatibility complexes (MHC) and accessory molecules B7-1 and B7-2 by 
epithelial cells, making them competent for antigen presentation.  The cytotoxin VacA 
and Fas-mediated apoptosis induced by tumor necrosis factor α leads to disruption of the 
epithelial barrier, facilitating translocation of bacterial antigens and leading to futher 
activation of macrophages.  Cytokines produced by macrophages can also alter the 
secretion of mucus, contributing to H. pylori-mediated disruption of the mucous layer.  
Cytokines produced in the gastric mucosa induce changes in gastric acid secretion and 
homeostasis (dashed lines).  TNF-α, interleukin 1β, and interferon γ increase gastrin 
release, stimulating parietal and enterochromaffin cells and thus acid secretion.  TNF-α 
also induces a decrease in the number of antral D cells, leading to decreased somatostatin 
production and indirectly enhancing acid production.  LPS denotes lipopolysaccharide. 
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particularly at the SHP2-binding site.  This again suggests nucleotide differences affect 
the carcinogenic potential of different strains of H. pylori (Azuma 2004; Hatakeyama 
2004; Higashi et al. 2004; Higuchi et al. 2004). 
 
Vacuolating cytotoxin 
 
The vacuolating cytotoxin of H. pylori induces vacuolation of eukaryotic cells in vitro 
and produces a serum immune response in patients, suggesting in vivo synthesis (Cover 
and Blaser 1992; Cover et al. 1992a; Cover et al. 1992b).  Recent work demonstrates 
variable toxicity, depending on sequence of the vacuolating cytotoxin, affecting apoptosis 
in epithelial cells. Other vacuolating cytotoxin capabilities include modulating the 
immune response via affecting the cytokine response of T cells, activation and 
proliferation of T cells, and antigen presentation of B cells (Aviles-Jimenez et al. 2004; 
Fischer et al. 2004; Gebert et al. 2004; Sundrud et al. 2004; Yahiro et al. 2004). 
 
H. pylori colonization factors 
 
H. pylori, with one of the smallest genomes of an extracellular, free-living bacteria, 
possesses the remarkable ability to colonize some hosts indefinitely.  The colonization 
factors allow gastic adherence and nutrient acquisition (Eppinger et al. 2004).  H. pylori 
colonization factor genes include alpA, alpB(de Jonge et al. 2004a), babA (Aspholm-
Hurtig et al. 2004; Hennig et al. 2004), sabA (de Jonge et al. 2004b; Lehours et al. 2004), 
hopZ (Lehours et al. 2004; Yamaoka et al. 2004), hpaA, omp18 (Voland et al. 2003a), 
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Nap (Nishioka et al. 2003), Hsp60, Hsp70, and genes encoding LPS, LPS core, LPS O 
antigen (Testerman et al, 2001).   
 
Urease, a gene expressed in H. pylori, consists of two subunits, UreA and UreB.  Urease 
protects H. pylori from gastic acid by the catalysis of urea to ammonium and carbon 
dioxide (Benoit and Maier 2003; Eaton et al. 1991; Hartmann and von Graevenitz 1987; 
Mobley et al. 1991; Sidebotham and Baron 1990; Voland et al. 2003b).  Urease isogenic 
mutants of H. pylori do not colonize mice nor gnotobiotic piglets (Eaton et al. 1991; 
Karita et al. 1995; Tsuda et al. 1994a; Tsuda et al. 1994b).   
 
Another colonization factor related to motility within the mucous layer of the gastric 
mucosa is the 2 to 6 unipolar sheathed flagella of H. pylori.  The flagellar system is 
complex, consist of over 40 genes that are expressed in a defined sequence for flagella 
construction (Niehus et al. 2004).  H. pylori isogenic mutants of flagellin genes flaA 
and/or flaB have reduced motility, or are non-motile, and exhibit reduced colonization or 
no colonization in gnotobiotic piglets and gerbils (Eaton et al. 1996; McGee et al. 2002; 
Niehus et al. 2004; Schmitz et al. 1997) 
 
Rodent models of gastric cancer 
 
Two rodent models of H. pylori-induced gastric cancer include H. pylori infection of the 
Mongolian gerbil and the INS-GAS FVB mouse.  H. felis infection of the C57BL/6 
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Rogers and Fox, 2004, with permission 
 
MALT, mucosal-associated lymphoid tissue; PAI, pathogenicity-associated islands; 
HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma. 
*Male predominant. 
  
Table 1. Summary of key rodent models of infectious gastrointestinal 
and liver cancer  
 
Rodent 
Infectious 
Agent/Transgene Tumor Comment 
C57BL mice H. felis Gastric 
adenocarcinoma 
Natural gastric pathogen, but lacks 
cag and vacA 
INS-GAS FVB mice* H. felis and  
H. pylori 
Gastric 
adenocarcinoma 
Constitutive hypergastrinemia 
promotes tumorigenesis 
Mongolian gerbil H. pylori Gastric 
adenocarcinoma 
Closely mimics human disease, 
but long time course and few 
reagents 
BALB/c mice Several 
Helicobacter spp. 
Gastric MALT 
lymphoma 
Usually requires 18—24 mo 
Genetically engineered mice: IL-10-, 
IL-2-, Gi2-, Muc2-, etc.-deficient; 
especially on 129Sv background 
"Endogenous 
microbiota" or H. 
hepaticus 
Lower bowel 
carcinoma 
Bacteria in endogenous microbiota 
models not well defined; H. 
hepaticus reliably induces disease
Lymphocyte-deficient mice: SCID or 
Rag-/-; especially on 129Sv 
background 
"Endogenous 
microbiota" or H. 
hepaticus 
Lower bowel 
carcinoma 
Often used for adoptive transfer 
studies; H. hepaticus induces 
tumors in untreated Rag2-/- mice 
Transgenic mice* HBV or HCV 
transgene(s) 
Hepatocellular 
carcinoma 
Prove tumorigenic potential of viral 
gene products; adoptive transfer or 
inducible gene strategies required 
for hepatitis 
A/JCr and other mice* H. hepaticus Hepatocellular 
carcinoma 
Natural murine pathogen induces 
chronic active hepatitis and HCC 
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mouse and the INS-GAS mouse also induces gastric cancer but H. felis lacks the cag PAI 
and vacA. (Fox 1998; Rogers and Fox 2004; Wang et al. 2000) (Table 1).  The 
Mongolian gerbil model mimics H. pylori pathogenesis in the human, but gastric 
adenocarcinoma develops only after a long period of time, i.e. greater than 15 months.  
The Mongolian gerbil model produces gastric ulcers prior to gastric atrophy and intestinal 
metaplasia (Bergin et al. 2003; Court et al. 2002; Wang and Fox 1998; Watanabe et al. 
1998; Yang et al. 2003).  The ING-GAS mouse exhibits constitutive hypergastrinemia, 
and combined with H. pylori or H. felis infection, promotes gastric cancer in less than 8 
months (Fox et al. 2003a; Wang et al. 2000).  As previously mentioned, the anatomical 
location of H. pylori induced gastritis is associated with two distinct clinical outcomes.  
The antral predominant gastritis promotes decreased somatostatin release from the D 
cells and increased gastrin release from the G cells, resulting in hypergastrinemia and 
increasing enterochromaffin-like cell histamine release (Blaser and Atherton 2004).  
Gastrin is a growth factor for H. pylori (Chowers et al. 2002).  The gastrin and histamine 
co-stimulate parietal cell acid production and increased parietal cell proliferation, thus 
decreasing gastric pH.  The increased acidity promotes duodenal ulceration, gastric 
metaplasia, and gastro-esophageal reflux disease.  Pangastritis also promotes 
hypergastrinemia, but inflammation inhibits enterochromaffin-like and parietal cell 
output.  The inhibition increases pH and hypochlorhydria persists, a risk factor for gastric 
ulcer, and gastric adenocarcinoma.  H. pylori associated gastric atrophy, intestinal 
metaplasia, and increased colonization of diverse enteric bacterial species due to 
increased gastric pH are also risk factors of gastric cancer (Blaser and Atherton 2004). 
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The signaling pathways contributing to gastric cancer likely include gastrin and 
incompletely processed gastrin, due to the growth factor’s trophic capabilities and 
involvement in other forms of cancer (Koh et al. 2004).  Gastrin is a downstream target 
of the Wnt/wingless pathway and a promoter of gastrointestinal cancer.  In the mouse, 
TGFβ/Smads and β-catenin/T-cell factors regulate the gastrin promoter (Lei et al. 2004).  
Other pathways affected include MAPK signaling and NF-κB signaling (Higashi et al. 
2004; Maeda et al. 2002; Sebkova et al. 2004; Yanai et al. 2003).  
 
Human gastric B-cell mucosa associated lymphoid tissue (MALT) lymphoma has been 
associated with H. pylori infection (Stolte 1992).  As previously mentioned, H. 
heilmannii has only been reported in a small number of human cases, but is associated 
with gastritis, peptic ulcers, gastric adenomcarcinoma, and MALT lymphoma.  H. 
heilmannii has a broader host range than H. pylori.  Experimental H. heilmannii and H. 
felis infections of BALB/c mice are animal models of MALT lymphoma (Enno et al. 
1995; Mueller et al. 2003; O'Rourke et al. 2004).  Temporal laser dissection of the 
lymphoid nodules and microarray profiling of the tissue has yielded insight into the 
stages of the molecular pathogenesis of MALT.  The microarry analysis revealed 
increased expression of genes previously associated with malignancy like laminin 
receptor 1 and multi-drug resistance channel 1 (Mueller et al. 2003). 
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Helicobacter hepaticus 
 
Overview 
 
H. hepaticus was initially discovered and isolated from control A/JCr mice in a long term 
toxicology study.  The control mice exhibited chronic hepatitis and there was a high 
inidence of hepatocellular carcinoma (HCC).  Mouse strains A/JCr, BALB/CAnNCr, 
SJL/NCr, C3H/HeNCr, SCID/NCr, AxB recombinant inbred mice, B6C3F1 mice, and 
B6AF1 mice exhibit susceptibility to H. hepaticus induced hepatitis (Fox et al. 1996b; 
Fox et al. 1996d; Hailey et al. 1998; Ihrig et al. 1999).  Many rodent models of 
gastrointestinal disease utilize H. hepaticus (Table 1, Rogers and Fox, 2004).  H. 
hepaticus causes chronic hepatitis and HCC in A/JCr mice (Fox et al. 1994; Fox et al. 
1996b; Ward et al. 1994).   A/JCr mice develop necrogranulomatous lobular and/or 
lymphocytic portal hepatitis.  Male A/JCr mice are more susceptible to hepatitis and 
tumors than females.  For reasons that are not clear, only a subset of H. hepaticus 
infected male mice are exhibit hepatitis (Boutin et al. 2004; Fox et al. 1996b; Rogers et 
al. 2004).  Many rodent studies, including long term carcinogenesis bioassays, have been 
confounded due to this murine pathogen (Fox et al. 1994; Hailey et al. 1998; Ward et al. 
1994; Whary and Fox 2004a).   
 
H. hepaticus also induces typhlocolitis in immunodeficient strains including athymic 
NCr-nu/nu, BALB/c, AnNCr-nu/nu, C57BL/6NCr-nu/nu, and  C.B17/Icr-scid/NCr 
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(Ward et al. 1996) and other mutant strains (Chin et al. 2000; Foltz et al. 1998; Kullberg 
et al. 2002; Kullberg et al. 2001; Kullberg et al. 1998; Li et al. 1998; Myles et al. 2003).  
Early experimental infections of Helicobacter free interleukin 10 deficient (IL-10-/-) mice 
with H. hepaticus produced typhlocolitis through an IL-12 and interferon gamma (IFNγ) 
dependent mechanism (Kullberg et al. 1998).  A novel urease negative Helicobacter 
species was also found to induce typhlocolitis in an IL-10-/- (Fox et al. 1999) and was 
subsequently named H. typhlonius (Franklin et al. 2001).  Another novel urease negative 
Helicobacter species induced typhlocolitis and cholangiohepatitis in A/JCr and 
Tac:Icr:Ha(ICR)-scidfRF mice and is associated with the formation of chronic, active 
lymphoid aggregates in the liver (Shomer et al. 2001; Shomer et al. 2003).  Further 
studies demonstrated H. hepaticus infected mice deficient in both IL-10 and IL-12p40 did 
not exhibit typhlocolitis, contributing additional evidence of a role for IL-12 (Kullberg et 
al. 2001).  CD4(+) T cells from IL-10-/- animals transferred to infected recombination 
activating gene (RAG) deficient mice initiated intestinal inflammation while the 
cotransfer of CD4(+) T cells from H. hepaticus-infected wild type mice (WT), but not 
uninfected WT mice prevented the colitis (Kullberg et al. 2002).  Regulatory T cells (TR) 
express the activation marker CD25 and represent 5%-10% of the total normal human 
CD4+ T cell population, and prevent immune mediated diseases (Powrie and Maloy 
2003).  Aberrant effector or regulator T cell responses to gut microbiota antigens may be 
the reason for the colonic and cecal inflammation (Kullberg et al. 2003; Thompson and 
Powrie 2004).   
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Recently, H. hepaticus infection in 129/SvEvRAG-/- mice has been demonstrated to 
induce chronic typhlocolitis progressing to colonic carcinogenesis.  (Erdman et al. 2003a; 
Erdman et al. 2003b).  These experiments demonstrated that the unregulated innate 
immune response, in this mouse strain, was sufficient to induce cancer due to persistent 
H. hepaticus infection.  Further, adoptive transfer with CD4+ CD45RBlo CD25+ 
regulatory T cells from uninfected 129/SvEv donors significantly inhibited H. hepaticus-
induced inflammation and development of cancer.  Past experiments had demonstrated 
accelerated colitis in RAG-/- can be induced by adoptive transfer of CD4+ CD45RBhi  T 
cells (Malmstrom et al. 2001; Singh et al. 2001a)  The experiments also indicated the 
timing of the adoptive transfer relative to the H. hepaticus incoculation was an important 
consideration, and that regulatory T-cell IL-10 was a necessary component for inhibition 
of chronic typhlocolitis and colonic carcinoma (Erdman et al. 2003b).   
 
Helicobacter hepaticus genome 
 
The complete genome sequence of H. hepaticus, the first enterohepatic Helicobacter spp. 
to be sequenced, revealed a larger genome and different virulence factors than H. pylori 
(Suerbaum et al. 2003).  The genome contains 1,799,146 base pairs, 1875 predicted 
proteins predicted, and a GC content of 35.9%.  H. hepaticus contains one large region 
and several smaller regions that differ from the rest of the genome in their GC content, 
suggesting horizontal transfer of genes. There are 499 proteins without similarity to any 
other known proteins. The H. hepaticus genome exhibits features of H. pylori, C. jejuni, 
and other enteric species (Eppinger et al. 2004).   
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Virulence factors 
 
H. hepaticus putative pathogenicity island  
 
Although H. hepaticus lacks orthologs of most known H. pylori virulence factors, it does 
possesse a putative pathogenicity island (HHGI1) of 71.0 kb (Figure 2).  HHGI1 contains 
70 ORFs and encompasses genes HH0233-HH0302.  It encodes at least 3 components of 
a T4SS including HH0252, HH0224, and HH260 which are orthologs of icmF/virB1, 
virD4, and virB4, respectively.  However, the percentage identities and similarities are 
low (Suerbaum et al. 2003).  The proteins VirB1, VirD4, and VirB4 are all components 
of the T4SS in A. tumefasciens, the most intensively studied T4SS, which translocates T-
DNA (Hoppner et al. 2004).  Five out of six male mice naturally infected with HHGI1-
carrying strains had liver disease (4 SCIDS, 1 A/J had lesions; 1 Swiss Webster did not).  
None of four mice (DBA/2 female 4 weeks, C57BL/6 female 4 weeks, Nude with Swiss 
Webster background female 1year, and unknown) naturally infected with HHGI1-
negative strains had evidence of liver disease (Suerbaum et al. 2003).  Further evidence 
of HHGI1 correlation with virulence is discussed in Chapter 4. 
 
Genes icmF/virB1, with similarity to HH0252, resides on the dot/icm 22kb genomic 
island in L pneumophila.  The genomic island contains 24 genes in L. pneumophila. 
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Figure 2 (Suerbaum et al, 2003; with permission) (A) The large genomic island of H. hepaticus 
(HHGI1). Red arrows represent genes encoding putative membrane-associated proteins, green 
arrows represent genes encoding proteins with a leader peptide, and blue arrows indicate genes 
coding for apparent homologs of other bacterial proteins (light blue, V. cholerae VCA0107–
VCA0115; violet, V. cholerae Hcp; dark blue, proteins from other bacteria). Turquoise arrows 
indicate the three genes that encode proteins (HH0252, HH0259, and HH0275) with homology to 
VirB10, VirD4, and VirB4. Some smaller ORFs transcribed in the same orientation are not 
depicted individually but shown as open arrows representing a block of genes. The lower part of 
the figure shows the same genomic region in one strain, 96-1809, where the complete island is 
lacking and where only the flanking sequences, HH0232 and HH0303, are present. (B) Genomic 
variation in H. hepaticus. Twelve H. hepaticus strains were tested for hybridization with a whole-
genome DNA microarray. Five strains (ATCC51448, ATCC51450, 95-225, 95-557, and 94-739) 
contained all genes detected by the array. The other seven strains did not hybridize with 85-229 
probes, and the positions of these missing genes in the genome of the sequenced strain 
ATCC51449 are indicated by red lines. The location of the genomic island HHGI1 that is totally 
or partially deleted in all seven strains is indicated by the blue rectangle. The array experiments 
identified six more clusters of at least five genes that were not detected in at least one of the 
strains.   
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The icm gene (intracellular multiplication locus gene), also know as dot (defect of 
organelle trafficking), encodes a protein which enables survival and multiplication within 
a macrophage, ultimately killing the macrophage.  The dot/icm locus possesses 4 
operons: icmTS, icmPO, icmMLKE, and icmJB; and 6 individual genes: icmR, icmQ, 
icmG, icmC, icmD, and icmF.  Genes icmP icmO, icmL, and icmE show sequence 
similarity to plasmid genes involved in conjugation and macrophage killing.  In 
particular, icmT and icmR mutants showed a severe reduction in conjugation frequency 
and macrophage killing (Segal et al. 1999; Segal and Shuman 1999a, b).  The dot/icm 
genes also correlate to growth and survival within certain protozoa and nonlytic release 
of the bacteria (Chen et al. 2004).   
 
The icmF gene exhibits homology among numerous gram negative bacteria in addition to 
H. hepaticus.  However, many of these gram negative bacteria do not possess a T4SS 
(Sexton et al. 2004a; Sexton et al. 2004b).  The gene is unique in that other constituents 
of the dot/icm locus do not possess this widespread homology.  Insertional mutants of 
icmF in L. pneumophila possess partially defective macrophage killing and were 
incapable of intracellular growth within Acanthameoba castellanii (Segal and Shuman 
1999b).  Double mutants of dotU and icmF exhibit decreased plasmid transfer capability 
(Sexton et al. 2004a).   
 
Chapter 4 and Chapter 5 provides experimental evidence that H.hepaticus strains with a 
partial deletion of the genomic island HHGI1, including HH0252 with IcmF homology, 
are less virulent in A/JCr mice (Chapter 4) and produce a reduced cytokine response in 
RAW264.7 murine macrophages (Chapter 5). 
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H. hepaticus cytolethal distending toxin 
 
Another virulence factor in enterohepatic Helicobacter spp. is cytolethal distending toxin 
(CDT).  CDT in H. hepaticus induces cell cycle arrest in the G2/M phase and progressive 
cell distension and eventual cytotoxicity in vitro (Chien et al. 2000; Taylor et al. 1995; 
Taylor et al. 2003; Young et al. 2004; Young et al. 2000).  CDT was first discovered in 
E. coli and Camplybacter spp. (Anderson et al. 1987; Johnson and Lior 1988a, b).  
Haemophilus ducreyi which produces the ulcerative lesions of chancroid also produces 
CDT (Cope et al. 1997).  The oral pathogen Actinobacillus actinomycetemcomitans 
produces CDT from a polymorphic region of its chromosome (Mayer et al. 1999).  
Salmonella typhi exhibits virulence when internalized and secretes only a protein subunit 
of CDT, CdtB.  This negates the need for the CdtA and CdtC subunits, putatively related 
to transport of CdtB into the cell (Haghjoo and Galan 2004). 
 
IL10-/- mice, on a C57BL/6 background, experimentally infected with an isogenic CDT 
mutant of H. hepaticus develop less severe disease than IL10-/- mice infected with wild 
type H. hepaticus (Young et al. 2004).  The authors also demonstrated that CDT in H. 
hepaticus appears to be the granulating cytotoxin previously reported by Taylor et al 
(Taylor et al. 1995; Young et al. 2004).  NF-kappa B-deficient mice infected with C. 
jejuni lacking CDT did not exhibit gastroenteritis whereas NF-kappaB-deficient mice 
infected with wild-type C. jejuni did develop severe gastroenteritis (Fox et al. 2004a).  
Previous studies of isogenic CDT mutants in H. ducreyi (Lewis et al. 2001; Stevens et al. 
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1999; Young et al. 2001) and C. jejuni (Purdy et al. 2000) did not yield conclusive 
evidence of a pathogenic role for CDT.   
 
H. hepaticus urease 
 
Urease contributes to pathogenesis in H. pylori and is a very stable and highly conserved 
gene in H. hepaticus (Fox et al. 1994; Mobley et al. 1991).  H. hepaticus urease isogenic 
mutants, constructed by allelic exchange, failed to colonize Swiss Webster and C57BL/6 
infected mice.  Since the isogenic urease mutant may not survive transit through the low 
pH in the stomach, experimental infection via the intragastric and intraperitoneal routes 
was performed and H. hepaticus colonization monitored.  These results suggest urease is 
an essential colonization factor for H. hepaticus (Chin et al, in press). 
 
Hepatocellular carcinoma in humans  
 
The major cause of hepatocellular carcinoma (HCC) in people is Hepatitis B virus (HBV) 
followed by the Hepatitis C virus (HCV).  The number of HCC cases worldwide caused 
by these two viruses is approximately 4% of all cancer cases.  A minority of HCC cases 
are associated with non-viral causes (Block et al. 2003; O'Brien et al. 2004; Omata and 
Yoshida 2004).  Human HCC presumably progresses from pre-neoplastic lesions, often 
in conjunction with cirrhosis.  While genetic alterations to the p53, Rb, and Wnt pathways 
do occur in HCC, the molecular pathogenesis of HBV-related HCC and HCV-related 
HCC differ (Suriawinata and Xu 2004).  HBV and HCV induce increased hepatocyte 
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turnover due to the immune system’s attack on infected hepatocytes, a commonality in 
the pathogenesis of viral-related HCC.   
 
Enteritis, hepatitis, and cholecystitis in humans, and even more severe disease in 
immunocompromised individuals, have recently been associated with enterohepatic 
Helicobacter sp. infection (Blaser and Atherton 2004; Chen et al. 2003; Fox 2002; Fox et 
al. 1998; Matsukura et al. 2002; Murakami et al. 2003; Murata et al. 2004; Nilsson et al. 
2003; Solnick and Schauer 2001; Sykora et al. 2004).  There is also definitive evidence 
of enteritis, hepatitis, and cholecystitis caused by enterohepatic Helicobacter sp. in 
animals (Rogers and Fox 2004; Solnick and Schauer 2001; Whary and Fox 2004a).  
However, non-viral related HCC, and HCC without the background of cirrhosis, receives 
little attention in the literature due to the low percentage of cases.  Helicobacter spp. 
association with HCC has been reported (Verhoef et al. 2003).  There is considerable 
debate regarding Helicobacter spp. involvement in HCC (Coppola et al. 2003).  
Helicobacter sp. infection in pediatric liver disease has received recent attention (Tolia et 
al. 2004), as has Helicobacter spp.autoimmune hepatic disease (Nilsson et al. 2003).   
 
Hepatocellular carcinoma in mice 
 
H. hepaticus infection of A/JCr mice induces HCC and is a mouse models of infectious 
liver cancer (Fox et al. 1996c).  Cumulative evidence suggests H. hepaticus is non-
genotoxic and possesses characteristics of a tumor promoter(Canella et al. 1996; Diwan 
et al. 1997).  One factor supporting its role in tumor promotion is mouse strain 
 46
susceptibility to H. hepaticus induced disease.  Tumor promoting agents have historically 
exhibited strain susceptibility differences.  Other evidence includes a persistent 
inflammatory state with increased exposure time to reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) (Whary et al. 1998).  Increased hepatocyte proliferation, 
the lack of p53 and ras mutations, a negative Ames assay, and the promotion of HCC by 
H. hepaticus after tumor initiation by hepatocarcinogenic chemicals are other examples 
(Canella et al. 1996; Diwan et al. 1997; Sipowicz et al. 1997).   
 
However, evidence demonstrating genotoxic activity of H. hepaticus has also been 
reported.  DNA adduct formation by H. hepaticus infection suggests a role of a tumor 
inititator (Josyula et al. 2000; Singh et al. 2001b; Sipowicz et al. 1997).  Both ROS and 
RNS species increase the risk of DNA mutation and adducts, particularly 8-oxo-2”-
deoxyguanosine (8-oxodG).  In vitro evidence suggests this adduct may be prone to 
peroxynitrite attack.  Peroxynitrite, a product of nitric oxide and superoxide from 
macrophages, may form other DNA adducts instead (Dedon and Tannenbaum 
2004).Methylation of CpG islands has been associated with HCC (Yu et al. 2003).  
Whether H. hepaticus has any epigenetic effects is an area of future investigation.   
 
The cumulative evidence to date suggests H. hepaticus may be a complete carcinogen, 
since it possesses characteristics of tumor initiation, promotion, and progression.  Further 
studies on the biochemical pathways affected by H. hepaticus are necessary, and 
comparison to pathways affected by chemical carcinogens or well established tumor 
promoters (e.g. phenobarbital) appear to be a fruitful areas of investigation.  Rodent 
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chemical carcinogenesis studies focus on gene expression and biochemical pathways 
afftected by the chemicals (van Delft et al. 2004).  Phenobarbital is non-genotoxic and 
has been the prototypical tumor promoter for decades.  It activates the constitutive 
active/androstane receptor (CAR) and promotes HCC in rodents after diethylnitrosamine 
(DEN) initiation.  CAR deficient mice do not get HCC after DEN initiation and 
phenobarbital promotion.  Recent evidence suggests commonality in biochemical 
pathways of phenobarbital promotion and H. hepaticus infection (Yamamoto et al. 2004). 
 
The biochemical pathways and genes associated with preneoplastic lesions exhibited 
during promotion are important in understanding tumor promotion and progression, and 
potential therapeutic intervention.  Microarray analysis of preneoplastic lesions in the 
liver due to H. hepaticus infection are the subject of Chapter 3.  An overview of 
microarray analysis is the subject of Chapter 2.  
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Overview of microarrays 
 
History 
 
Microarray technology has generated considerable interest in the scientific field since 
1995 (Schena et al. 1995).  Microarrays provide the entire transcriptome at a single point 
in time.  It yields a global, instantaneous perspective of the dynamic, complex 
interactions among thousands of genes. This includes genes in a heterogeneous 
population of cells in a tissue sample or a more homogenous cell population such as yeast 
or bacteria.  Initial applications focused primarily on cancer (DeRisi et al. 1996; Golub et 
al. 1999; Tamayo et al. 1999; Welford et al. 1998) and yeast cell cycle analysis 
(Spellman et al. 1998).  The number and diversity of experiments has increased 
tremendously as more genomes are sequenced.  Microarray expression databases from all 
types of microarray experiments, and across microarray platforms, have emerged (Ball et 
al. 2005; Su et al. 2002).   
 
This chapter focuses on microarray applications as they pertain to disease and the host-
pathogen interaction.  A gene expression signature is a unique transcription profile that 
characterizes a specific physiologic or pathologic state of an organ or tissue.  This has 
allowed the establishment of new subtypes of previously recognized diseases.  These 
disease subtypes present prognostic implications for existing therapeutic interventions 
(Armstrong et al. 2003; Campbell and Ghazal 2004; Ebert and Golub 2004; Mirnics and 
Pevsner 2004; Ramaswamy and Golub 2002; Russo et al. 2003).  Thus, microarray 
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technology provides a powerful approach to diagnostics and contributes to prognoses.  A 
gene signature of lesions provides important etiological and diagnostic clues.  However, 
lesions consist of a heterogeneous population of cells and may be highly variable in size.  
This necessitates increased sensitivity and technological capabilities as the cell 
population in tissue samples become smaller.  The transcriptional profile of an individual 
cell is not an unrealistic goal due to linear amplification strategies of minute amounts of 
total RNA (Van Gelder et al. 1990) and the introduction of laser capture microdissection 
(Kunz and Chan 2004; Player et al. 2004).  Laser capture microdissection is an 
advancement for analyzying small, targeted tissue samples and is discussed in  
appendix 2.   
 
Microarray types and technology 
 
The three most commonly used microarray-based platforms are spotted oligonucleotide 
arrays, in situ oligonucleotide arrays (e.g, Affymetrix, Nimblegen), and spotted cDNA 
arrays.  Oligonucleotide arrays have shorter gene target sequences (typically between 25-
70 base pairs).  The arraying technique differentiates the two oligonucleotide platforms 
(Bjorkbacka 2004).  Spotted oligonucleotides are manufactured by robotic placement of 
oligonucleotide probes on a chemically treated microscope slide ( www.agilent.com ).  
Microscope slide surface coatings reduce background fluorescence and non-specific 
binding (Bjorkbacka 2004).  In-situ oligonucleotide probes are synthesized by 
photolithographic techniques utilizing masks for in-situ oligonucleotide arrays (Fodor et 
al. 1993) (www.affymetrix.com) or by maskless photodeposition chemistry using digital 
 76
light processing ( www.nimblegen.com ).  Oligomer and cDNA robotic spotting 
technologies include spotting pens (contact spotting) and ink-jet printing (non-contact 
spotting).  Oligomer synthesis by ink-jet spotting of free nucleotides is another popular 
technology (Agilent).  Probes consist of one single long oligomer (50-70 bases) per gene 
or multiple (16-20) shorter oligomers  (25 bases) per gene.  Increasing the probe density 
of oligomer arrays allows more genes per array.  Oligonucleotide arrays offer higher 
probe density and greater specificity than cDNA arrays.  However, cDNA arrays are the 
only option for species where the genome has not been sequenced.  Microarrays are 
available containing the complete genome of the species of interest on one microarray.  
Arrays are also available containing multiple genomes, and the number of genomes is 
dependent on genome size and probe density technological limitations. 
 
Hybridization differences for microarray platforms 
 
Spotted oligonucleotide and spotted cDNA arrays utilize two fluorescent dyes while in 
situ oligonucleotide microarrays use one.   Both spotted array types are hybridized with 
labeled test and reference samples simultaneously.  The fluorescent dyes are of a specific 
wavelength that allows their signals to be clearly distinguished.  The in situ 
oligonucleotide microarrays use one sample per microarray.  The total RNA isolated 
from samples are subjected to a number of processing steps that yield cDNA molecules 
that are labeled with fluorescent dyes.  The one dye method for in-situ olignucleotide 
microarrays allows for array to array comparisons, with one array serving as a reference 
array.  The two dye method for spotted arrays allows within array comparisons.  The 
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most popular fluorescent dyes used for spotted arrays to label test and reference samples 
are Cyanine-3 (green) and Cyanine-5 (red).  After hybridization, the microarray slides are 
scanned using a confocal scanner that illuminates every spot and measures fluorescence 
intensity for each dye. 
 
Microrray analysis 
 
Scanning and image analysis 
 
The image acquisition, analysis, normalization, modeling, and identification of 
differentially expressed genes in microarray experiments are non-trivial processes. 
Sophisticated hardware and software tools provide robust data visualization and analysis. 
Image analysis software facilitates acquisition of raw signal data from each probe.  A 
final signal value is dependent upon several important parameters such as oligomer 
probe(s) fabrication, location, orientation, size, shape, and uniformity.  The scanner 
parameters, the resolution of the scanner, and the alignment of the chip represent 
additional important variables.  Computer algorithms intrinsically account for the spatial 
distribution, cumulative signal, number of oligomers, and number of pixels that 
collectively represent the final signal value recorded for each gene.   
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Normalization 
 
Normalization is an integral step of data analysis.  The purpose is to minimize variation 
across multiple arrays from factors that are not biological.  For example, the total RNA 
concentration initially processed and the sample concentration applied to the array(s) will 
exhibit sample variability.  For two dye microarray experiments, dye bias occurs, thus  
normalization approaches differ for one dye and two dye platforms.  Non-linear 
relationships can exist between arrays, negating the use of a simple scaling factor. 
 
Rank invariant normalization in the dChip software package was utilized for all 
microarray studies in Chapter 3 (Li and Wong 2001a; Li and Wong 2001b).  The model 
based expression index (discussed next) derived in dChip requires normalization prior to 
comparing expression levels between arrays.  All arrays are normalized to a baseline 
array exhibiting the median signal intensity.  The normalization is based on the 
assumption that non-differentially expressed genes in two arrays should have similar 
intensity rankings. The dChip rank invariant normalization algorithm determines a 
proportion rank difference (PRD) defined as the absolute rank difference in two arrays 
divided by the number of probes.  The algorithm is an iterative procedure that utilizes an 
empirically determined threshold for the PRD in determining if a probe should be kept or 
eliminated, thus establishing a new set of probes.  The algorithm is applied to each new 
set, during each iteration, until the number of the probes does not change. 
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Modeling 
 
The statistical model utilized in dChip for probe level data generates model-based 
estimates for gene expression indexes (Li and Wong 2001a; Li and Wong 2001b).  The 
Affymetrix arrays consist of 16-20 probes per gene, with a probe oligonucleotide length 
of 25 mer, and each probe having a corresponding mismatch probe.  The mismatch probe 
contains a different nucleotide in the middle of the probe.  The expression level for 
different probes of a probe set for the same gene can be highly variable.  A single 50-70 
mer probe per gene versus 16-20 Perfect Match (PM) and Mismatch (MM) 25 mer probe 
pairs per gene would imply two substantially different statistical models.  The latter case 
provides more information due to 32-40 sample points per gene.  Initial gene expression 
studies with Affymetrix microarrays did not employ a statistical model for expression 
levels, and simply used the average of the PM-MM probe values as an expression index 
for each gene.  In earlier studies, this value was used in gene expression analysis 
algorithms such as hierarchical clustering and self-organizing maps (Alon et al. 1999; Li 
and Wong 2001b; Tamayo et al. 1999).  The dChip model generates a gene expression 
index at the probe level, a statistical model based expression index (MBEI), and allows 
for probe-specific biases due to their high reproducibility and predictability.  Probe-
specific effects are extremely important in the model (Li and Wong 2001b). The MBEI is 
a weighted average of the PM and MM differences, with larger weights given to probes 
with larger probe sensitivities.  The probe sensitivity standard error is zero for an 
individual probe, if there are no cross-hybridizing probes for that individual probe.  Thus, 
the probe sensitivity standard error is large for cross-hybridizing probes.  The MBEI 
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standard error is large for image contamination.  The software thus identifies cross-
hybridizing probes and contamination.  Therefore, the dChip model states the PM and 
mismatch MM difference for one probe set is the product of the MBEI and the probe 
sensitivity index, plus random error.   
 
Algorithms 
 
Algorithms for microarray data analysis are usually classified in two categories: 
“unsupervised or clustering” (implying no a priori classification of data) and “supervised 
or classification” (using data from known a priori classifications and applying predictors 
from this data to new data).  A hybrid approach can also be utilized.  These algorithms 
may recognize a pattern in the data that correlates with a disease or a previously 
unrecognized sub-type of a disease as alluded to earlier, thus complementing 
histopathologic classifications.  Algorithms used for microarray analysis in this thesis 
include comparison analysis (ratio and difference thresholds), hierarchical clustering with 
two dimensional dendrograms and heat-maps (Eisen et al. 1998), linear discriminant 
analysis (Dudoit and Fridlyand 2002; Hakak et al. 2001), and principal component 
analysis (Raychaudhuri et al. 2000) 
 
Two dimensional dendrograms and heat maps cluster genes based on the similarity of 
expression.  There are a number of mathematical measures of similarity, and dChip 
utilizes the standardized correlation coefficient (r) and defines the distance between two 
genes as 1-r.  The algorithm merges the first two genes encountered in the search for the 
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closest distance into a “supergene”.  The genes are connected by branches to form the 
evolving tree (dendrogram) with length representing their distance.  These individual 
genes are deleted for the next iteration of merging and are replaced by the “supergene.”  
The supergene is the average of standardized expression levels of the two genes across 
samples.  In the next iteration, the next pair of genes (including supergenes) with the 
smallest distance is chosen to merge and another branch of the dendrogram is formed.  
The number of iterations is necessary to merge all the genes (and form the final 
dendrogram) is n-1, where n is the number of genes.  This algorithm can be applied twice 
to obtain two dendrograms, one across genes and the other across samples (Li and Wong 
2003). 
 
Linear discriminant analysis classifies unknown samples based on training by known 
classes.  Each individual gene is examined as to how well it separates all samples into 
two groups, and how well it correlates with the samples within one of these groups.  The 
algorithm then selects a linear combination of genes in an attempt to maximize the ratio 
of the “ between-group variance” and the “within-group variance”(Hakak et al. 2001).  
The dChip algorithm calculates two linear discriminants that map the multidimensional 
samples to a plane.  The number of dimensions is equal to the number of genes used.  The 
number of genes used in linear discriminant analysis is often a list of most differentially 
expressed genes, which was the approach used in Chapter 3.  However, other lists of 
genes can be used and empirically tested to find the set of genes that exhibits the best 
predictive value. 
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Principal component analysis is a technique to find patterns in multidimensional data and 
has been utilized in facial recognition, image compression, and microarray gene 
expression analysis.  Formally, the principal component of a data set is the eigenvector 
with the highest eigenvalue.  It allows the dimension of the data to be reduced.  This can 
be accomplished when there is a high correlation between two data points.  There is 
redundancy in this case and the two variables can be reduced to one.  For example, using 
a mathematical transformation to convert 3 dimensional data into 2 dimensional data, can 
possibly maintain most of the variability of the original data.  Principal component 
analysis can transform gene expression data into a vector of any dimension, but for 
visualization purposes of microarray data, it is either a 3 or 2 dimensional vector that is 
plotted.  Hopefully, the analysis yields regions on the plot that differentiates the groups of 
interest, e.g. control and treated (Raychaudhuri et al. 2000; Smith 2002). 
 
Gene ontology, standardized vocabulary and gene annotation 
 
Gene annotation requires a standardized vocabulary to prevent redundant nomenclature 
for gene function.  Standardized vocabulary for biological processes, cellular 
components, and molecular function has been proposed by the Gene Ontology 
consortium (www.geneontology.org) (Ashburner et al. 2000; Harris et al. 2004).  Genes 
characterized as “hypothetical”, an open reading frame (ORF) determined by gene 
prediction algorithms with no protein match in Basic Local Alignment Search Tool 
(BLAST)-Extend-Repraze (BER) or The Institute for Genomic Research protein families 
(TIGRFAM), represent a very large percentage of all the genomes sequenced at present.  
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The same situation exists for “conserved hypothetical proteins”, a pair-wise match with a 
hypothetical protein from another species but no TIGRFAM match (Fraser et al. 2004).  
Transitive errors arise when an aberrant annotation on one gene is transferred to another 
gene(s) due to database matches and subsequent annotation based on that match.  
Phylogenetic classification of proteins contributes to the annotation task and the cluster of 
orthologous gene (COG) database (http://www.ncbi.nlm.nih.gov/COG/) established 
phylogenetic lineages (Karlin et al. 2003; Tatusov et al. 2001).  Biochemical 
classification of protein function presents an arduous task and in silico solutions are being 
actively pursued.  The sequencing of more genomes within a species contributes to gene 
annotation (Kellis et al. 2003).   
 
Identification of pathways and therapeutic targets 
 
Microarray analysis generates tremendous amounts of data, producing lists of genes 
exhibiting differential expression under various experimental conditions.  The list reveals 
genes that are potential targets for therapeutic intervention.  However, hundreds or 
thousand of genes are often affected and identifying true therapeutic targets becomes 
problematic.  Presently, a relatively large percentage of the genes in any genome may not 
have a functional annotation.  Therefore, the molecular pathway(s) a gene product 
participates in is also unknown.  How genes behave as a group under various 
experimental perturbations can suggest potential interactions with known pathways, but 
not the topology of the signaling network.  Microarray analysis may yield potential clues.  
The hierarchical clustering mentioned earlier may group genes with known function and 
 84
pathways with genes with no functional annotation.  This may suggest the unknown gene 
is directly or indirectly influenced by the known gene and pathway, and may warrant 
further investigation.  Common sequence motifs within differentially expressed genes 
may imply a common transcriptional regulatory factor, or a common co-factor, 
depending on the whether other genes with the same motif are also differentially 
expressed.  Transcriptional regulation experiments highlighting protein-DNA interaction 
provide further insight into network topology (Harbison et al. 2004). 
 
Another approach to identifying genes in a pathway is chemical genomics.  Chemical 
genomics approaches have added alternatives to traditional high-throughput screening 
(HTS).  This approach focuses on the microarray target list, the differentially expressed 
genes in an experiment, for effects on biochemical pathways (Stegmaier et al. 2004).  
Extensive chemical library screens are utilized to search for potential target interaction as 
well as in-vitro effect.   
 
Pathways also include protein-protein interactions in multi-protein complexes which are 
temporally and spatially regulated, and modulated by protein kinases (Yaffe and Smerdon 
2004).  Identifying all the targets of the different protein kinases and all the 
phosphorylation states of these targets may also contribute to deciphering cellular 
pathways.  The smallest number of pathways is presumed to be in organisms with the 
smallest genomes.  Hence, the recent interest in minimal organisms and synthetic 
biology.   The complete genome and proteome for “minimal organisms” may be a start to 
elucidating the minimal set of pathways necessary for life (Jaffe et al. 2004). 
 85
Verification of microarray gene expression by quantitative real-time PCR 
 
Microarray results have been criticized for a number of reasons.  The reasons most often 
cited include cross platform discrepancies such as cDNA versus oligo, long oligo versus 
multiple short oligo, spotting versus photolithography, and others.  The maturation of the 
technology contributed to the discrepancies.  Some of the advantages and disadvantages 
of the different technologies have already been discussed.  Early microarrays were often 
custom printed with a multitude of manufacturing variables to be considered.  The 
hybridization, scanning, algorithms, and other factors inherent in these assays contributed 
to variability.  One of the most controversial topics was defining when there was 
differential gene expression.  The problem of recognizing and pursuing false positives 
obviously wastes resources.  Missing true positives, when low level transcript changes 
are biologically significant, is also a problem.  (Brown et al. 2001; Dobbin and Simon 
2005; Etienne et al. 2004; Kothapalli et al. 2002; Woo et al. 2004; Yauk et al. 2004).  
One approach to verifying microarray results was employing quantitative real-time PCR 
for randomly selected genes.  We used this approach in Chapter 3 and found the 
technology we chose to be in complete agreement with the microarray results at higher 
levels of signal.  In fact, the microarray fold changes appeared systematically lower for 
higher differential expression.  This indicated a narrower dynamic range for microarray 
technology as compared to quantitative real-time PCR.  At lower fold changes, we found 
general agreement, but found some discrepancies as would be expected when signal 
levels are close to the noise floor.   
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Microarray Applications 
 
Gene expression  
 
Gene expression analysis of a tissue sample represents the most common use of 
microarrays.  In an individual human cell, transcription of a subset of roughly twenty to 
twenty five thousand genes produces various forms of coding and non-coding RNA.  
Non-coding RNA molecules may be post transcriptionally modified and perform a 
regulatory, enzymatic, or transport role.  Coding RNAs may also undergo further 
processing and are subsequently translated into protein products.  The population 
distribution of transcripts depends on the number, type, and state of the cells in the 
sample.  The microarray signal level for each gene represents the quantity of each 
individual transcript within a population of transcripts in a tissue sample at a single point 
in time. 
 
DNA-DNA hybridization for strain differences 
 
Another common application utilizes microbial species microarrays to highlight strain 
differences at the gene level.  The utility of this approach has been demonstrated with H. 
pylori, the first bacteria to have two strains sequenced.  H. pylori strains compared at the 
sequence level demonstrated 6% to 7% of the genes specific to each strain, with roughly 
half of those genes in a single hypervariable region (Alm et al. 1999; Alm and Trust 
1999).  Subsequent microarray analysis of H. pylori strain differences yielded genes 
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correlated to virulence.  (Bjorkholm and Salama 2003; Israel et al. 2001a; Israel et al. 
2001b; Suerbaum et al. 2003; Thompson et al. 2004).  The same approach applied to H. 
hepaticus revealed numerous genetic differences in strains including a putative 
pathogenicity island (Suerbaum et al. 2003).  Microarrays with multiple strains of 
microbial species are commercially available.  The applicability of this technique 
depends on the sequence diversity of the organism and the probe capacity of the 
microarray. 
 
Microarrays as a complement to histology 
 
Histopathology provides the present-day definitive diagnosis and classification of lesions 
based on subjective assessment of the microarchitecture of a tissue, including 
assessments of cell appearance and morphology in relation to their function.  
Histopathology, along with other medical tests and patient history, provide the 
framework for diagnostic, prognostic, and therapeutic decisions.  Any reduction of the 
subjectivity of histopathological measurements to more quantitative assessment of lesions 
would be an improvement.  In the instance where multiple diseases look very similar 
histologically, a gene expression signature may be a differentiating factor.  For example, 
a transcription profile may predict whether a neoplasia is benign or malignant, and if 
malignant, the risk of metastases.  Molecular characterization of lesion classification may 
contribute previously unknown sub-classifications, potentially affording improvement in 
therapeutic development, the prediction of disease behavior, and the response of existing 
therapeutic regimens.  The molecular characterization of lesions could consist of, but not 
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be limited to, gene expression, proteins (including modifications), metabolites, protein 
interactions, and protein-DNA interactions.  Molecular characterization of the temporal 
nature of lesions may prove invaluable via capturing sequential states of molecular 
pathogenesis.   This may provide further insight into the progression of lesions, and 
identify potential therapeutic targets at each stage of disease progression. 
 
Microarray investigation of the host-pathogen interaction 
 
The host-pathogen interaction exemplifies a temporal pathogenic process where 
differential gene expression due to the pathogen can be investigated by microarray 
analysis.  It allows the transcription profile of infected and control tissues in experimental 
animals to be monitored at any time interval desired.  The preneoplastic events leading to 
a tumor cannot easily be investigated in people.  Microarray analysis of human tumors, 
although very valuable, is complicated by the noise contributed by the heterogeneity of 
the humanpopulation and the genomic instability of the tumor.  The use of tissue outside 
the tumor margins as controls is problematic if that tissue is also abnormal at the 
molecular level.  The inability to match for age, gender, nutrition, environment, and other 
factors may also add noise to the analysis.  A mouse model of an infectious cause of HCC 
presents an excellent opportunity to monitor the preneoplastic molecular pathogenesis.  
The experimental parameters controlled in the experiment in Chapter 3 include host 
strain, gender, nutrition, environment, and age at infection, thus avoiding the previously 
mentioned effects in human molecular pathogenesis studies.  Chapter 3 and appendix 1 
examine the AJ/Cr mouse-H. hepaticus interaction in the liver at 3, 6, and 12 months post 
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infection.  These joint papers demonstrate the utility of combining conventional 
histopathology and microarray analysis. 
 
Microarray analysis of neoplasia 
 
Some of the first microarray experiments focused on tumor biology and have yielded 
valuable characterizations and new diagnoses, with prognostic and therapeutic 
implications (DeRisi et al. 1996; Golub et al. 1999).  Tumor biology focuses on 
neoplastic cells and their microenvironment including stromal cells, inflammatory 
infiltrates, and blood vessels.  Transcriptional profiling of tumors from the same tissue, or 
different tissues, provides considerable insight into the commonality and differences of 
tumors.  Tumors with the same histopathological classification and grade can be 
compared, and potentially be further differentiated by gene signature.  The classification 
of a tumor may be even further refined as additional proteomic and metabolomic data 
become available.  This information may correlate with prognoses or therapeutic 
outcomes.  It may prevent a patient from being subjected to a rigorous therapeutic 
regimen with little chance of success.  It may promote new therapeutic focus on newly 
defined tumor subtypes.  To what degree further refinement of tumor classification 
represents valuable information as opposed to ancillary information remains to be seen, 
since genomic instability of a tumor may imply a stochastic aspect of tumor gene 
expression. 
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Helicobacter spp. microarray experiments 
 
Microarray experiments associated with Helicobacter spp. include human peripheral 
blood mononuclear cell response to H. pylori infection (Yamasaki et al. 2004), tissue 
response in experimental Helicobacter spp. infection in animal models, cell response to 
in-vitro infection, mutant and wild-type Helicobacter spp. gene expression under various 
experimental conditions, and mutant and wild-type Helicobacter spp. strain comparison 
via DNA hybridization.  There are numerous reports dealing with microarray analysis of 
primary gastric carcinoma cells and gastric cells lines which will not be discussed here.  
The Helicobacter pylori genome reportedly varies over the course of years of infection 
within the same host, presumably due to phase variability and/or lack of mismatch repair 
enzymes, deletion of nucleotides, and acquisition of DNA (Falush et al. 2001; Kuipers 
and Grool 2001; Salaun et al. 2004; Suerbaum et al. 1998).  Recently, acute experimental 
infection of rhesus macaques demonstrated H. pylori genomic changes including antigen 
variation and phase variation within a few months post-infection (Solnick et al. 2004).  A 
mouse model of mucosal associated lymphoid tissue (MALT) lymphoma due to H. pylori 
or H. felis infection demonstrated distinct histopathological stages correlating with a gene 
expression profile (Mueller et al. 2003).  H. pylori infection in the gerbil model indicated 
gastric ulcer strain B128 induced more severe gastritis, proliferation, and apoptosis in 
gerbil mucosa than did duodenal ulcer strain G1.1.  Microarray analysis identified several 
strain-specific differences in gene composition including a large deletion of the cag 
pathogenicity island in strain G1.1  (Israel et al. 2001a).  Regulatory studies revealed a 
transcriptional hierarchy and feedback regulation in the flagellar system via mutational 
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analysis of H. pylori (Niehus et al. 2004).  Finally, in addition to the microarray analysis 
of H. hepaticus associated gene expression in the liver discussed in Chapter 3, there has 
been only one other enterohepatic Helicobacter sp. microarray study.  This was a H. 
hepaticus experimental infection in A/JCr mice demonstrating differentially expressed 
genes in the cecum at 3 months post-infection (Myles et al. 2003).   
 
Histological and microarray analysis of H. hepaticus infection in the A/JCr mouse  
 
Histopathological characterization and classification of the preneoplastic stages and types 
of hepatic tumors due to chemical and infectious agents have existed for decades 
(Bannasch et al. 2001).  Clinical classification of liver cancer relies upon morphological 
characteristics of tumors, lymph node status, and histology, as well as expression of 
specific markers associated with clinical course.  Microarray analysis of preneoplastic 
stages complements the existing knowledge.  Chronic, active hepatitis contributes to 
hepatic proliferation, a key component of the development of HCC in humans as well as 
livers of mice infected with H. hepaticus (Fox et al. 1996; Hailey et al. 1998).  A 
previous study of H. hepaticus infection in six 18 month old mice reported similar 
findings (Ramljak et al. 1998).  The histopathology of H. hepaticus induced liver disease 
up to 12 months post inoculation of H. hepaticus is presented in the appendix 1.  The 
microarray analysis of H. hepaticus induced liver disease is presented in Chapter 3.  The 
combination of microarray analysis and histopathology contribute valuable insight into 
the preneoplastic pathophysiology of H. hepaticus induced liver tumorigenesis in the 
A/JCr mouse. 
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Abstract 
 
Helicobacter hepaticus infection of A/JCr mice is a model of infectious liver cancer.  We 
monitored hepatic global gene expression profiles in H. hepaticus infected and control male 
A/JCr mice at 3 months, 6 months, and 1 year of age using an Affymetrix-based oligonucleotide 
microarray platform on the premise that a specific genetic expression signature at isolated time 
points would be indicative of disease status. Model based expression index comparisons 
generated by dChip yielded consistent profiles of differential gene expression for H. hepaticus 
infected male mice with progressive liver disease versus uninfected control mice within each age 
group.  Linear discriminant analysis and principal component analysis allowed segregation of 
mice based on combined age and lesion status, or age alone.  Up-regulation of putative tumor 
markers correlated with advancing hepatocellular dysplasia.  Transcriptionally down-regulated 
genes in mice with liver lesions included those related to peroxisome proliferator, fatty acid, and 
steroid metabolism pathways.  In conclusion, transcriptional profiling of hepatic genes 
documented gene expression signatures in the livers of H. hepaticus infected male A/JCr mice 
with chronic progressive hepatitis and preneoplastic liver lesions, complemented the 
histopathological diagnosis, and suggested molecular targets for the monitoring and intervention 
of disease progression prior to the onset of hepatocellular neoplasia.   
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Introduction 
 
Microbial causes of enterohepatic cancer are well known. Helicobacter pylori infection is the 
single greatest risk factor for gastric adenocarcinoma and has been classified a class I carcinogen 
by the World Health Organization (Fox et al. 2003a). Liver cancer in humans is associated with 
hepatitis B and C virus infection. Similarly, Helicobacter spp. may potentiate inflammation and 
risk of hepatocellular carcinoma (HCC) in humans with or without viral hepatitis. (Ponzetto et al. 
2000).  Infection-associated inflammation is widely recognized as a contributor to human HCC 
and cholangiocarcinoma  (Avenaud et al. 2000; Fox et al. 1998a; Nilsson et al. 2001) 
 
Helicobacter hepaticus is associated with chronic hepatitis and HCC in A/JCr and other 
susceptible mouse strains, including AxB recombinant inbred mice, B6C3F1 mice and B6AF1 
mice (Fox et al. 1994; Fox et al. 1996b; Hailey et al. 1998; Ihrig et al. 1999; Ward et al. 1994).  
A/JCr mice infected with H. hepaticus develop necrogranulomatous lobular and/or lymphocytic 
portal hepatitis. Male mice are more susceptible to hepatitis and tumors than females.  For 
reasons that are not clear, only a subset of H. hepaticus infected male mice are affected (Fox et 
al. 1996b). In the present study, we monitored by microarray analysis chronological changes in 
hepatic gene expression due to H. hepaticus induced chronic hepatitis in the preneoplastic phase. 
We compared gene expression profiles in H. hepaticus infected male A/JCr mice with severe 
liver disease to uninfected mice and to infected non-diseased mice at 3 months, 6 months, and 1 
year of age.  Unique gene expression signatures obtained from the microarray analysis allowed 
us to segregate H. hepaticus infected diseased liver from H. hepaticus infected disease-free livers 
and uninfected controls. Furthermore, the gene expression profiles allowed segregation of liver 
  102
profiles based on age of the mice. This study provides for the first time a chronological 
transcriptional characterization of a microbially induced progressive inflammation of the liver 
resulting in preneoplastic liver lesions. 
 
Materials and methods 
 
Animals 
 
Thirty-six Helicobacter-free female A/JCr mice (National Cancer Institute, Frederick, MD) were 
bred to 18 males, and pregnant dams were divided into groups. Dams received 107 colony-
forming units H. hepaticus or vehicle only by gastric gavage every 48 hours for 3 doses at 
conception (confirmed by vaginal plug visualization) or beginning midway (day 10) through 
pregnancy.  Pups received a similar bacterial or sham inoculum regimen at 3 or 12 weeks 
postnatally.  Assessment of transplacental bacterial or antigenic exposure was not performed. 
Offspring were euthanatized by CO2 inhalation at 3, 6, or 12 months of age. A total of 117 mice 
were evaluated: 33 at 3 months, 41 at 6 months, and 43 at 12 months. Animals were maintained 
in a facility certified by the Association for the Assessment and Accreditation of Laboratory 
Animal Care in compliance with the National Academy of Sciences' Guide for the Care and Use 
of Laboratory Animals, and all protocols were approved by the Massachusetts Institute of 
Technology (MIT) Committee on Animal Care. 
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Helicobacter hepaticus infection 
 
H. hepaticus type strain ATCCC 51449 was grown on TSA 5% sheep blood agar (Remel, 
Lenexa, KS) under microaerobic conditions (N2, H2 and CO2; 90:5:5) for two days and 
transferred with a sterile applicator to 1.5 ml of Brucella broth and 30% glycerol.  This was 
immediately deposited into 150 ml of Brucella broth in a flask, enclosed in an BBL GasPak 100 
polycarbonate anaerobic jar (Becton Dickison Microbiology Systems, Cockeysville, MD) under 
microaerobic conditions, and placed on a PsychroTherm incubator-shaker table (New Brunswick 
Scientific Co., Edison N.J.) at 30 RPM at 37°C overnight.  Approximately 108 bacteria/ml were 
placed in phosphate buffered saline (PBS) for one dose.  Bacterial count was confirmed by a 
reading of 1.0 at 660 nm on a DuPro 640 spectrophotometer (Beckman Coulter, Fullerton, CA). 
Bacterial viability, motility, and morphology were confirmed by phase-contrast microscopy.   
 
Histopathology  
 
At necropsy, ileocecocolic junction and two sagittal sections of each liver lobe (median, caudate, 
left, and right) were collected for histopathology. Tissues were immersion fixed overnight in 
10% neutral-buffered fromalin (VWR Scientific, West Chester, PA) and Prefer (Anatech, Ltd., 
Battle Creek, MI). Fixed tissues were processed and embedded by routine histologic methods, 
sectioned at 4 µm, and stained with hematoxylin and eosin (H&E). The 8 liver sections 
representing replicate samples from each lobe were examined by a veterinary pathologist blinded 
to sample identity and graded on a 0-4 scale for lobular histologic activity (lobular hepatitis), 
portal activity (portal and/or interface hepatitis), and staged on the same scale for fibrosis using 
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criteria established by Scheuer (Ferrell 2002; Scheuer et al. 2002).  Additionally, dysplastic 
progression was scored using criteria adapted from published schemes for the terminology of 
rodent and human liver lesions: (0) normal, (1) foci of cellular alteration or dysplastic foci, (2) 
nodules of cellular alteration or low grade dysplastic nodules, (3) high grade dysplastic nodules 
or focal well differentiated HCC, and (4) multifocal and/or moderately differentiated HCC 
(Bannasch et al. 2001; IWP 1995). 
 
Special stains, immunohistochemistry, and morphometric analysis 
 
Selected liver sections were stained by the Warthin-Starry stain for visualization of bacteria, or 
diastase periodic acid-Schiff or Perl's iron for demonstration of activated macrophages. 
Formalin- and Prefer-fixed liver sections were subjected to standard microwave heat-induced 
epitope retrieval and immunostained for cell phenotype markers or specific biomolecules using 
mouse monoclonal or rabbit polyclonal primary antibodies according to previous methods 
(Erdman et al. 2003c; Fox et al. 2003b).  For mouse primary antibodies the ARK kit was used 
(DAKO, Carpinteria, CA), a system that employs prelabeled same-species antibodies to 
overcome labeling of endogenous immunoglobulins, a strategy proven as well in other settings 
(Rogers et al. 2002). Rabbit primary antibodies were labeled with biotinylated goat anti-rabbit 
IgG (Sigma). Cell phenotypes and other biomolecules demonstrated included T cells (rabbit anti-
CD3, Sigma), B cells (CD45R/B220) and the mitosis marker Ki-67 (BD Pharmingen, San Diego, 
CA), macrophages (F4/80, Caltag Laboratories, Burlingame, CA), iNOS (NOS2) and COX-2 
(PGH2; Santa Cruz Biotechnology, Santa Cruz, CA), and the apoptosis marker cleaved caspase-
3 (Cell Signaling Technology, Beverly, MA). Diaminobenzidine (DAB) or Vector VIP was used 
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as chromogen, and tissues were counterstained with Gill's hematoxylin.  Morphometric analysis 
of immunohistochemically stained tissue sections was performed by a comparative pathologist 
using IPLab 3.6 software for Macintosh (Scanalytics, Inc., Fairfax, VA) according to previously 
described methods (Fox et al. 2003b).   
 
Liver Samples 
 
Samples were sections of the left liver lobe of A/JCr mice (Mus musculus).  Sections of the liver 
were used for histology and total RNA isolation.  Total RNA was used for microarray and 
quantitative real-time fluorogenic PCR assays.  Mouse liver was aseptically removed 
immediately after CO2 euthanasia and placed in an individual cryogenic vial (Corning, NY). The 
cryogenic vial was immediately placed in the vapor phase of liquid nitrogen.  At the end of the 
necropsy for the total experiment, the cryogenic vials were transferred to an -80°C freezer.   
 
Representative samples at 3, 6, and 12 months from 6 male mice were selected for microarray 
analysis based on known infection status and presence or absence of hepatitis as demonstrated by 
histopathology. Biological replicates representing 2 uninfected mice, 2 infected mice without 
significant liver lesions, and 2 infected mice with severe hepatitis were analyzed at each time 
point. Samples for microarray analysis were selected from groups of pups born to dams 
inoculated during pregnancy with subsequent H. hepaticus inoculation of pups at 3 weeks 
postnatally.  H. hepaticus infected litter- and cagemates with and without hepatitis were chosen 
for direct comparison whenever possible.   
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RNA isolation and quality assessment  
 
The standard protocols followed were per Affymetix’s instructions (Genechip  Expression 
Analysis Technical Manual 701021 Rev 4). Briefly, total RNA was isolated from two sections 
(each approximately 35 mg) of flash frozen liver using Trizol  (Invitrogen, Carlsbad, CA) as per 
manufacturer’s instructions.  The RNA pellet was resuspended in 100 ul of RNAse free water.  
The RNeasy Clean-up kit (Qiagen, Valencia, CA) was utilized per manufacturer’s instructions 
resulting in 30 ul total RNA sample.  The total RNA concentration and 260/280 ratio was 
evaluated on a NanoDrop ND-1000 UV-Vis Spectrophotomter (NanoDrop Technologies, 
Rockland, DE).  Only samples with a 260/280 ratio greater than 1.9 were further processed.  An 
aliquot of 1 ul from each of the samples was diluted to be within the dynamic range of the 
Agilent RNA 6000 Nano Labchip kit (Agilent, Palo Alto, CA), with a target of 100 ng.  The 
Nano Labchip protocol was followed as per manufacturer’s instructions and was placed on an 
Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA) for evaluation.  Samples with the highest 
concentration, only two distinct 18S and 28 S peaks, and no evidence of degradation were further 
processed.   To obtain 15 µg of total RNA for first strand cDNA synthesis, samples were 
sometimes combined and placed on a spin-vacuum to obtain the necessary concentration (1.66 
µg/µl) and volume (9 µl).  Six hundred units of SuperScript II reverse transcriptase were used for 
the first strand cDNA synthesis reaction.  Half of the samples were prepared at the Division of 
Comparative Medicine at MIT and the other half of the samples were prepared at the Whitehead 
Institute (JAL) for comparison.  The second strand DNA synthesis, the clean-up of the double-
stranded cDNA, the synthesis of the biotin-labeled cRNA, and the clean-up of the biotin-labeled 
cRNA were per Affymetrix instructions.  The Genechip  Sample Clean-up module was used 
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for the clean-up steps of the double-stranded cDNA and the biotin-labeled cRNA.  Quantification 
of the cRNA was evaluated on the NanoDrop.  Samples were used for hybridization only if 20 
µg of cRNA were obtained in an individual sample or by combining samples.  
 
Array design 
 
Affymetrix Murine Genome Arrays U74Av2.  (Affymetrix, Santa Clara, CA) Array size: 
Standard Format.  Feature size 20 µm. Sensitivity: 1:100,000.  See www.affymetrix.com for the 
probe sequences or reference sequence from which the probe was derived.  Microarrays were 
hybridized overnight, washed in a fluidics station, and scanned using the GeneArray scanner 
per manufacturer’s instructions (Affymetrix, Santa Clara, CA). The U74Av2 oligonucleotide 
array contained ~6000 functionally characterized gene sequences (Unigene Murine Database, 
Build 74) and a similar number of expressed sequence-tagged (EST) clusters. There were 16-20 
pairs of 25-mer oligonucletide probes per sequence, with a sensitivity of ~1:100,000. Control 
sequences on the microarray included bioB, bioC, bioD, and cre, and house-keeping genes 
considered were actin, GAPDH, and hexokinase. 
 
Hybridization 
 
Fragmentation, hybridization, washing, staining, and scanning were done according to the 
Affymetrix protocol. Briefly, reagent preparation included 12X MES stock (1.22M MES, 0.89M 
[Na+]) and 2X hybridization buffer (1X hybridization buffer: 100mM MES, 1M [Na+], 20 mM 
EDTA, .01% Tween 20).  The hybridization cocktail components and final concentrations 
consisted of fragmented cDNA (.05 µg/µl), control oligonucleotide B2 (50 pM), 20X eukaryotic 
  108
hybridization controls bioB, bioC, bioD, and cre (1.5, 5, 25, 100 pM, respectively), herring 
sperm DNA (.1 mg/ml), acetylated BSA (.5 mg/ml), 1X hybridization buffer with a final volume 
of 300 µl.  The GeneChip array was filled with 250 µl of the hybridization cocktail and 
hybridized for 16 hours, rotated at 60 RPM, and maintained at 45°C.   
 
Reagents prepared for washing and staining included a non-stringent wash buffer (6X SSPE, 
.01% Tween 20), a stringent wash buffer (100 mM MES, 0.1 M [Na+], 0.01% Tween 20), and a 
2X stain buffer (1X: 100 mM MES, 1M [Na+], 0.05% Tween 20).  The wash procedure was 
carried out in an Affymetrix Fluidics Station 400 controlled by Affymetrix Microarray Suite 5.0 
software resident on a personal computer.  The fluidics station first went through a priming step 
and subsequently did the washing and staining by a software protocol designed for the 
Affymetrix Murine Genome Array U74Av2. 
 
Measurements 
 
The microarrays were scanned using the GeneArray scanner per manufacturer’s instructions 
(Affymetrix, Santa Clara, CA). The quality control algorithms for eliminating an array are based 
on recommendations in both the Affymetrix and dChip software packages.   
 
Normalization 
 
For dChip software, a invariant-set normalization method is used (Li and Hung Wong 2001; Li 
and Wong 2001).  Briefly, the expectation is that a probe of a non-differentially expressed gene 
in two arrays will have similar intensity ranks in two separate arrays.  The ranks are calculated 
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separately in the two arrays. Although it is unknown which genes are non-differentially 
expressed, an iterative procedure is used to determine rank differences with an empirically 
derived threshold for inclusion.  All arrays are normalized, except the baseline array, to the 
common baseline array with median intensity. 
 
Data analysis  
 
Two software packages were utilized for data analysis, dChip (Li and Hung Wong 2001; Li and 
Wong 2001) and Affymetrix Microarray Suite 5.0.  Microarray Suite 5.0 was used to generate a 
cell intensity file (*.cel).   The *.cel file and the perfect match model (PM) were used for the 
dChip analysis and is the data presented.   The dChip software is model based, and generates a 
“model based expression index” (MBEI) and a standard error.  The software utilizes the response 
characteristics of individual probe sets.  Unless otherwise specified, default settings were used.  
Comparison analysis, hierarchical clustering, linear discriminant analysis (LDA), and principal 
component analysis (PCA) within dChip were performed.  Comparison analysis used the default 
setting of 1.2 fold change, positive or negative.  For hierarchical clustering, default settings were 
used, the distance metric was 1-correlation and the linkage was centroid.    
 
Quantitative real-rime flurogenic PCR (Taqman)   
 
To confirm microarray data, quantitative real-time flurogenic PCR was utilized.  Assay-on-
Demand gene expression kits (Applied Biosystems, Foster City, CA) were used to quantitate 
cytochrome P450 4a14 (Cyp4a14), interferon γ-induced GTPase (Igtp), H19 fetal liver mRNA 
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(H19), hydroxysteroid dehydrogenase-5, delta<5>-3-beta (Hsd3b5), CD5 antigen-like (Cd5l) 
(formerly known as apoptosis inhibitor 6), trefoil factor 3, intestinal (Tff3) genes were 
normalized against the expression of glyceraldehyde 3 phosphate dehydrogenase (Gapdh) as the 
housekeeping standard. Two µg of total RNA from the uninfected and infected A/JCr mouse 
liver samples was reverse-transcribed to single strand cDNA using the Superscript Reverse 
Transcriptase II (Invitrogen, Carlsbad, CA) protocol.  The single strand cDNA from the reverse 
transcriptase reaction was amplified by real-time quantitative flourogenic PCR.  Eighty 
microliters of 1X TE was added to the 20 ul reaction volume.  The Taqman protocol was per 
manufacturer’s instructions for the Applied Biosystems 7700 Sequence Detection System except 
that 25ul total volume was used.  The reaction consisted of the Taqman Universal 2X PCR 
Master Mix (12.5 ul), 5 ul of the cDNA/1XTE solution, 20X target (1.25 ul) and 6.25 ul of water.  
That RNA expression level fold changes were calculated as described by the Taqman protocol. 
 
Results 
 
Histopathology 
 
Inflammatory lesions in mice infected with H. hepaticus followed one of two courses, resulting 
in necrogranulomatous lobular and/or lymphocytic portal hepatitis.  In cases of lobular hepatitis, 
necroinflammatory lesions consisted primarily of Kupffer cells and recruited macrophages 
surrounding and infiltrating foci of spotty or confluent hepatocellular necrosis (Fig. 1a), resulting 
in translobular coagulative necrosis in severe cases. Neutrophils and lymphocytes made a 
minority contribution to lobular lesions. Larger lesions were evident grossly as round white foci 
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up to 2 mm diameter. Lobular lesions were often but not always situated near terminal hepatic 
venules. Acidophil bodies were mildly increased in number in mice with lobular hepatitis, 
though not always located near inflammatory foci.  
 
Portal hepatitis consisted primarily of lymphocytoid cells forming expansile nodular lesions, 
either in conjunction with lobular lesions or comprising the main disease process. Uncomplicated 
portal hepatitis was most common in females. Because bacteria were rarely identified in portal 
regions, it is possible these lesions developed due to circulating antigens or cytokines from the 
lower bowel. Lobular necrogranulomatous lesions were evident at all sampled timepoints, 
whereas chronic portal inflammation was not fully developed until 12 months of age. Especially 
in conjunction with lobular lesions, portal mononuclear infiltrates disrupted the hepatic limiting 
plate, resulting in interface hepatitis (Fig. 1b).  Lymphocytoid cells filled and expanded reactive 
portal lymphatic vessels, and in larger lesions surrounded and infiltrated bile ductules inducing 
epithelial loss, hypertrophy, and atypia (Fig. 1b). Expansile aggregates sometimes were 
organized into follicles consistent with “tertiary lymphoid tissue” (Fig. 1c) (Shomer et al. 2003).  
Unlike the case of H. hepaticus infection in mice with targeted immune mutations (Erdman et al. 
2003b; Erdman et al. 2003c; Tomczak et al. 2003a; Young et al. 2004) but in agreement with 
previous studies utilizing A/JCr mice (Whary et al. 2001; Whary et al. 1998), inflammation of 
the cecum and colon (typhlocolitis) in these  
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Figure 1. Histopathology of H. hepaticus induced liver disease. (a) Lobular hepatitis with infiltrating 
leukocytes and coagulative necrosis. (b) Portal and interface hepatitis with dilated lymphatics containing 
many mononuclear cells (black arrows); leukocytes surround and infiltrate a reactive bile ductule (white 
arrow). (c) Portal tertiary lymphoid follicle. (d) Dysplastic nodule (arrows). (e) Tigroid cells in focus of 
cellular alteration; note radial subplasmalemmal striations (arrows). (f) Oval cell hyperplasia with 
pseudocholangiole formation (arrow) in dysplastic nodule. (g) F4/80+ macrophages surrounding and 
infiltrating a sheet of hepatocytes undergoing coagulative necrosis. Lobular necroinflammatory focus with 
upregulated expression of (h) iNOS in inflammatory cells and (i) COX-2 in intralesional hepatocytes. Portal 
tertiary lymphoid tissue with (j) CD45R/B220+ follicular B cell aggregates , and (k) individually dispersed 
CD3+ T cells. (l) Intrahepatic lymphoid expansion with abundant Ki-67+ nuclei in portal tertiary lymphoid 
follicle (IHC). H&E (a—f), immunohistochemistry (g—l); bar ~100 µm (a, c, g, j—l), 50 µm (b, h, i), 250 
µm (d), 10 µm (e), 25 µm (f). 
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immunocompetent animals was generally mild, with inflammation scores typically in the range 
of 0.5--1 out of 4. Typhlocolitis was limited to mice infected at or before 3 weeks of age, but was 
not present in all animals, and there were no statistically significant differences between groups. 
Although morphologic changes were mild, microarray experiments have shown that lower bowel 
colonization of A/JCr mice with H. hepaticus induces prominent transcriptional responses 
(Myles et al. 2003). 
 
At 12 months of age, male mice with severe lobular hepatitis exhibited dysplastic and 
proliferative lesions similar to those previously documented (Bannasch et al. 2001; Canella et al. 
1996; Fox et al. 1998b; Fox et al. 1996c; Hailey et al. 1998; Haseman et al. 1998; Rice 1995; 
Ward et al. 1996a; Ward et al. 1996b).  Foci of cellular alteration or dysplastic foci were 
multifocal, and often merged imperceptibly into adjacent zones of more normal hepatocytes. In 
some instances expansile dysplastic nodules were sharply delineated from surrounding less 
affected lobules (Fig. 1d). Inflammation was concentrated at the perimeter of dysplastic nodules. 
Foci of cellular alteration, putative precursors to HCC (Bannasch et al. 1985; Bannasch et al. 
2001) were of the clear cell, eosinophilic, or basophilic-tigroid (Fig. 1e) phenotype, often 
comingled. Hepatocellular atypia was manifest as marked anisocytosis and anisokaryosis, 
structural and tinctorial pleomorphism, irregular cytoplasmic vacuolation and molding, aberrent 
multinucleation, and nuclear clearing with bizarre chromatin patterns. Oval cell hyperplasia, with 
occasional pseudocholangiole formation (Fig. 1f), was common within foci of cellular alteration. 
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Special stains and immunohistochemistry 
 
Confirmation of the primarily granulomatous nature of lobular necroinflammatory lesions was 
provided by F4/80 immunohistochemistry (Fig. 1g). As described in human viral hepatitis, 
activated macrophages containing diastase-resistant PAS-positive material were present in some 
inflammatory lesions (Ferrell 2002).  In contrast, phagocytes with accumulated iron were 
extremely rare. Argyrophilic spiral bacteria, some undergoing longitudinal fission, were readily 
identified in bile canaliculi of Warthin-Starry-stained liver sections near histologically active 
lobular lesions, but were rare near portal tracts. In agreement with PCR results, organisms were 
absent in uninfected mice, and very rarely visualized in Warthin-Starry stained liver sections 
from mice lacking lobular inflammation. Immunohistochemical demonstration of iNOS and 
COX-2 was limited to necroinflammatory lesions; however, the cell populations expressing each 
of these proteins were different. iNOS was demonstrated almost exclusively within inflammatory 
cells (Fig. 1h), while COX-2 was upregulated in intralesional hepatocytes (Fig. 1i). Scattered 
acidophil bodies and some leukocytes, but not sheets of hepatocytes within zones of coagulative 
necrosis, contained cleaved caspase-3.  
 
Morphometric analysis 
 
Observational quantitation of lesions in liver sections proved problematic due to variable 
densities of leukocellular aggregation, and confluence of adjoining inflammatory foci. We 
therefore applied morphometric analysis to 5 affected and 2 control immunohistochemically 
stained livers from the 12-month timepoint in order to determine percent area occupied by 
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specific cell subsets within a defined region of interest (Fox et al. 2003a).  We examined ten left 
lobe fields per mouse under the 10X ocular objective (0.61mm2/field). In mice with lobular 
and/or portal hepatitis (histologic activity ≥2), the median hepatic tissue area comprised of 
leukocyte-common antigen CD45+ white blood cells was 4%. One liver with severe disease 
contained 9% leukocytes, and when leukocytes were combined with zones of coagulative 
necrosis 25% of the most affected lobe was effaced. Portal tertiary lymphoid nodules contained a 
median of 72% CD45+ leukocytes, the remaining tissue being comprised of resident portal 
arterioles, bile ductules, lymphatic channels, and connective tissue (portal venules were excluded 
from the manually defined region of interest). Among the inflammatory cells, 45% displayed the 
B cell marker CD45R/B220 (Fig. 1j), 7% were CD3+ T cells (Fig. 1k), and 3% were identified as 
F4/80+ professional antigen-presenting cells (macrophages ± dendritic cells). Unlabeled portal 
tertiary lymphoid tissue included arterioles and bile ducts as well as presumptive NK cells, 
scattered granulocytes, and other cells unrecognized by our antibody panel. Within tertiary 
lymphoid nodules, B cells were aggregated into follicular structures (Fig. 1j) while T cells (Fig. 
1k) and antigen-presenting cells were more widely dispersed. In portal tracts where bile ducts 
were surrounded and transmigrated by leukocytes, ductular epithelium exhibited  atrophy, 
hypertrophy, and decreased cytokeratin expression. Scattered throughout portal tertiary lymphoid 
tissue, and focally concentrated at the periphery, were many actively proliferating cells attesting 
to intrahepatic lymphoid expansion (Fig. 1l). The Ki-67 labeling index per 10X field was >100 in 
tertiary lymphoid tissue. Increased cell proliferation was also evident in foci of cellular alteration 
and dysplastic nodules, with a Ki-67 labeling index of 7 hepatocyte nuclei per 10X field, versus 
<1 in normal hepatic lobules (P<0.0001). 
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Microarray results overview 
 
Certain clusters of gene expression (Tables I and II), gene categories (Table III), and protein 
domains (Table IV) persisted throughout the 12 month experimental period, while other clusters 
arose at 6 months or at 12 months.  (Gene categories and protein domains are standardized 
vocabulary defined by the Gene Ontology consortium (http://www.geneontology.org)).  A Venn 
diagram (Figure 2) presents this scenario in a simplified form for illustrative purposes.  Tables III 
and IV are color coded to represent the 3 month (red), 6 month (blue), and 12 month (green) time 
points.  Group 1 represents all the genes, gene categories, and protein domains exhibited at 3, 6, 
and 12 months. It contains many signatures of an acute-phase response which persisted over 12 
months.  Group 2 represents most, but not all, of the Group 1 clusters, plus new genes, gene 
categories, and protein domains at 6 months. Group 2 encompasses biological processes of both 
the acute immune response of Group 1, plus a more mature or chronic immune response.  Table 
V and VI lists genes within the Gene Ontology category corresponding to the immune response 
and the pathogen response.  Group 3 again intersects most of Group 1 and Group 2, but new 
entries indicate tubulin, microtubule, cytoskeletal, peroxisome, scavenger, and structural and 
proliferative activity.  Table VII lists specific genes in the Gene Ontology categories of cell 
proliferation, growth, and death. Genes expressed during fetal development or imprinted genes 
are also evident in Group 3.   
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Figure 2. Simplified Venn diagram representation of clusters of hepatic differential gene expression, gene 
categories, and protein domains arising during the course of the H. hepaticus experimental infection of male 
A/JCr mice. Group 1 figuratively represents the acute phase of lobular hepatitis observed histologically 
throughout the course of the experiment due to persistent infection.  Group 2 intersects Group 1 and 
additionally represents the maturation of inflammatory response and the portal hepatitis first recognized at 6 
months which became progressively more severe.  Group 3 intersects Group 1 and Group 2 and additionally 
represents tubulin, microtuble, scavenger, peroxisome, and structural gene categories, plus genes suggestive 
of hepatic pre-neoplasia. 
3 months 6 months 12 months 
 
  Group 1 
Group 2
Group 1 
Group 3
 
Group 2
Group 1 
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Genes up-regulated and down-regulated 
 
Age matched H. hepaticus infected mice with progressive disease, exhibiting altered gene 
expression as defined by dChip software with default settings (Li and Wong 2001), yielded 188 
differentially expressed genes at 3 months, 401 at 6 months, and 678 at 12 months.  Immune 
response genes, including the acute phase response, histocompatibility, macrophage, T and B cell 
development, and complement represented most of the up-regulated genes at 3 months (Table I). 
These genes continued to be up-regulated throughout the 12 month experiment.  The acute phase 
lipocalin family and serum amyloid family are represented in this group.  At 6 months, there was 
a further increase in expression of these genes plus new differential expression levels of genes 
suggestive of further inflammatory response and repair including chemokine ligands (such as 
lymphocyte attracting chemokines Cxcl9 and Cxc13), chemokine receptors of the CC motif, 
ADAM family members, lysozyme, procollagen, cellular retinol binding protein (Lepreux et al. 
2004), and detoxification enzymes.  At 12 months post H hepaticus infection, new genes up-
regulated represented more structurally related genes and more detoxification genes including 
tubulin, growth factors, carriers, and cytochrome P450 genes.  Genes historically linked to 
neoplasia and up-regulated in the 12 month group included H19, intestinal trefoil factor 3, the ras 
family, and Jun-B.  Up-regulated genes predominated over down-regulated genes at all time 
points for H. hepaticus infected A/J mice with hepatic lesions.  Interestingly, the vast majority of 
down-regulated genes were at 12 months (Table II).  Down-regulated genes at 12 months were 
associated with steroid hormones, heme metabolism, and sodium/bile acid co-transport (Fraser et 
al. 2003; Jung et al. 2004).  There was a consistent segregation of the most highly up-regulated 
and select down-regulated genes for H. hepaticus infected mice with lesions.  Genes up-
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regulated or down-regulated at 12 months, along with their corresponding values at 3 and 6 
months are exhibited in Tables I and II, respectively.  
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Table I. Genes with up-regulated transcription in the livers of of H. hepaticus infected male 
A/JCr mice with severe disease versus sham-infected age-matched controls (fold increase). 
 
Gene 3 months  6 months 12 months 
lipocalin 2 7.91 46.72 30.27 
T-cell specific GTPase 9.26 22.37 24.96 
trefoil factor 3, intestinal * 8.4 20.09 
ubiquitin D 1.96 21.04 15.36 
Ia-associated invariant chain 3.18 11.9 15.06 
histocompatibility 2, class II antigen A, 
alpha 3.75 13.98 10.5 
tubulin, beta 2 * * 7.4 
chemokine (C-X-C motif) ligand 13 * 4.61 5.99 
apoptosis inhibitor 6 2.38 4.77 5.99 
glycoprotein 49 A * 3.04 5.69 
cathepsin S 2.35 4.24 5.38 
insulin-like growth factor binding 
protein 1 * * 5.31 
ADP-ribosyltransferase 2a 3.37 5.47 5.07 
chemokine (C-X-C motif) ligand 9 2.16 17.3 5.05 
procollagen, type IV, alpha 1 * 2.08 5.04 
immunoglobulin kappa chain variable 
28 (V28) * * 4.93 
CD53 antigen 1.84 3.82 4.92 
Fc receptor, IgE, high affinity I, gamma 
polypeptide * 5.82 4.79 
phospholipase A2 group VII (platelet-
activating factor acetylhydrolase, 
plasma) 
* 4.02 4.71 
chemokine (C-C) receptor 5 * 5.33 4.7 
complement component 1, q 
subcomponent, beta polypeptide 1.91 4.6 4.69 
proteosome (prosome, macropain) 
subunit, beta type 8 (large 
multifunctional protease 7) 
3.7 5.93 4.59 
complement component 1, q 
subcomponent, alpha polypeptide 1.81 4.33 4.09 
expressed sequence AU046135 * 2.88 3.82 
glycoprotein 49 B * * 3.81 
lysozyme * 5.82 3.79 
leukocyte specific transcript 1 1.68 4.54 3.78 
complement component 1, q 
subcomponent, c polypeptide 1.79 4.15 3.71 
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Table 1 (continued) 
Gene 3 months  6 months 12 months 
cytochrome P450, 2b9, phenobarbitol 
inducible, type a * * 3.62 
serum amyloid A 3 2.21 15.37 3.6 
H19 fetal liver mRNA * * 3.56 
proteoglycan, secretory granule * 3.02 3.52 
protein tyrosine phosphatase, non-
receptor type substrate 1 * 3.43 3.51 
cytochrome P450, 2b13, phenobarbitol 
inducible, type c * * 3.46 
serum amyloid A 2 5.14 2.22 3.29 
ESTs, Moderately similar to  
hypothetical protein FLJ11127 (Homo 
sapiens) (H.sapiens) 
* 3.54 3.28 
Mus musculus, Similar to hypothetical 
protein FLJ20509, clone 
IMAGE:3489119, mRNA, partial cds 
* * 3.27 
ESTs, Weakly similar to  RIKEN 
cDNA 0610011E17 (Mus musculus) 
(M.musulus) 
* * 3.21 
histocompatibility 2, T region locus 17 2.11 2.85 3.19 
CD52 antigen 2 4.71 3.17 
lectin, galactose binding, soluble 3 * 5.28 3.14 
TAP binding protein 1.64 3.42 3.14 
signal transducer and activator of 
transcription 1 2.57 5.75 3.11 
proteosome (prosome, macropain) 
subunit, beta type 9 (large 
multifunctional protease 2) 
3.77 6.28 3.1 
chemokine (C-X-C motif) ligand 1 * 4 3.1 
Cluster Incl M17790:Serum amyloid A 
pseudogene /cds=(0,251) /gb=M17790 
/gi=200920 /ug=Mm.56949 /len=252  
4.22 13.87 3.06 
macrophage receptor with collagenous 
structure 6.49 * 3 
C-type (calcium dependent, 
carbohydrate recognition domain) 
lectin, superfamily member 13 
1.43 * 2.99 
RIKEN cDNA 2310057H16 gene * * 2.96 
lymphocyte antigen 6 complex, locus A 6.45 5.38 2.95 
histocompatibility 2, T region locus 10 2.14 2.99 2.95 
guanylate nucleotide binding protein 2 2.55 7.62 2.91 
expressed sequence AI854770 1.7 2.28 2.9 
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Gene 3 months  6 months 12 months 
macrophage expressed gene 1 2.45 3.79 2.84 
ADAM-like, decysin 1 * 2.11 2.83 
interferon gamma inducible protein, 47 
kDa 1.83 2.92 2.81 
retinol binding protein 1, cellular * 2.74 2.8 
hydroxyacid oxidase (glycolate 
oxidase) 3 * * 2.72 
expressed sequence AW112010 2.02 2.84 2.68 
tubulin, beta 3 * * 2.68 
tubulin, beta 5 * * 2.67 
CREBBP/EP300 inhibitory protein 1 * 2.24 2.63 
retinoic acid early transcript gamma * 1.69 2.63 
carbon catabolite repression 4 homolog 
(S. cerevisiae) * 2.03 2.6 
paired-Ig-like receptor A1 * 3.24 2.6 
vascular cell adhesion molecule 1 4.06 4.64 2.59 
histocompatibility 2, class II, locus 
Mb1 2.95 5.94 2.59 
histocompatibility 2, class II antigen E 
beta 2.44 5.06 2.53 
transporter 2, ATP-binding cassette, 
sub-family B (MDR/TAP) 1.76 3.1 2.52 
orosomucoid 2 * 1.94 2.52 
protamine 2 2.08 * 2.52 
solute carrier family 4 (anion 
exchanger), member 4 * * 2.49 
glutathione S-transferase, mu 2 * 2.3 2.48 
cystatin B * 2.96 2.48 
 Cluster Incl U38967:Prothymosin beta 1.56 2.88 2.48 
reticulon 4 1.9 2.88 2.48 
cytochrome b-245, alpha polypeptide 1.53 3.04 2.47 
lipoprotein lipase * * 2.44 
intercellular adhesion molecule * 2.19 2.44 
IQ motif containing GTPase activating 
protein 1 * 2.11 2.42 
amyloid beta (A4) precursor protein-
binding, family B, member 1 
interacting protein 
* 2.52 2.4 
lymphocyte antigen 6 complex, locus E 2.01 2.92 2.36 
myristoylated alanine rich protein 
kinase C substrate * 1.91 2.34 
 
Table 1 (continued) 
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Table 1 (continued) 
Gene 3 months  6 months 12 months 
histocompatibility 2, D region locus 1 1.73 2.64 2.31 
fibrinogen-like protein 2 2.21 4.3 2.31 
lipoprotein lipase * * 2.31 
intracisternal A particles * 1.95 2.3 
TAP binding protein 1.64 3.42 2.3 
MARCKS-like protein * 1.96 2.28 
lipopolysaccharide binding protein 1.71 2 2.27 
circadian locomoter output cycles 
kaput * * 2.27 
eukaryotic translation initiation factor 
1A * * 2.26 
interferon gamma induced GTPase 2.86 3.97 2.26 
mitogen activated protein kinase kinase 
kinase 1 * * 2.24 
ribosomal protein L7 * * 2.23 
secreted phosphoprotein 1 * * 2.21 
chloride intracellular channel 1 * 2.56 2.2 
decorin * * 2.17 
annexin A1 * 1.98 2.16 
expressed sequence AW547365 * * 2.16 
transporter 1, ATP-binding cassette, 
sub-family B (MDR/TAP) 1.84 2.99 2.15 
long chain fatty acyl elongase -1.46 * 2.14 
acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member A * * 2.14 
lymphocyte antigen 86 1.58 2.39 2.13 
CD9 antigen * 1.93 2.12 
ADP-ribosylation-like factor 6 
interacting protein 5 * * 2.1 
polymerase (DNA directed), gamma * * 2.1 
hypothetical protein MGC47434 * * 2.08 
properdin factor, complement 1.42 2.92 2.07 
B-cell translocation gene 1, anti-
proliferative * * 2.06 
erythroid differentiation regulator * * 2.06 
tubulin, alpha 6 * * 2.06 
annexin A5 * 2.39 2.03 
guanylate nucleotide binding protein 3 3.03 6.67 2.03 
chemokine (C-X-C motif) ligand 1 * 4 2.02 
flavin containing monooxygenase 3 * * 2 
dystroglycan 1 * * 2 
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Table II. Genes with down-regulated transcription in the livers of of H. hepaticus infected male 
A/JCr mice with severe disease versus sham-infected controls (fold decrease). 
 
Gene 3 months  6 months 12 months
hydroxysteroid dehydrogenase-5, delta<5>-3-beta -3.32 -13.47 -28 
aminolevulinic acid synthase 1 * * -5.45 
D site albumin promoter binding protein * * -5.37 
cytochrome P450, 7b1 * -2.09 -4.68 
thyroid hormone responsive SPOT14 homolog (Rattus) * * -3.94 
metallothionein 1 +4.3 +2.14 -3.59 
kidney expressed gene 1 * * -3.57 
cytochrome P450, 7b1 * * -3.36 
RIKEN cDNA 2410041F14 gene * * -2.99 
epidermal growth factor receptor * * -2.97 
expressed sequence AI467657 * * -2.88 
G0/G1 switch gene 2 * * -2.83 
homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 * * -2.78 
sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-
sialyltransferase) +2.24 * -2.78 
Cluster Incl V00722:Mouse gene for beta-1-globin  * * -2.65 
sulfotransferase-related protein SULT-X1 * * -2.64 
eleven-nineteen lysine-rich leukemia gene * -1.94 -2.58 
ubiquitin specific protease 2 * * -2.56 
serine (or cysteine) proteinase inhibitor, clade E, member 2 * * -2.53 
expressed sequence AI266885 +1.51   -2.5 
period homolog 2 (Drosophila) * * -2.39 
solute carrier family 10 (sodium/bile acid cotransporter family), 
member 1 * * -2.36 
MAP kinase-interacting serine/threonine kinase 2 * * -2.35 
glucose-6-phosphatase, transport protein 1 * * -2.24 
expressed sequence C77405 * * -2.24 
amiloride-sensitive sodium channel * * -2.23 
hemoglobin, beta adult major chain * * -2.21 
angiopoietin-like 4 * * -2.19 
pre-B-cell colony-enhancing factor +1.51 +1.58 -2.18 
P450 (cytochrome) oxidoreductase * * -2.17 
peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase * -1.61 -2.14 
DnaJ (Hsp40) homolog, subfamily A, member 1 * * -2.11 
epidermal growth factor receptor * * -2.1 
BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 * * -2.03 
elastase 1, pancreatic -1.43 -1.85 -2.01 
colony stimulating factor 2 receptor, beta 1, low-affinity 
(granulocyte-macrophage) * * -2.01 
interleukin 1 receptor, type I +1.82 * -2 
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Gene ontology clusters 
 
Gene ontology (www.geneontology.org) describes gene products in three structured controlled 
vocabularies related to biological process, cellular components, and molecular functions.  
Microarray analysis generated multiple biological process ontology clusters for hepatic lesions of 
H. hepaticus infected A/JCr mice at all three time points (Table III).  There were several 
biological processes involved over the entire 12 month time period pertaining to an active 
infection including gene products associated with the defense response, immune response, acute 
phase response, antigen presentation and processing, MHC receptor activity, lysosomes, and 
others represented in red print in Table III. At 6 months post H. hepaticus infection, the 3 month 
inflammatory biological processes were maintained and a chemokine activity cluster was added.   
Gene products associated with electron transport and lipid transport demonstrated increased 
activity (Table III, blue print).  At 12 months, new clusters of biological processes indicated gene 
products involved with structural change, increased signal transduction, and peroxisome 
organization (Table III, green print).   
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Table III: Gene Ontology Clusters 
 
Gene Categories at 3, 6, 12 months  
 
Endoplasmic reticulum (3,6,12) 
Cytosol (3,6,12) 
Defense response (3,6,12) 
Acute-phase response (3,6,12) 
Immune response (3,6,12) 
Cell surface (3,6,12) 
Membrane (3,6,12) 
Integral to membrane (3,6,12) 
Antigen presentation, endogenous antigen (3,6,12) 
Antigen presentation, exogenous antigen (3,6,12) 
Antigen processing, endogenous antigen via MHC 
 class I (3,6,12) 
Antigen processing, exogenous antigen via MHC 
 class II (3,6,12) 
MHC Class I receptor activity (3,6,12) 
MHC class II receptor activity (3,6,12) 
Extracellular space (3,6,12) 
Lysosome (3,6,12) 
Plasma membrane (3,6,12)  
Monooxygenase activity (3,6,12) 
Oxidoreductase activity (3,6,12) 
Complement activation (3,6) 
External side of plasma membrane (3,6) 
Antigen presentation, exogenous antigen via  
MHC class II (3,6) 
Complement activation /classical pathway (3,6) 
Peptidase activity (3,6) 
Mitochondrion (3,12) 
GTPase (3) 
Microsome (3) 
Chemokine activity (6,12) 
Electron transport (6,12) 
Integral to plasma membrane (6,12) 
Lipid transporter activity (6,12) 
Inflammatory response (6) 
Extracellular (6) 
Catalytic activity (6) 
GTPase activity (12) 
GTP binding (12) 
Microtubule (12) 
Carboxylic ester hydrolase activity (12) 
Microtubule-based process (12) 
Microtubule-based movement (12) 
Serine esterase activity (12) 
Peroxisome organization and biogenesis (12) 
Scavenger receptor activity (12) 
Structural molecule activity (12) 
Structural constituent of cytoskeleton (12) 
Signal transduction (12) 
Transporter activity (12) 
Structural constituent of ribosome (12)
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Protein domain clusters 
 
Protein domain clusters produced via microarray analysis indicated regulatory proteins and 
systems involved during H. hepaticus pathogenesis (Table IV).  These domains often mediate 
interactions of regulatory protein construction or have enzymatic activity (Pawson and Nash 
2003).  As with the gene ontology clusters, some protein domain clusters were involved 
throughout the 12 month experimental period and were immunoglobulin related (Table IV, red 
print).  The immunoglobulin C-type protein domain involvement began at 6 months, as did 
chemokine and serum amyloid protein interactions (Table IV, green print).  At 12 months, 
structural activity promoted by tubulin domains was evident (Table IV, blue print). 
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Table IV: Protein Domain Clusters 
 
Protein Domains 
 
ATP/GTP-binding site motif A (P-loop) (3,6,12) 
Immunoglobulin/major histocompatibility complex (3,6,12) 
Immunoglobulin-like (3,6,12) 
Serum Amyloid A protein (6) 
 
Small chemokine, interleukin 8 like (6) 
 
Immunoglobulin, C-type (6,12) 
 
Small chemokine, C-X-C subfamily (6,12) 
 
Tubulin family (12) 
Tyrosine protein kinase, active site (12) 
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Immune response gene expression 
 
The individual genes members of the immune response biological process and their differential 
response at 3, 6, and 12 months are presented in Table V.  Four hundred sixteen genes are 
members of this gene ontology biological process category.  Table V genes include individual 
histocompatibility, chemokine, serum amyloid, and complement, and confirm the gene category 
clusters and protein domain clusters results. 
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Table V. Gene Ontology category: Immune Response. Genes with up-regulated transcription in 
the livers of of H. hepaticus infected male A/JCr mice with severe disease versus sham-infected 
age-matched controls (fold increase). 
 
Symbol Gene 3 months 
6 
months 12 months
Ii Ia-associated invariant chain 3.18 11.9 15.06 
H2-Aa histocompatibility 2, class II antigen A, alpha 3.75 13.98 10.5 
Cxcl13 chemokine (C-X-C motif) ligand 13 * 4.61 5.99 
Cxcl9 chemokine (C-X-C motif) ligand 9 2.16 17.3 5.05 
Igk-V8 immunoglobulin kappa chain variable 8 (V8) * * 4.93 
Pla2g7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) * 4.02 4.71 
C1qb complement component 1, q subcomponent, beta polypeptide 1.91 4.6 4.69 
Psmb8 proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional protease 7) 3.7 5.93 4.59 
C1qa complement component 1, q subcomponent, alpha polypeptide 1.81 4.33 4.1 
C1qg complement component 1, q subcomponent, gamma polypeptide 1.79 4.15 3.71 
Saa3 serum amyloid A 3 2.21 15.37 3.6 
Saa2 serum amyloid A 2 5.14 12.87 3.29 
Cxcl1 chemokine (C-X-C motif) ligand 1 * 4 3.1 
Psmb9 proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2) 3.77 6.28 3.1 
H2-T10 histocompatibility 2, T region locus 10 2.14 2.99 2.95 
Gbp2 guanylate nucleotide binding protein 2 2.55 7.62 2.91 
H2-DMb1 histocompatibility 2, class II, locus Mb1 2.95 5.94 2.59 
H2-Eb1 histocompatibility 2, class II antigen E beta 2.44 5.06 2.53 
Tap2 transporter 2, ATP-binding cassette, sub-family 
B (MDR/TAP) 
1.76 3.1 2.53 
Orm2 orosomucoid 2 * 2.92 2.52 
H2-D1 histocompatibility 2, D region locus 1 1.73 2.64 2.3 
Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.84 2.99 2.16 
Ly86 lymphocyte antigen 86 1.58 2.39 2.13 
Pfc properdin factor, complement 1.42 2.92 2.07 
Il1rn interleukin 1 receptor antagonist * * 2.05 
Gbp3 guanylate nucleotide binding protein 3 3.03 6.67 2.03 
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Pathogen response gene expression 
 
The Gene Ontology pathogen response biological process category consists of 241 genes and is a 
sub-category of the immune response.  The individual genes and their differential response at 3, 
6, and 12 months are presented in Table VI.  This pattern of individual chemokine, 
immunoglobulin, acute phase, and complement genes change expression putatively due to H. 
hepaticus infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  132
Table VI. Gene Ontology category: Pathogen Response. Genes with up and down regulated 
transcription in the livers of of H. hepaticus infected male A/JCr mice with severe disease versus 
sham-infected controls (fold increase/decrease). 
 
 
 Symbol Gene 3 months 6 months 12 months 
Cxcl13 chemokine (C-X-C motif) ligand 13 * 4.61 5.99 
Cxcl9 chemokine (C-X-C motif) ligand 9 2.16 17.3 5.05 
Igk-V8 immunoglobulin kappa chain variable 8 (V8) * * 4.93 
Pla2g7 
phospholipase A2, group VII 
(platelet-activating factor 
acetylhydrolase, plasma) 
* 4.02 4.71 
C1qb complement component 1, q subcomponent, beta polypeptide 1.91 4.6 4.69 
C1qa complement component 1, q subcomponent, alpha polypeptide 1.81 4.33 4.1 
C1qg 
complement component 1, q 
subcomponent, gamma 
polypeptide 
1.79 4.15 3.71 
Saa3 serum amyloid A 3 2.21 15.37 3.6 
Saa2 serum amyloid A 2 5.14 12.87 3.29 
Cxcl1 chemokine (C-X-C motif) ligand 1 * 4 3.1 
Orm2 orosomucoid 2 * 2.92 2.52 
Ly86 lymphocyte antigen 86 1.58 2.39 2.13 
     
Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 * * -2.11 
Herpud1 
homocysteine-inducible, 
endoplasmic reticulum stress-
inducible, ubiquitin-like domain 
member 1 
* * -2.78 
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Cell proliferation, growth, and death 
 
Gene ontology categories suggestive of pre-neoplasia were investigated and included cell 
proliferation, cell growth, and cell death (Table VII).  Some of the genes, as would be expected, 
suggest inflammatory cell turnover.  Other genes do not necessarily fit into the inflammatory 
category including two oncogenes, the Kirsten rat sarcoma oncogene 2 (K-ras) and the Jun-B 
oncogene, that were slightly up-regulated 12 months post infection.   
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Table VII. Gene Ontology category: Cell Proliferation, Growth, and Death. Genes with up and 
down regulated transcription in the livers of of H. hepaticus infected male A/JCr mice with 
severe disease versus sham-infected controls (fold increase/decrease). 
 
 
 Symbol Gene 3 months 6 months 12 months
Cxcl1 chemokine (C-X-C motif) ligand 1 * 4 3.1 
Tgfa transforming growth factor alpha * * 2.9 
Prm2 protamine 2 2.08 -1.62 2.52 
Polg polymerase (DNA directed), gamma * * 2.1 
Btg1 B-cell translocation gene 1, anti-proliferative * * 2.06 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 2.95 2.96 1.95 
Nfkbia 
nuclear factor of kappa light 
chain gene enhancer in B-
cells inhibitor, alpha 
* 1.39 1.92 
Ahr aryl-hydrocarbon receptor * * 1.9 
Kras2 Kirsten rat sarcoma oncogene 2, expressed * * 1.69 
Macf1 microtubule-actin crosslinking factor 1 * * 1.54 
Ccnd1 cyclin D1 1.69 3.21 1.53 
Ifnar2 interferon (alpha and beta) receptor 2 * * 1.51 
Gas2 growth arrest specific 2 * * 1.46 
Stat6 signal transducer and activator of transcription 6 * * 1.44 
Junb Jun-B oncogene * * 1.3 
          
Cul4a cullin 4A * * -1.42 
Gspt2 G1 to phase transition 2 * * -1.45 
Nfix nuclear factor I/X * * -1.62 
Ches1 checkpoint suppressor 1 * * -1.67 
Fgf1 fibroblast growth factor 1 * -1.71 -1.71 
G0s2 G0/G1 switch gene 2 * * -2.83 
Egfr epidermal growth factor receptor * * -2.97 
     
*  No Differential Expression     
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Microarray Model Validation 
 
Microarray results were tightly correlated  (r>0.99 for controls and r>0.97 for mice with lesions) 
between biological replicates (individual mouse liver per array) (Figure. 3A). There was a 
moderate correlation between infected male mice that did not develop significant disease and 
uninfected controls (Figure 3C). In contrast, the correlation lessened substantially (r<0.79) 
between infected mice that developed severe disease and uninfected controls (Figure.3D).  These 
results confirm that histologic assessment of lesion severity is reflected by global gene 
expression profile alterations, represented by all the genes not on the linear scatterplot as seen in 
Figure 3D.  These genes have differential expression as compared to the controls in Figure 3A.  
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Figure 2
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scatterplots highlighting variable degrees of correlation between microarray results from 
different groups of male A/JCr mice at 12 months. (a) High correlation between biological replicates 
(r>0.99). (b) H. hepaticus-infected mice that did not develop disease are better correlated with sham-
infected controls (r>0.97) (c) than with infected diseased mice. (d). Marked discorrelation between 
infected mice with disease and sham-infected controls (r<0.79) 
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Differential gene expression for aging 
 
The experimental design enabled comparisons of transcription profiles due to aging.  Aging 
control mice yielded 402 differentially expressed genes at 6 months versus 3 months, 675 at 12 
months versus 3 months, and 437 at 12 months versus 6 months.  Although a large number of 
genes were associated with aging, the magnitude of hepatic expression differences was small (–6 
to +10).  Additional aging results are presented under linear discriminant analysis and principal 
component analysis. 
  
Hierarchical clustering  
 
Hierarchical clustering allowed age-matched A/JCr mice pairs with lesions to be differentiated 
from controls.  The dChip option of combined hierarchical clustering of mouse microarray 
samples and genes produced very similar ‘heatmap’ patterns between mouse microarray sample 
pairs within 6 groups, with each group displaying a different pattern (Figure 4).  The increasing 
intensity of red (green) in the heatmap indicates an increasing (decreasing) expression level.  The 
mice groups are labeled at the top of each column of the heatmap and consisted of the following 
pairs of arrays: (1) 3 month controls (3u1, 3u2) (u: uninfected) (2) 6 month controls (6u1, 6u2) 
(3) 12 month controls (12u1, 12u2) (4) 3 month H. hepaticus infected A/J mice with lesions 
(3L1, 3L2) (L: lesions)  (5) 6 month H. hepaticus infected A/J mice with lesions (6L1, 6L2) (6) 
12 month H. hepaticus infected A/J mice with lesions (12L1, 12L2) (Figure 4).   
 
  138
Legend:
12L1 and 12L2: A/JCr mice 12 month 
post Helicobacter hepaticus infection 
with hepatic lesions.
12u1 and 12u2: 12 months uninfected
6L1 and 6L2: 6 months post H. 
hepaticus infection with lesions.
6u1 and 6u2: 6 months uninfected
3L1 and 3L2: 3 months post H. 
hepaticus infection with lesions.
3u1 and 3u2: 3 months uninfected
Figure 3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Hierarchical clustering and two dimensional dendrogram. Columns represent individual A/JCr 
mice and rows represent genes.  Every 2 columns represent the same group with a total of 6 groups.  Columns 
exhibiting similar patterns are representative of groups of mice based on age and lesion status.  The A/JCr 
mice illustrated are H. hepaticus infected with lesions and age matched uninfected controls. 
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Linear discriminant analysis and principal component analysis 
 
Linear discriminant analysis also differentiated between controls and H. hepaticus infected A/J 
mice with hepatic lesions (Figure 5).  The control mice and the mice with hepatic lesions 
occupied opposite sides of the plot.  Principal component analysis provided even more powerful 
classification of A/JCr mice groups.  This algorithm produced regions of different ages for 
controls and for age groups of H. hepaticus infected A/J mice with lesions (Figure 6).  However, 
these clear demarcations occurred only when the analysis omitted the transcription profile data 
for infected mice without lesions. Therefore, the LDA and PCA did not clearly differentiate the 
infection status of the mice when the livers were histologically normal at 3 and 6 months, but did 
indicate differences at 12 months post infection (data not shown).  
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Controls Lesions
3 month with lesions
6 month with lesions
12 month with lesions
12 month controls
6 month controls
3 month controls
 
 
 
 
 
 
 
Figure 5.  Linear discriminant analysis demonstrating differentiation of the 6 groups by 
lesion status.  Each box represents an A/JCr mouse.  Note the mice on different sides of 
the plot. The A/JCr mice illustrated are H. hepaticus infected with lesions and age 
matched controls. 
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12 month controls
3 month controls
6 month controls
3 month with lesions
6 month with lesions
12 month with lesions
 
 
 
 
 
 
Figure 6.  Principal component analysis demonstrating differentiation of the groups by age 
and lesion status.  Each box represents an A/JCr mouse.  Note the mice are clustered in 
separate regions.  The A/JCr mice illustrated are H. hepaticus infected with lesions and age 
matched controls. 
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Microarray result verification by quantitative real time RT-PCR  
 
The Assay on Demand results validated the Affymetrix microarray values except for 2 data 
points where fold changes were less than 2 for both methods (Figure 7). 
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Microarray -1.28 3.14 -23.25 11.58 16.28 6.53 2.05
Cyp4a14 H19 Hsd3b5 Ubd Tff3 Api6 Igtp
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Microarray (Affymetrix) result validation with RT-PCR (Assay on Demand). Rank 
invariant normalization to a baseline microarray was used for the microarray results (dChip). 
Normalization to GAPDH is used for the quantitative real time RT-PCR. 
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Discussion 
 
Microarray analysis of the livers of H. hepaticus infected A/JCr mice demonstrated reproducible 
changes in global transcription profiles at 3, 6, and 12 months that were indicative of the 
progressive liver disease illustrated by histopathology.  The progressive severity of hepatitis and 
dysplasia in infected mice was associated with an increasing number of differentially expressed 
genes and a specific transcription profile. The gene expression signature of age matched controls 
and age matched infected mice with lesions could be differentiated from each other utilizing 
hierarchical clustering and principal component analysis.  Whether the hepatic transcription 
profile can be used to identify the age at infection, the time post-infection, and the temporal 
course of the molecular pathogenesis will require additional study.  The gene expression 
signature complements histopathology and PCR techniques and aids in diagnosis and prognosis 
for this experimental infection.  Whether another strain of H. hepaticus, a different liver 
pathogen, or other liver insult yields a unique gene expression signature over time in various 
strains of mice is under investigation.  Recent studies indicate a specific gene signature for 
virally induced HCC (Iizuka et al. 2004).  Many of the same differentially expressed genes in 
mice infected with H. hepaticus have also been documented in other models of murine hepatic 
injury and hepatic tumor promotion (Graveel et al. 2001; Meyer et al. 2003; Nyska et al. 1997) . 
Some studies suggest the transcription profile of a small set of highly up-regulated or down-
regulated genes are indicative of a particular disease while other studies indicate even very 
modest changes in a larger set of genes and pathways are suggestive of a specific disease 
(Etzioni et al. 2003; Mootha et al. 2003a).   
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Genes associated with neoplasia and proliferation 
 
Two putative tumor markers, H19 fetal liver mRNA and intestinal trefoil factor 3 (Table I), were 
increasingly up-regulated over time in mice with progressive hepatocellular dysplasia.  The 
product of the H19 gene is considered a non-messenger polyadenylated RNA molecule (Brannan 
et al. 1990).  H19 has putative regulatory roles in normal development, hepatocyte proliferation, 
and in oncogenesis (Kaplan et al. 2003; Yamamoto et al. 2004).  H19 shares the non-protein 
coding property with a rapidly growing number of novel transcripts, and recent experiments 
indicate that as much as an order of magnitude more chromosomal DNA is transcribed than 
accounted for by currently predicted and characterized exons (Kapranov et al. 2002).  H19 is an 
imprinted gene with maternal allele expression. Loss of imprinting is a recognized human cancer 
risk, including genes H19, insulin-like growth factor 2 (Igf2), and cyclin dependent kinase 
inhibitor 1C (p57, KIP, CDK1NC) (Brannan and Bartolomei 1999; Kaplan et al. 2003; Vernucci 
et al. 2000). H19 and Igf2 are reciprocally imprinted, with Igf2 being expressed from the 
paternal allele (Vernucci et al. 2000).  Igf2 is an anti-apoptotic factor associated with 
hepatocarcinogenesis, and is putatively activated and regulated by H19 (Vernucci et al. 2000). 
Although Igf2 up-regulation was not observed at 12 months by microarray analysis, there was 
nearly 2-fold down-regulation of the Igf2 receptor (Table II), and an inverse relationship has 
been observed between epidermal growth factor and its cognate receptor in mice infected with H. 
hepaticus (Ramljak et al. 1998). Insulin-like growth factor 1 (Igf1) is an acute phase protein that 
is decreased in plasma serum levels during systemic responses to inflammation (Gabay and 
Kushner 1999).  Insulin-like growth factor binding protein 1 (Igfbp1) (Table I) was highly up-
regulated in H. hepaticus infected A/JCr mice at 12 months with liver lesions and foci of altered 
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hepatocytes.  Igfbp1 binds both Igf1 and Igf2 with high affinity.  Igfbp1 putatively functions as a 
critical survival factor in the liver by suppressing the level and activation of specific proapoptotic 
factors via its regulation of integrin-mediated signaling (Leu et al. 2003).  Igf1 is important in 
fetal growth and development (along with Igf2, the imprinted gene described above). Igf1 is 
expressed predominantly in the liver, and targeted gene knockout results in embryonic lethality 
in mice (Le Roith et al. 1999; Scharf et al. 2001; Yakar et al. 1999).  Intestinal trefoil factor 3 is 
associated with enterohepatic inflammation, gastric cancer, colon cancer, pancreatic cancer, and 
breast cancer (Al-azzeh et al. 2002; Katoh 2003; Khan et al. 2003; Kimura et al. 2002; Leung et 
al. 2002; Rodrigues et al. 2003).  This factor promotes epithelial cell migration and mucosal 
restitution during inflammation, and is differentially expressed in primary biliary cirrhosis 
(Kimura et al. 2002).   
 
Cyclin D1 is overexpressed in many human and murine tumors (Hinds et al. 1994; Hinds and 
Weinberg 1994; Parker et al. 2003).  Cyclin D1 (Ccnd1) affects G1 and was slightly up-
regulated. Cyclin-dependent kinase inhibitor 1A (p21) (Cdkn1a) was also slightly up-regulated 
(Table VII).  It maintains the G2 checkpoint and, after DNA damage, can arrest cells in G2.  
Cytolethal distending toxin (CDT) in several Helicobacter spp. including H. hepaticus causes 
cell cycle arrest in the G2/M phase resulting in cell distension in selected cell culture lines 
(Taylor et al. 2003; Young et al. 2000).  An isogenic mutant of H. hepaticus lacking CDT 
activity when inoculated into C57BL/6 IL-10-/- produced less inflammatory bowel disease (IBD) 
when compared to its wild type counter part (Young et al. 2004).   In another isogenic CDT 
mutant study, wild type Campylobacter jejeuni infected NF-κB deficient mice exhibited a 
moderately severe gastritis and proximal duodenitis at 4 months post infection while C. jejeuni 
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CDT mutant infected NF-κB deficient mice were consistently cleared of C. jejeuni at 4 months 
post infection. These results suggest CDT plays a role in inflammation and potentially 
participates in avoiding the immune response (Fox et al. 2004).   
 
In addition to CDT’s possible role in inflammation, dChip analysis indicates cytoskeletal 
organization effects by H. hepaticus, possibly in part due to CDT activity in the liver.  Protein 
domain clusters associated with tubulin (Table III) and gene category clusters associated with 
structural constituents of the cytoskeleton, structural molecule movement, and microtubules are 
evident at 12 months (Table IV).  CDT reportedly damages DNA via its CdtB subunit, a 
homologue of mammalian type I Dnase.  CDT has putative nuclear localization signals and may 
induce apoptosis through activation of caspase 2 and caspase 7 (Lara-Tejero and Galan 2000; 
McSweeney and Dreyfus 2004; Ohara et al. 2004). Caspase 3 and caspase 2 were slightly 
upregulated in this study, but caspase 7 was not. 
 
Two oncogenes, K-ras and Jun-B, were slightly upregulated at 12 months post H. hepaticus 
infection.  The ras family, K-ras, N-ras, and H-ras are guanine nucleotide binding proteins 
involved in cell proliferation, differentiation, and survival (Chan et al. 2004).  K-ras mediates 
cytokine signaling in formation of E-cadherin based adherens junctions in hepatocyte 
development(Matsui et al. 2002). Jun-B suppresses cell proliferation through its inhibition of 
activation protein transcription factor (AP-1), however overexpression of Jun-B putatively 
perpetuates undifferentiated cancers (Song et al. 2004).  LPS from gram negative bacteria 
induces AP-1, but there was no differential expression of any of the sub-units of the AP-1 
complex in this study.  Mutations and increased expression in these genes have been reported in 
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myeloproliferative disease, colon cancer, breast cancer, prostate cancer, and metastases to the 
liver (Chan et al. 2004; Edwards et al. 2003; Frasor et al. 2003; Matsui et al. 2002; Palmer et al. 
2003; Selvamurugan et al. 2004; Song et al. 2004).  Although K-ras mutations have been 
reported in chemically induced hepatocellular carcinoma in the A/J mouse (Bai et al. 2003), K-
ras, H-ras, and N-ras mutations have not been reported in A/J mice infected with H. hepaticus 
(Diwan et al. 1997; Sipowicz et al. 1997b).  These data, indicating that H. hepaticus is non-
genotoxic, are further documentation that H. hepaticus is acting as a tumor promoter.   
 
Genes associated with inflammation 
 
Chronic inflammation is a risk factor for cancer, and acute-phase proteins indicative of ongoing 
inflammation persisted at high levels over time in H. hepaticus -infected male mice with 
progressive disease (Gabay and Kushner 1999; Rogers and Fox 2004). One acute-phase protein, 
lipocalin 2 (Table I), was prominently up-regulated in the liver as a result of H. hepaticus 
infection.  Lipocalin 2 is highly expressed in hepatocellular carcinoma via genotoxic or 
peroxisomal mechanisms (Meyer et al. 2003) and the lipocalin family is expressed in other forms 
of cancer including pancreatic, colorectal, and ovarian (Bartsch and Tschesche 1995; Bratt 2000; 
Furutani et al. 1998; Nielsen et al. 1996). Lipocalin 2 (Lpn2, uterocalin, 24p3, NGAL, SIP24) 
was discovered as a secreted, inducible protein from BALB/c 3T3 cells (Nilsen-Hamilton et al. 
1982) and later identified as a product of mouse 24p3 mRNA and as an acute-phase protein (Liu 
and Nilsen-Hamilton 1995). Lipocalin 2 in the Gene Ontology system is considered a 
transporter.  Reported roles of lipocalin 2 include mucosal immunity, epithelial development in 
the kidney, signaling, transport of non-transferrin-bound iron, chaperoning, apoptosis, retinol 
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transport, prostaglandin synthesis, and male scent expression (Cavaggioni and Mucignat-Caretta 
2000; Devireddy et al. 2001; Tong et al. 2003; Xu and Venge 2000; Yang et al. 2003). Other 
lipocalins, up-regulated in this study include orosomucoid and retinol-binding protein.  Other 
acute-phase proteins were up-regulated in H. hepaticus infected male A/JCr mice with severe 
disease. For example, serum amyloid A (Tables IV and V) is a hallmark indicator of active 
inflammation, and putatively activates neutrophils in addition to direct antimicrobial properties 
(Hatanaka et al. 2003; Ribeiro et al. 2003).  Also up-regulated was properdin factor (Table V), a 
member of the alternative complement pathway of the innate immune system which binds to 
microbial surfaces. Ceruloplasmin, a plasma metalloprotein, binds copper and is involved in 
transferrin peroxidation. Haptoglobin protects against microbial growth by binding hemoglobin 
and preventing microbial access to iron (Eaton et al. 1982). Hemopexin binds heme and 
transports it to the liver for iron recovery.  
 
Genes associated with Cytochrome P450 
 
As seen in other rodent and human studies of hepatic injury, H. hepaticus infection in male 
A/JCr resulted in altered expression of several members of the cytochrome P450 (CYP) family. 
At 3 months, CYP2c37, 4a10, and 4a14 were down-regulated (Table II) while CYP2b10 was up-
regulated (Table I). At 6 months, CYP2c37, 4a10, 4a14, 51, and 7b1 were down-regulated (Table 
II). At 12 months, the previously listed group remained down-regulated (Table II) while 
CYP2b9, 2b10, and 2b13 were up-regulated (Table I). Phenobarbital also up-regulates Cyp2b10 
(Rivera-Rivera et al. 2003; Yoshinari et al. 2003).  Phenobarbital promotes hepatic tumors 
initiated by compounds such as N-nitrosodiethylamine (NDMA) (Thirunavukkarasu and 
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Sakthisekaran 2003). These data are consistent with the hypothesis that H. hepaticus is a tumor 
promoter in the mouse liver initiated by NDMA (Diwan et al. 1997; Sipowicz et al. 1997b). 
Members of the cytochrome P450 family are integral to detoxification, and play key roles in 
steroid, lipid, and bile acid metabolism. Reactive oxygen species are postulated to contribute to 
DNA damage and tumorigenesis, and electrophilic cytochrome P450 molecules are a major 
source of these highly reactive radicals (Bondy and Naderi 1994). Oxidative DNA damage 
including increased 8-hydroxydeoxyguanosine adducts have been reported in H. hepaticus 
infected A/JCr mice, along with alterations in glutathione S-transferase and CYP2a5 (Chomarat 
et al. 1997; Sipowicz et al. 1997a).  It has been noted, however, that CYP2a5 induction may not 
be dependent on oxidative damage alone given reactive oxygen species are also produced in liver 
injury caused by LPS which results in CYP2a5 down-regulation (Bautista and Spitzer 1990).  
This cumulative data suggests H. hepaticus infection has genotoxic and non-genotoxic effects 
and may be a complete carcinogen. 
 
Genes associated with steroids 
 
The male predominance of HCC in humans suggests sex steroid involvement but 
epidemiological studies of serum levels have been controversial (Kuper et al. 2001; Tanaka et al. 
2000).  Therapeutic trials of steroid receptor inhibitors on patients with diagnosed HCC yielded 
mixed results (Nowak et al. 2004).  One gene prominently and consistently down-regulated 
(Table II) in H. hepaticus infected male A/JCr mice with severe hepatitis and preneoplastic liver 
lesions was hydroxysteroid dehydrogenase-5, delta<5>-3-beta (Hsd3b5).  This 3-ketosteroid 
reductase gene, expressed only in the male mouse liver after puberty, reduces 
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dihydrotestosterone to the relatively inactive 3β,17β-androstanediol, in preparation for 
conjugation and elimination (Payne et al. 1997).  Hsd3b5 is also down-regulated in the liver of 
mice exposed to peroxisome proliferators and genotoxins (Wong and Gill 2002; Wong et al. 
2002).  
 
Genes associated with aging 
 
Splicing factor 3b subunit 1 (Sf3b1), a subunit of the spliceosome complex; peroxisome 
proliferation activated receptor alpha (Ppara), a transcription factor involved in regulation of 
fatty acid oxidation, glycerol metabolism, and amino acid metabolism in the liver (Kersten et al. 
2001; Patsouris et al. 2004); pre-B cell colony enhancing factor 1 (Pbef1), a growth factor for 
early stage B cells and recently identified as an inflammatory cytokine affecting neutrophil 
apoptosis(Jia et al. 2004); and D site albumin promoter binding protein (Dbp), a liver enriched 
transcription factor, were up-regulated greater than 5 fold at 12 months of age versus 3 months of 
age.  Syndecan (Sdc4), a heparan sulfate proteoglycan promotes focal adhesion and stress fibers  
and delays healing and impairs angiogenesis when deleted in mice (Echtermeyer et al. 2001; 
Keum et al. 2004); and tubulin beta 2 (Tubb2) were down-regulated by 5 fold.  Although there 
were few genes substantially up-regulated or down-regulated with aging, the principal 
component analysis graph spatially clustered regions of age groups at 3, 6, and 12 months in the 
A/JCr mouse.  Aging may be associated with slight but coordinated changes in gene expression 
over time, implying that co-regulated groups of genes or pathways may be modified more 
predictably as a group pattern change rather than individual gene changes. Future analysis should 
examine this approach (Mootha et al. 2003b). For example, aging is associated with an increased 
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level of inflammation, and the present analysis confirms inflammation-associated genes being 
differentially expressed, but few individual genes change substantially over the course of 12 
months.  It is interesting to note that some genes such as insulin-like growth factor binding 
protein 1 (Igfbp1), apoptosis inhibitor 6 (now named CD5 antigen-like (Cd5l)), lysozyme (Lyzs), 
complement component 1 subcomponents (C1qa, C1qb, C1qg), tubulin beta 2 (Tubb2), Ia 
associated invariant chain (Ii), lipoprotein lipase (Lp1), and vascular cell adhesion molecule 
(Vcam1) are up-regulated due to H. hepaticus related lesions but are down-regulated with aging. 
In the aggregate, however, aging down-regulates more genes than it up-regulates in this study 
and others (Cao et al. 2001). 
 
Similar studies analyzing gene expression in H. hepaticus infected A/JCr mice  
 
H. hepaticus initially colonizes the lower bowel before migrating to the liver. Although infection 
generally results in minimal-to-moderate inflammation in the lower bowel in immunocompetent 
mice, this murine pathogen induces severe typhlocolitis and lower bowel cancer in mutant mice 
with targeted immune dysfunctions (Erdman et al. 2003a; Rogers and Fox 2004; Tomczak et al. 
2003b). In an H. hepaticus infection study in A/JCr mice, a cDNA array consisting of 1176 
genes demonstrated 31 up-regulated and 2 down-regulated genes in the cecum at 3 months post-
infection (Myles et al. 2003).  Some up-regulated genes in common in both studies at the 3 
month time point included Ia associated invariant chain (Ii), interferon gamma inducible protein 
(Ifi47), and chemokine (CXC motif) ligand 9 (Cxcl9), and several different serum amyloid A 
components.  Opioid receptor sigma 1 (Oprs1) was slightly up-regulated at 12 months in the 
present study. Continued study of host responses to H. hepaticus in the lower bowel may help 
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identify factors responsible for protection or susceptibility to typhlocolitis as well as H. hepaticus 
translocation to the liver. 
 
Hepatic proliferation is a key component of the development of HCC in the livers of mice 
infected with H. hepaticus (Fox et al. 1996a; Hailey et al. 1998).  In agreement with a previous 
study of H. hepaticus infection in 6-18 month old mice, we documented increased transcription 
of cyclin D1 and decreased epidermal growth factor receptor 2 in mice with progressive hepatic 
disease (Ramljak et al. 1998). However, our microarray results did not confirm previously 
reported differences in other genes including c-myc, cyclin-dependent kinase 4, hepatocyte 
growth factor, and transforming growth factor-α (Ramljak et al. 1998).  Further studies are 
required to determine the contribution of different cell proliferation pathways related to 
tumorigenesis and their transcriptional, translational, and post-translational regulatory 
mechanisms.   
 
Summary 
 
In summary, we characterized time-dependent gene expression signatures in the H. hepaticus 
infected A/J mouse liver with progressively severe liver disease. Transcription profiles in the 
livers of H. hepaticus infected male A/JCr mice exhibiting liver lesions yield a consistent 
ranking of differentially expressed genes. Importantly, the bimodal distribution of disease 
severity in infected male mice, as demonstrated by histopathology, corresponds with global 
hepatic gene expression differences. The reasons for the variable H. hepaticus colonization 
density and disease susceptibility in males, however, remain unexplained. There was an 
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increased number of genes exhibiting differential expression for aging mice, in both H. hepaticus 
infected A/JCr mice and controls. Two putative tumor markers, intestinal trefoil factor 3 and H19 
fetal liver mRNA were up-regulated in progressively dysplastic livers.  Further investigations 
will determine if the gene expression signature of a target organ is diagnostic of a specific 
pathogen and whether there is prognostic value in data derived from this type of analysis.  Global 
gene expression profiling by microarray analysis will continue to play an important role in 
elucidating molecular events in pre-neoplasia and cancer induced by microbial agents. 
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Abstract 
H. hepaticus induces chronic hepatitis and hepatocellular carcinoma in the A/JCr mouse.  A 70kb 
genomic island in Helicobacter hepaticus strain ATCC 51449 is a putative pathogenicity island 
(HHGI1).  This low GC content region comprises genes HH0233-HH0302, and codes for three 
orthologs of a putative type IV secretion system (T4SS).  A/JCr mice were experimentally 
infected with three naturally occurring strains of H. hepaticus; strain H. hepaticus ATCC 51449 
strain (Hh3B1) isolated from A/JCr mice, MIT 96-1809 (HhNET) isolated from mice shipped 
from the Netherlands, and MIT-96-284 (HhG) isolated from mice acquired from Germany.  
HhNET and HhG lack an intact HHGI1 island and each exhibit other individual gene differences 
when compared to Hh3B1.  HhNET infected male A/JCR mice exhibited a significantly lower 
prevalence of hepatic lesions at 6 months post infection (pi) than mice infected with Hh3B1 
possessing the HHGI1 island.  HhG also demonstrated a lower prevalence of hepatic lesions at 6 
months pi.  This variability in lesions was evident in male mice only.  The inflammation scores 
in the liver of the H. hepaticus infected A/JCr mouse correlated with H. hepaticus liver 
colonization levels.  The results suggest the presence or absence of the H. hepaticus 70 kb 
genomic island, a pathogenicity island, is a legitimate virulence determinant and predictor of 
severity of liver lesions in H. hepaticus infected A/JCr male mice. 
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Introduction 
Helicobacter hepaticus causes chronic hepatitis and hepatocellular carcinoma in A/JCr mice 
(Fox et al. 1994; Fox et al. 1996a; Ward et al. 1994b) and typhlocolitis in susceptible mouse 
species  as well as lower bowel cancer in 129S6 Rag 2-/- mice (129SG/SvEvTac-
Rag2tm1Fwa)(Erdman et al. 2003a; Erdman et al. 2003b; Rogers and Fox 2004).  H. hepaticus is 
the best studied member of the enterohepatic Helicobacter species, a group of bacteria of 
increasing biomedical importance (Fox 2002; Rogers and Fox 2004; Solnick and Schauer 2001).  
The genome of H. hepaticus was recently sequenced and shares many genes with the gastric 
pathogen H. pylori and the enteric pathogen, Campylobacter jejuni (Suerbaum et al. 2003).  
Although H. hepaticus and H. pylori occupy different niches in the gastrointestinal tract, they 
both cause persistent infection in their respective hosts and have the potential to induce chronic 
inflammation which progresses to carcinoma.  C. jejuni, the most frequent bacterial cause of 
human diarrhea, and H. hepaticus both inhabit the intestinal crypts of the lower bowel.  H. pylori 
and C. jejuni possess numerous virulence factors, including a Type IV secretion system 
(Batchelor et al. 2004; Larsen et al. 2004; Poly et al. 2004).  C. jejuni possesses invasion 
antigens (Cia proteins) and certain proteins with similarity to flagellar components contributing 
to secretion (Konkel et al. 2004; Song et al. 2004).  The H. pylori genome contains a 
pathogenicity island (PAI) referred to as the cag PAI (Censini et al. 1996) (HP0520-HP0547 in 
H. pylori 26695; jhp0469-jhp0495 in H. pylori J99) and several other genes important for 
adherence to the gastric epithelium and persistent colonization.  The presence of the cag PAI in 
H. pylori strains has been reported as a risk factor for atrophic gastritis and gastric cancer 
(Azuma et al. 2004; Backert et al. 2004; Blomstergren et al. 2004; Yang et al. 2004).  
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Pathogenicity islands reside in many other bacterial pathogens including Escherichia coli (Blum 
et al. 1994), Shigella flexneri (Rajakumar et al. 1997), Yersinia pestis (Buchrieser et al. 1998; 
Schubert et al. 1998), Salmonella enterica (Bajaj et al. 1995), Vibrio cholerae (Ogierman et al. 
1997), Staphylococcus aureus (Lindsay et al. 1998), and Haemophilus influenzae (Martin et al. 
1998).  Bacterial secretion systems include Types I-V (T1SS, T2SS, T3SS, T4SS, and T5SS).  
The secretion systems consist of several different structural components to accommodate the 
variable biochemical composition of virulence factors (Remaut and Waksman 2004).  
Pathogenicity islands often possess one of these secretion systems for injecting virulence factors 
into the medium surrounding the bacteria or directly into cells.     
 
Here we report histopathological changes in the liver of A/JCr mice infected with three different 
wild type (WT) strains of H. hepaticus.  H. hepaticus type strain ATCC 51449 (Hh3B1) has an 
intact genomic island (HHGI1) and produced a lobular, necrogranulomatous hepatitis in all 
Hh3B1 infected male mice, whereas the other 2 WT strains, each possessing unique, individual 
partial deletions of HHGI1 (Suerbaum et al. 2003) were less virulent. One of these strains 
induced a significantly lower frequency of hepatitis and the other exhibited the same trend.  Our 
results suggest that the 70 kb pathogenicity island in H. hepaticus 3B1 was, in part, responsible 
for the increased chronic, active hepatic inflammation seen in infected A/JCr mice versus mice 
infected with two strains of H. hepaticus lacking a large segment of HhPAI.   
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Materials and methods 
Animals 
Specific pathogen free male (n=34) and female (n=30) A/JCr mice that were viral antibody-free, 
free of pathogenic bacteria, parasites, and Helicobacter-free were purchased from the National 
Cancer Institute (NCI, Frederick, MD).  Mice were maintained in an animal facility accredited 
by the Association for Assessment and Accreditation of Laboratory Animal Care, International 
(Rockville, MD).  Mice were housed in 7.5 x 11.5 x 5 in. microisolator cages (Lab Products, 
Inc., Seaford, DE) on heat-treated hardwood bedding (Sanichips, PJ Murphy Inc., Montville, 
NJ), under environmental conditions of 22°C, 40 to 70% humidity, 15 nonrecirculated air 
changes/hour and a 12:12 h light: dark cycle.  Pelleted diet (RMH 3000, Purina Mills Inc., 
Richmond, IN) and water produced by reverse-phase osmosis were provided ad libitum.  Mice 
were euthanized by carbon dioxide asphyxiation at 3 months post-inoculation (one mouse from 
each cage; a total of 8 males and 8 females) and 6 months post-inoculation (Controls: 7 males, 4 
females; Hh3B1: 6 males, 6 females; HhG: 6 males, 6 females; HhNET; 7 males, 6 females) 
(Table 1).  Experimental use of animals was approved by the MIT Committee on Animal Care.   
 
Bacteria 
H. hepaticus strains ATCC 51449 (Hh3B1), MIT 96-284 (HhG), and MIT 96-1809 (HhNET) 
were utilized in this experiment.   MIT 96-284 (HhG) and MIT 86-1809 (HhNET) were isolated 
at MIT from mice obtained from mouse colonies in Germany and the Netherlands, respectively.  
Strain differentiation was determined by DNA microarray hybridization (Suerbaum et al. 2003) 
and empty site polymerase chain reaction (PCR) utilizing the Expand Long Template PCR 
System (Roche, Indianapolis, IN) according to manufacturer’s instructions.  The empty site PCR 
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reaction was performed at the Suerbaum laboratory and utilized the primer set flanking the 
genomic island: fw 5’-ctaaatggctcatcaaccgg-3’ which binds gene Hh0232 at position 221758-
221777 and rv 5’-cacaaagtcatttgttgtgcc-3’ and binds Hh0303 at position 294919-294938.  No 
PCR product was obtained for Hh3B1 due to the 70kb length of HhPAI.  PCR product obtained 
for HhNET was approximately 2.5 kilobases and for HhG was approximately 8 kb.  The premix 
for each reaction was 5 ul buffer 2, 14 ul dNTP-mix, 2.5 ul of both primers (4 pmol/ul), 0.3 ul 
polymerase, 20.7 ul water added to 5 ul DNA.  The cycling conditions were 94 °C for 5 minutes; 
30 cycles at 94 °C for 1 minute, 55°C for 1 minute, 68 °C for 10 minutes; then 68 °C for 15 
minutes.  Additional standard PCR methods performed at MIT to verify strains utilized primers 
PCR1 (fw:5’-ggagcttcctcttgtatgcc-3’; rv: 5’-tacaaccctgcattttgcacc-3’) binding to Hh0082, PCR2 
(fw 5’-atcacttagattgacatagagc-3’; rv:5’-ataatccaaacaatgcaactcg-3’) binding to Hh0236, and PCR3 
(fw5’-gtgtttgattaactcctatccc-3’; rv:5’aaagaacggataactcatcgc-3’) binding to Hh0298.  All primer 
sequences were kindly provided by Suerbaum laboratory. The cycling conditions were: 94° C for 
5 minutes; 30 cycles of 94° C for one minute, 55° C for one minute, 68° C for 1 minute; then 68° 
C for 15 minutes. H. hepaticus strains ATCC 51449 (Hh3B1) and MIT 96-1809 (HhNET) will 
generate a 461bp product and MIT 96-284 (HhG) will generate no product with primer PCR1.  
H. hepaticus strains ATCC 51449 (Hh3B1) generates a 461bp product and MIT 96-1809 
(HhNET) and MIT 96-284 (HhG) will generate no product with primer PCR2. H. hepaticus 
strains ATCC 51449 (Hh3B1) and MIT 96-284 (HhG) will generate a 461bp product and MIT 
96-1809 (HhNET) will generate no product with primer PCR3.   
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Bacterial inoculation 
H. hepaticus strains ATCC 51449 (Hh3B1), MIT 96-284 (HhG), and MIT 96-1809 (HhNET) 
were cultured as previously described (Fox et al. 1994).  Briefly, cultures were first grown on 
trypticase soy blood agar (Remel Laboratories, Lenexa, Kansas) at 37°C under microaerobic 
conditions in vented jars containing N2, H2, and CO2 (80:10:10).  After 48-72 hours, the cultures 
were inoculated into brucella broth containing 5% fetal calf serum and placed on a rotary shaker 
(New Brunswick Scientific, Edison, N.J.) at 130 rpm.  After 48-72 hours, the culture was 
examined by phase microscopy for proper morphology and motility and Gram stained for 
detection of contaminants.  The culture was centrifuged at 10,000 rpm (Microcentrifuge 235C; 
Fisher Scientific, Hampton, N. H.) for 20 minutes at 4°C.  The pellet was resuspended in a 
solution of phosphate buffered saline (PBS) to approximately 108 bacteria per ml as estimated by 
optical density (OD600) (Fox et al. 1996a).  At 10 weeks of age, mice (Hh3B1: 8 males, 8 
females; HhG: 8 males, 8 females; HhNET; 9 males, 8 females) received 0.2 ml of fresh H. 
hepaticus inoculum, per dose, by oral gavage on three different days over a two week time 
period.  Controls consisting of 9 males and 6 females received phosphate-buffered saline (PBS) 
alone (Table 1)  
 
Helicobacter hepaticus isolation and colonization from feces, cecal contents, and cecum 
Pooled fecal samples from all cages representative of all the experimental groups were cultured 
for H. hepaticus (Shames et al. 1995).  DNA was extracted from the cecal contents using Qiagen 
DNA Stool Mini Kit #51504 (Qiagen, Valencia, CA) per manufacturer’s instructions.  DNA was 
extracted from paraffin-embedded cecal samples using EX-WAX DNA extraction kit (Chemicon 
International, Temecula, CA) per manufacturer’s instructions. 
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Helicobacter hepaticus isolation and colonization from liver 
H. hepaticus colonization in the liver for all 48 mice were assessed by real-time quantitative PCR 
using the PE Applied Biosystems Sequence Detection System (Model 7700, Applied 
Biosystems, Foster City, CA) as previously described (Ge et al. 2001).  RNA and DNA were 
extracted from the liver using Trizol (Invitrogen, Carlsbad, CA) and RNA clean-up with RNeasy 
(Qiagen, Valencia, CA) following the manufacturer’s protocol for the isolation of nucleic acids 
from tissue.  Samples were separately probed with 18S rRNA-based primers for quantifying host 
DNA (Applied Biosystems) and with H. hepaticus primers complementary to a portion of the H. 
hepaticus cdtB gene as previously described (Ge et al. 2001).  For quantitation, the PCR mix 
contained the following in duplicate 25 µl volumes: 5 µl template DNA, 12.5 µl of Universal 
Master Mix, 1.5 µl of cdtB probe and primer, and the balance DNAse-free ddH2O.  
Thermocycling was performed at 50 °C for 2 minutes (min) and 95°C for 10 min, and then 40 
repeats of 95°C for 15 seconds (sec) and 60°C for 60 sec.  Seven H. hepaticus DNA standards 
including 2 femtograms (fg), 20 fg, 200 fg, 2 picograms (pg), 20 pg, 200 pg, and 2 nanograms 
(ng) , were used to generate a standard curve.  The genome of H. hepaticus is 1.8 megabases 
with an approximate molecular weight (MW) of 845 x 106 daltons (Suerbaum et al. 2003).  One 
ng of H. hepaticus DNA is the equivalent of 1.18 x 106 molecules (or bacteria).  This relationship 
was used to estimate the number of H. hepaticus targets (genomes) per sample of liver (Ge et al. 
2001). 
 
Histopathology 
Sagittal sections of each liver lobe (median, caudate, and left and right) were collected for 
histopathology.  Tissues were immersion fixed overnight in 10% neutral-buffered formalin 
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(VWR Scientific, West Chester, PA).  Fixed tissues were processed and embedded by routine 
histologic methods, sectioned at 5 µm, and stained with hematoxylin and eosin. The liver 
sections representing replicate samples from each lobe were examined by a board certified 
veterinary pathologist blinded to sample identity and graded on a 0—4 scale for lobular 
histologic activity, portal activity, and staged on the same scale for fibrosis using established 
criteria (Rogers et al. 2004; Scheuer 1991) 
 
Dual fluorescence immunohistochemistry  
To detect the predominant cellular infiltrate and evidence of reactive oxygen species, dual 
fluorescence immunohistochemistry with primary antibodies F4/80 and Nos2 was performed.  
Formalin fixed liver was deparaffinized and hydrated for antigen retrieval.  The sequence of 
antibody applications and incubation times were as follows: avidin (Sigma, St. Louis, MO) for 5 
minutes, biotin (Sigma, St. Louis, MO) for 5 minutes, primary antibodies Nos2 (Santa Cruz 
Biotech, Santa Cruz, CA) and F4/80 (Burlingame, CA) were combined at 1:100 for 30 minutes, 
biotinylated α rat (Sigma, St. Louis, MO) at 1:100 for 10 minutes, secondary antibody (SA)-
fluorescein (FITC) at 1:100 for 5 minutes (green fluorochrome), biotin block for 1 minute, 
biotinylated α rabbit (Sigma, St. Louis, MO) at 1:1000 for 10 minutes, and (SA)-CY3 (Sigma, 
St. Louis, MO) at 1:100 for 5 minutes (red fluorochrome).  All the preceding antibody 
applications were followed by an phosphate buffered saline and Tween 20 (Sigma, St. Louis, 
Mo) rinse: Slides were partially air-dried and cover slips with Vectorshield (Burlingame Lab, 
Burlingame, CA) with 4',6-Diamidino-2-phenylindole (DAPI) applied. 
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Statistical analysis  
Analysis of hepatitis scores of all H. hepaticus infected A/JCr mouse groups and controls was 
performed by the Kruskal-Wallis nonparametric test and the Dunn’s post test (GraphPad Prism, 
San Diego, CA).  H. hepaticus colonization levels in the liver were obtained from quantitative 
real-time PCR and were analyzed by the same methods.  Normalization of the H. hepaticus liver 
colonization data utilized the 18S rRNA levels in the total DNA content of the liver. 
 
Results 
Bacterial colonization in feces, cecal contents, and cecum 
Each of the three strains of H. hepaticus was cultured from feces of 2 mice each from cages 
housing H. hepaticus infected mice at 12 weeks post infection, but H. hepaticus was not isolated 
from controls.  The identity of the three strains at the start of the experiment, as well as H. 
hepaticus isolated from the feces of the experimental mice at 12 weeks post infection, was 
confirmed by PCR (Figure 1, Table 2).  H. hepaticus colonization was detected in 36 of 37 
infected mice via PCR of the cecum or cecal contents at 6 months post infection, but not from 
the 11 uninfected controls. 
 
Bacterial copy number in liver 
DNA from the liver of 48 mice necropsied at 6 months were tested for H. hepaticus cdtB by real-
time quantitative PCR (Figure 2) (Ge et al. 2001).  Serial dilutions of H. hepaticus DNA from 2 
fg to 2 ng served as the positive control.  H. hepaticus 3B1 ranking and median copy numbers in 
the male A/JCr mouse were consistently higher than the other two strains.  Interestingly, one 
male mouse (03-6535) infected with the H. hepaticus HhNET strain and one male mouse 
  176
infected with strain HhG   (03-6548) had high copy numbers and correspondingly severe 
composite hepatitis scores.  For 6 of 8 composite hepatitis scores greater than or equal to 4.0, the 
H hepaticus copy numbers exceeded 1500.  The maximum copy number measured was 23,300.   
  
Histopathology 
Sixteen mice representing each gender and all four groups were euthanized at 3 months post-
infection.  The mice exhibited varying degrees of lobular and portal hepatitis depending on H. 
hepaticus strain and gender.  As expected, controls had no lesions while male mice infected with 
Hh3B1 had higher composite hepatitis index scores than other groups (Figure 3).  
 
At 6 months post infection, all 6 male A/JCr mice infected with H. hepaticus ATCC 51449 
(Hh3B1) developed severe liver disease resulting in necrogranulomatous lobular and/or 
lymphocytic portal hepatitis (Figures 4 and 5).  The predominant cellular infiltrate of the lobular 
hepatitis was macrophages, and was accompanied by hepatocellular coagulative necrosis.  Portal 
hepatitis was manifest as either well defined aggregates of mononuclear cells (chronic persistent 
hepatitis) or locally invasive lesions which disrupted the hepatic limiting plate (interface 
hepatitis).    The results indicate a significant difference in hepatitis index (composite lobular 
hepatitis and portal hepatitis scores) between the Hh3B1 infected A/JCr mice versus controls 
(p<.01) and Hh3B1 versus HhNet (p<.05) (Figures 6 and 7).  There is a trend, but not a 
significant difference, for Hh3B1 versus HhG.  The male mice infected with MIT 96-284 (HhG) 
and MIT 96-1809 (HhNET) exhibited a bimodal histological index score as seen previously in a 
larger study of H. hepaticus 3B1 infection in A/J mice (Rogers et al, 2004).  Four of six (4/6) 
HhG infected male A/JCr mice had minimal scores while two mice had moderate to severe 
hepatitis scores.  Four of seven (4/7) HhNET infected A/JCr mice had minimal scores while 
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three mice had moderate to severe hepatitis scores.  Sixteen of eighteen (16/18) female A/JCr 
mice in all three H. hepaticus infected groups had minimal hepatitis except for two mice (one 
Hh3B1 infected, one HhNET infected) where the hepatitis was judged moderate.  The control 
mice had no or minimal hepatitis scores (Figures 6 and 7).   
 
Dual fluorescence immunohistochemistry 
Dual fluorescence immunohistochemistry confirmed that activated macrophages were the 
predominant cellular infiltrate in necrogranulomatous lobular hepatitis.  The F4/80 primary 
antibody indicated the presence of macrophages and the Nos2 primary antibody indicated 
inducible nitric oxide synthase (iNOS) production.  The dual fluorescence confirmed the 
presence of activated macrophages inducing iNOS within the foci of lobular hepatitis (Figure 8). 
 
Discussion 
Helicobacter hepaticus causes hepatocellular carcinoma in certain strains of mice, but the 
virulence factors responsible for this have not been identified (Fox et al. 1994; Fox et al. 1996a; 
Hailey et al. 1998; Ihrig et al. 1999; Ward et al. 1994a). The H. hepaticus strain ATCC 51449 H. 
hepaticus (Hh3B1) possesses a genomic island (HHGI1) hypothesized to play a key role in 
disease development (Suerbaum et al. 2003).  To determine the importance of the putative PAI , 
we compared the wild type strain to two other strains, MIT 96-1809 (HhNET) isolated from mice 
originating in the Netherlands and MIT-96-284 (HhG) isolated from mice shipped from 
Germany; both of these strains lacked the genomic island (Suerbaum et al. 2003).  In HhNET 
infected male A/JCR mice there was a significantly lower prevalence of hepatic lesions than 
Hh3B1 at 6 months post infection.  Males exhibited more severe liver lesions than females.  HhG 
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infected mice also had lower prevalence of hepatic lesions.  Hepatitis scores greater than or equal 
to 2.5 generally corresponded with copy numbers of the H. hepaticus greater than 1500, with a 
maximum copy number of 22,300.  However, there a large variance in H. hepaticus copy number 
did occur.  Previous studies have demonstrated much larger copy numbers of H. hepaticus and 
more numerous and larger lobular lesions at 12 months post infection (Rogers et al. 2004).  
Nevertheless, in this experiment, all the H. hepaticus 3B1 infected male A/JCr mice had severe 
hepatic lesions at 6 months.  The male A/JCr mice infected with the two HHGI1-defective H. 
hepaticus strains exhibited a bimodal distribution of hepatitis scores.  This male predominance 
and bimodal distribution of lesions has been exhibited in other H. hepaticus 3B1 studies where 
there was a positive correlation of bacterial copy number to hepatitis score at 12 months post-
inoculation (Rogers et al. 2004).  Interestingly, this was the colony of mice where Hh3B1 was 
first isolated (Fox et al. 1994).  This bimodal distribution was first noted in A/JCr mice naturally 
infected with H. hepaticus (Fox et al. 1996b) 
 
As has been demonstrated in previous studies, the lobular hepatitis cellular infiltrate was 
predominantly macrophages (Rogers et al. 2004).  In this study, we demonstrated that 
macrophages were activated as evidenced by iNOS protein synthesis (Figure 8).  The reactive 
oxygen and nitrogen species generated by nitric oxide chemistry (this reads strange) increases 
cancer risk due to DNA mutation and DNA adducts (Dedon and Tannenbaum 2004).  Results of 
several in vitro experiments show H. pylori induces iNOS expression in gastric epithelial cells 
(Kim et al. 2003; Perfetto et al. 2004).  H. pylori infected iNOS-/- mice exhibit reduced apoptosis 
as compared to iNOS+/+ mice (Miyazawa et al. 2003).  Also, recent studies with H. felis 
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infected iNOS-/- mice demonstrated significantly reduced gastritis scores relative to H. felis 
infected wild type mice at 32 weeks post infection (Ihrig et al., in press). 
 
In summary, our findings demonstrate that A/JCr mice infected with two strains of H. hepaticus 
(HhG and HhNET), with large deletions in a 70kb genomic island as compared to  ATCC 51449 
(Hh3B1), exhibited a lower prevalence of hepatic lesions than Hh3B1 at 6 months post infection.  
The histologic index depended on H. hepaticus colonization levels and only male mice exhibited 
hepatic lesions with high histological indices.  These results suggest that the HHGI1 plays a role 
in pathogenesis of liver disease in A/JCr male mice, and supports that this island represents a 
functional pathogenicity island.  Additional infection studies are needed using isogenic mutants 
of H. hepaticus 3B1, lacking the HhPAI, to confirm these findings. 
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Table 1  A/JCr mouse groups at inoculation and at 6 months post-infection.  Eight males and 
eight females, two mice from each group, were euthanized at 3 months. 
 
Intial groups at inoculation 
 
Groups Males  Females 
Control 9 6 
Hh3B1 8 8 
HhG 8 8 
HhNET 9 8 
 
 
6 months post infection 
Groups Males  Females 
Control 7 4 
Hh3B1 6 6 
HhG 6 6 
HhNET 7 6 
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Figure 1.  H. hepaticus strain identification via PCR prior to A/JCr mouse inoculation and after 
isolation from feces at 3 months post infection.  Three primers, 83, 236, and 298 were utilized to 
differentiate H. hepaticus strains.  Hh3B1 is in lane 1,5, and 9.  HhG is in lane 2, 6, and 10.  
HhNET is in lane 3, 7, and 11.  The gel exhibits the PCR primer products for each strain.  The 
code for each strain is in Table 2. 
 
 
 
 
 
Table 2  H. hepaticus strain differentiation via PCR.  Primer combinations that produce bands 
(indicated by +) identify the individual strain. 
 
 Primer 82 236 298 
Group     
Hh3B1  + + + 
HhG  - - + 
HhNET  + - - 
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Figure 2. H. hepaticus 3B1, HhG, and HhNET copy number in male A/JCr livers at 6 months. 
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Figure 3  Hepatitis index (combined lobular and portal hepatitis scores) of all groups of A/JCr 
mice infected with the type strain H. hepaticus 3B1 and two other wild type strains of H. 
hepaticus at 3 months post-inoculation.  
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Figure 4  Necrogranulomatous lobular hepatitis in an H. hepaticus 3B1 infected male A/JCr at 6 
months post-inoculation.  The predominant cellular infiltrate of the lobular hepatitis was 
macrophages, and was accompanied by hepatocellular coagulative necrosis. Magnification: 
200X 
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Figure 5  Portal hepatitis in an H. hepaticus 3B1 infected male A/JCr mouse at 6 months post 
inoculation.  Portal hepatitis was manifest as either well defined aggregates of mononuclear cells 
(chronic persistent hepatitis) or locally invasive lesions which disrupted the hepatic limiting plate 
(interface hepatitis). Magnification: 200X    
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Figure 6.  Hepatitis index (combined lobular and portal hepatitis scores) of all groups (both 
genders combined) of A/JCr mice infected with the type strain H. hepaticus 3B1 and two other 
wild type strains of H. hepaticus at 6 months post-inoculation.   * Statistical significance (p<.05) 
versus control and HhNET, trend toward HhG 
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Figure 7.   Hepatitis index (combined lobular and portal hepatitis scores) of all male groups of 
A/JCr mice infected with the type strain H. hepaticus 3B1 and two other wild type strains of H. 
hepaticus at 6 months post-inoculation.  * Statistical significance (p<.05) versus control and 
HhNET, trend toward HhG 
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Figure 8.  Dual fluorescence immunohistochemistry.  The slide illustrates activated 
macrophages producing iNOS in necrogranulomatous lobular hepatitis.  Colors: blue: nuclei; 
green: macrophages, red: iNOS, and yellow/orange: co-localization of iNOS and macrophage. 
Magnification: 400X 
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Abstract 
 
Helicobacter hepaticus ATCC 51449 (Hh3B1) induces hepatocellular carcinoma (HCC) 
in A/JCr mice and colon cancer in certain immunodeficient lines of mice.  Recent studies 
demonstrated the virulence of H. hepaticus to be bacterial strain dependent based on the 
possession of a 70kb genomic island.  The genomic island, a putative pathogenicity 
island (HhPAI), consists of genes HH233-HH302 and components of a Type IV secretion 
system (T4SS).  In order to characterize the differences in virulence between H. 
hepaticus strains isolated from mouse colonies from different regions of the world and 
isogenic mutants, in vitro experiments were performed.  Since macrophages are the 
predominant inflammatory cell type in H. hepaticus induced lobular hepatitis, the 
location of progressively dysplastic lesions, and the development of HCC, the murine 
macrophage cell line RAW264.7 was utilized for in vitro infection studies.  Hh3B1, 
possessing the HhPAI, induced significantly increased cytokine expression from murine 
macrophages as compared to an HhPAI isogenic mutant and one wild type strain lacking 
the HhPAI.   
 
 
 
 
 
 
  195
Introduction 
 
Helicobacter hepaticus induces hepatocellular carcinoma (HCC) in A/JCr mice and colon 
cancer in certain immunodeficient lines of mice (Erdman et al. 2003a; Erdman et al. 
2003b; Fox et al. 1994; Fox et al. 1996; Ihrig et al. 1999; Ward et al. 1994).  We recently 
demonstrated the virulence of H. hepaticus to be bacterial strain dependent based on the 
possession of a 70kb genomic island (Boutin et al, in preparation).  In that study, the 
hepatitis of the A/JCr male mice infected with the type strain H. hepaticus ATC51449 
(Hh3B1), possessing a genomic island (HHGI1), was more severe than two wild type 
strains lacking the HHGI1, at 6 months post inoculation.  The genomic island, a putative 
pathogenicity island (HhPAI), consists of genes HH233-HH302.  Hh3B1 was first 
isolated from in H. hepaticus infected A/JCr mice exhibiting HCC (Fox et al. 1994; Fox 
et al. 1996; Ward et al. 1994).  Most of the PAI is absent in H. hepaticus MIT 96-1809 
(HhNET) (Suerbaum et al. 2003).  HhNET was isolated at MIT from murine samples 
obtained from mouse colonies in the Netherlands.  HhNET and Hh3B1 contain gene 
differences in the rest of the genome as determined by DNA hybridization to a H. 
hepaticus microarray (Suerbaum et al. 2003).   
 
In order to further characterize the differences in virulence between the H. hepaticus 
strains, in vitro experiments were performed.  Since macrophages are the predominant 
inflammatory cell type in lobular hepatitis due to H. hepaticus infection as demonstrated 
by histopathology (Rogers et al. 2004) (Appendix 1) and microarray studies (Boutin et al. 
2004) (Chapter 3), a murine macrophage cell line, RAW264.7, was chosen for 
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experiments.  Macrophages are ubiquitous in normal tissues, as well as in cancers 
(Mantovani et al. 2003; Ohno et al. 2003; van Ravenswaay Claasen et al. 1992).  The 
tumor microenvironment differs depending on tumor type and can influence the 
activation and differentiation of tumor-infiltrating monocytes generating macrophages 
with tumor-specific phenotypes (Lewis et al. 1999; Mantovani et al. 2003; Mantovani et 
al. 2004; Ohno et al. 2003).  The activation and differentiation of macrophages can also 
depend on microbial stimuli, particularly the lipid A component of lipopolysaccharide 
(LPS) (Ulevitch et al. 2004; Ulevitch and Tobias 1999).  There are other biochemical 
structures such as lipoproteins, flagellin, and peptidoglycans recognized by macrophage 
toll-like receptors and intracytoplasmic receptors (Li and Cherayil 2004; Viala et al. 
2004).  H. hepaticus LPS is recognized by toll-like receptor 4 whereas whole H. 
hepaticus is recognized by LPS toll-like receptor 2 as determined by cytokine response 
(Mandell et al. 2004).  The expression of specific cytokine genes of a murine macrophage 
cell line in response to H. hepaticus allowed comparisons of these in vitro results to 3, 6, 
and 12 month microarray studies of H. hepaticus infected A/JCr mouse liver (Chapter 3) 
and an infection study with the Hh3B1, HhG, and HhNET at 6 months post-innoculation 
(Chapter 4). 
 
In this study. we infected RAW264.7 murine macrophage cell cultures with two wild 
type strains (Hh3B1, HhNET) and an isogenic mutant strain (HhBac26) of H. hepaticus.  
One wild type strain, HhNET, lacks most of a putative PAI of H. hepaticus.  The mutant 
strain lacks genes HH250-HH268 of the PAI.  The goal was to test the hypothesis that 
HhNET was less virulent than Hh3B1 in vivo (Boutin et al, in preparation) due to the 
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absence of a type IV secretion system (T4SS).  This was done by comparing the cytokine 
response of RAW264.7 murine macrophages to Hh3B1, HhNET, and HhBac26.  
Cytokines Cxcl4, Cxcl10, Cxcl1, Cxcl2, Ccl2, Ccl3 and Tnf were selected since they are 
up-regulated by macrophages in response to bacterial components (Burke and Lewis 
2002; Mantovani et al. 2004; Moller et al. 2003).  Hh3B1 possessing the HhPAI induced 
significantly increased cytokine expression from the murine macrophage cell line RAW 
264.7 as compared to the wild type HhNET strain lacking the HhPAI, as well as the 
isogenic mutant HhBac26.  
 
Materials and methods 
 
Macrophage infection assay  
 
All experiments utilized murine macrophage cell line RAW264.7 (ATCC: TIB-71) 
maintained in Dulbecco's Modified Eagle Medium (12800-058 Gibco/Invitrogen, 
Carlsbad, CA) supplemented with 3.7 g/L sodium bicarbonate (# 3506-01 Sigma, St. 
Louis, MO), 100 ml/L fetal calf serum (FCS)  (#10082-147 Gibco/Invitrogen, Carlsbad, 
CA) at 37°C and 5% CO2.  Macrophages were seeded at 5.5 x 106 cells per 25 cm2 flask 
for the experiment and incubated for 24 hours at 37°C at 5% CO2.  After 24 hours, the 
medium was removed and replaced with medium without fetal calf serum.  The cells 
were incubated an additional 24 hours prior to bacterial inoculation at a multiplicity of 
infection (MOI) of 0.1. The number of tissue culture flasks prepared allowed a minimum 
of three replicate flasks for each test group. 
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Bacterial inoculation  
 
 
H. hepaticus strains ATCC 51449 (Hh3B1), MIT 96-1809 (HhNET), and isogenic mutant 
HhBac26 were utilized in this experiment.  Genes HH0250-HH0268 are deleted in 
HhBac26.  Both H. hepaticus strains and the isogenic mutant were cultured as previously 
described (Fox et al. 1994).  Briefly, cultures were first grown on trypticase soy blood 
agar (Remel Laboratories, Lenexa, Kansas) at 37°C under microaerobic conditions in 
vented jars containing N2, H2, and CO2 (80:10:10).  After 72 hours, the bacteria were 
removed from the plates and resuspended in sterile phosphate buffered saline (PBS).  The 
suspension was examined by phase microscopy for proper morphology, motility, and 
contaminants.  A 50µl sample of the bacterial suspension was diluted 1:20 and a 
spectrophotometer (Beckman Coulter, Fullerton, CA) reading was performed at 660 nm 
to determine the number of bacteria. An optical density of 1.0 corresponds to 
approximately 3 x 109 H. hepaticus /ml.  The bacterial inoculum was prepared by diluting 
the bacterial suspension with PBS to obtain the desired multiplicity of infection (MOI). 
 
Lipopolysaccharide (LPS) (LPS ECO55:B5 cat. # 62326 Sigma, St. Louis, MO) was used 
as a positive control.  LPS was purified using hot phenol and water as previously reported 
(Hirschfeld et al. 2000).and prepared at a concentration of 100 ng/ml.  The inoculation 
final concentration was 100ng LPS per 25 cm2 cell culture flask.   
 
MOI and exposure time were empirically determined and included MOI = 0.1, 1.0, and 
10.0 at 4 and 24 hours.  One ml of Trizol (Invitrogen, Carlsbad, CA) was pipetted into 
each flask for one minute and a sterile cell scraper (Becton Dickinson, Franklin Lakes, 
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NJ) was used to remove the cells.  The cell/Trizol solution was stored at –80°C for 
subsequent RNA isolation. 
 
RNA isolation and reverse transcription reaction 
 
RNA and DNA were extracted from the RAW264.7 cells using Trizol (Invitrogen, 
Carlsbad, CA) for the isolation of nucleic acids from cell culture as specified by the 
manufacturer.  Total RNA was further purified with RNeasy (Qiagen, Valencia, CA) 
following the manufacturer’s protocol.  All RNA samples used had a 260/280 ratio 
greater than 1.9.  The Reverse Transcription reaction was performed according to 
manufacturer’s instructions with the Superscript II system (Invitrogen, Carlsbad, CA) at a 
uniform total RNA concentration of 1µg per sample volume.  Eighty microliters of TE 
was added to the resultant cDNA.  For quantitation, real-time quantitative PCR was 
performed.   
 
Gene expression measurements 
 
Gene expression was assessed by real-time quantitative PCR using the PE Applied 
Biosystems Sequence Detection System per manufacturer’s instructions (Model 7700, 
Applied Biosystems, Foster City, CA).  For each replicate, the PCR mix contained the 
following in 25 µl volumes: 5 µl template DNA, 12.5 µl of Universal Master Mix, 1.5 µl 
of probe and primer, and the balance DNAse-free ddH2O.  Thermocycling was performed 
at 50 °C for 2 minutes (min) and 95°C for 10 min, and then 40 repeats of 95°C for 15 
seconds (sec) and 60°C for 60 sec.  Control samples were probed with 18S rRNA-based 
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primers (Applied Biosystems, Foster City, CA) for quantifying host RAW cell RNA for 
normalization calculations.  The Taqman Gene Expression system probes and primers 
utilized were cytokines Cxcl4, Cxcl10, Cxcl1, Cxcl2, Ccl2, Ccl3 and Tnf (Applied 
Biosystems, Foster City, CA). 
 
Normalization 
 
Normalization and fold change calculations for cytokine expression values were 
calculated by the comparative CT method as recommended in User Bulletin #2: ABI 
Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA).  
Reference samples for normalization were assessed by 18S Taqman Gene Expression 
(Applied Biosystems, Foster City, CA)   
 
Statistical analysis 
 
The  ∆CT value was determined by subtracting the average 18S CT value from a average 
positive control, cytokine, or LPS value.  The standard deviation of ∆CT is the square root 
of the sum of the squares of the standard deviations of the individual CT values.   The 
standard deviation of ∆∆CT is the same as the standard deviation of ∆CT.  Analysis of 
∆∆CT scores from all H. hepaticus infected RAW264.7 groups and positive and negative 
controls was performed by One Way Analysis of Variance and Dunnett’s post test.   
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Results 
 
The RAW264.7 murine macrophage cell line was exposed to the type strain Hh3B1 
which contains the HhPAI, a wild type strain HhNET lacking the PAI, and an isogenic 
mutant HhBac26 with genes HH0250-HH0268 deleted.  The MOI was 0.1 and the 
exposure time was 24 hours. 
 
Quantitative real time RT-PCR  
HhBac26 (isogenic mutant of HhPAI) did not elicit a cytokine increase for any cytokine 
tested.  Hh3B1 (with HhPAI) and LPS produced a significant increase (p<.05) of 
cytokine level versus control for Cxcl2, Ccl2, Ccl3, and Tnf  (Figure 1).  The average 
fold changes for these cytokines are shown in Table 1.  Hh3B1, HhNET (without 
HhPAI), and LPS induced a significant increase of Cxcl4 versus control (p<.05).  Only 
LPS produced a significant Cxcl1 response (p<.01), while no treatment exhibited 
significant differences for Cxcl10.  The results indicate cytokine increases for 4 out of 6 
cytokines tested due to the presence of the HhPAI. 
 
Discussion 
 
H. hepaticus virulence factors may reside on the 70kb genomic island HHGI1, a putative 
H. hepaticus pathogenicity island (HhPAI) contained in the type strain H. hepaticus 
ATCC 51449 strain (Hh3B1).  HHGI1 encodes three basic components of a T4SS and 
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other virulence protein homologs (Suerbaum et al. 2003).  Our experiments demonstrate 
a significant difference in selected cytokine responses of the murine macrophage cell line 
RAW264.7 (ATCC: TIB-71) when infected by Hh3B1 versus control but not HhNET or 
HhBac26 versus control (Figure 1).  Wild type strain MIT 96-1809 (HhNET) has most of 
the HhPAI deleted and isogenic mutant strain HhBac26 has a partial deletion of the 
HhPAI.  The RAW264.7/H. hepaticus infection experiments were performed at an 
MOI=0.1 for 24 hours.  Previous in vivo studies of different wild type strains of H. 
hepaticus in the A/JCr mouse have demonstrated the type strain H. hepaticus ATCC 
51449 strain (Hh3B1), which contains the HhPAI, to be more virulent than two other 
strains MIT 96-1809 (HhNET) and MIT-96-284 (HhG) which lack most of the HhPAI 
(Chapter 4).  These data support the hypothesis that HhNET and HhG are less virulent 
due to the lack of a T4SS and other virulence components.  Hh3B1 produced both more 
severe hepatitis scores and a higher frequency of hepatitis than HhG and HhNET 
(Chapter 4).   
 
Previous microarray studies of chronic active hepatitis and dysplasia of H. hepaticus 
infected A/JCr mice at 3, 6, and 12 months post-infection demonstrated a consistent 
grouping of inflammation associated genes exhibiting differential expression (Chapter 3).  
The cytokines and cytokine receptors in hepatic tissue were up-regulated more than 2 
fold in those studies included Cxcl9, Cxcl10, Cxcl13, and Ccr5.  Interestingly, 
macrophages have recently been categorized by activation and polarization phenotypes as 
M1, M2a, M2b, and M2c, analogous to the Th1 and Th2 lymphocytes (Mantovani et al. 
2004).  Cxcl9 and Cxcl10 produced by monocytes bind receptor Cxcr3 on natural killer 
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(NK) and Th1 cells in a polarizing Type 1 response, and Cxcr3 and Ccr5 are also 
expressed on polarized Type I T cells (Mantovani et al. 2004).  Cxcl13, formerly known 
as B cell activating cytokine, also binds with Cxcr5 on B cells.   
 
In this study, H. hepaticus 3B1 and LPS, but not HhNET or HhBac26, significantly 
increased the expression of Ccl2, Ccl3, Ccl4, Cxcl2, and Tnf of RAW264.7 murine 
macrophages versus controls.  These macrophages are from a BALB/c mouse cell line, a 
mouse strain susceptible to Hh3B1 infection and a Th2 dominant strain.  LPS increased 
the expression of an additional cytokine, Cxcl1.  Interestingly, Cxc10 did not show a 
significantly different expression level with Hh3B1 at an MOI=0.1 or LPS at 100 ng/ul.  
Ccl2 is a proinflammatory cytokine and binds to Ccr2 on monocytes, NK cells, basophils, 
immature dendritic cells, activated T cells, and B cells.  Ccl3 and Ccl4 are also pro-
inflammatory cytokines produced by macrophages and bind to Ccr5 on monocytes, 
macrophages, Th1 cells, activated T cells and NK cells.  Ccl3 also binds to Ccr1 on 
monocytes, macrophages, immature dendritic cells, and NK cells (Mantovani et al. 
2004).  Interestingly, while Tnf was upregulated in RAW264.7 BALB/c murine 
macrophages at 24 hours, it was not differentially expressed in the liver of H. hepaticus 
infected A/JCr mice at 3, 6, and 12 months.   
 
Since the HhPAI isogenic mutant HhBac26 lacked an increased cytokine response in 
RAW264.7 for all cytokines tested, the HhPAI presumably influences this outcome.  
HhNET also lacks the HhPAI and did not exhibit an increased cytokine response for 4/6 
cytokines, adding further support to the contribution of the HhPAI as a virulence factor.  
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The one cytokine that was increased for HhNET could imply that other genes outside the 
HhPAI, and not in Hh3B1 or HhBac26, could also influence the macrophage response.  
The HhPAI was demonstrated to affect virulence in both the in vivo experiments of 
Chapter 4 and the in vitro experiments in this chapter.  Whether the PAI will affect HCC 
in A/JCr mice is an on-going investigation.   
 
In summary, our findings demonstrate that RAW264.7 murine macrophages infected with 
the type strain Hh3B1 possessing the HhPAI exhibited a significantly higher cytokine 
response than HhNET and mutant HhBac26 at an MOI=0.1 and 24 hours post infection.  
Both HhNET and HhBac26 have large deletions in the HhPAI.  These results suggest that 
the HhPAI plays a role in pathogenesis. 
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Table 1  Summary of fold change versus controls for significantly increased cytokine 
responses induced by the type strain H. hepaticus 3B1 possessing the HhPAI.  Fold 
changes for the positive control LPS, HhNET (without HhPAI), and the isogenic mutant 
HhBac26 are also listed. 
 
Cxcl2  Average Fold Change
Hh3B1  68.59 
HhNET  5.54 
HhBac26  0.88 
LPS  897.64 
   
   
Ccl2  Average Fold Change
Hh3B1  59.03 
HhNET  4.72 
HhBac26  0.36 
LPS  116.97 
   
   
Ccl3  Average Fold Change
Hh3B1  9.26 
HhNET  1.82 
HhBac26  0.15 
LPS  44.63 
   
   
Tnf  Average Fold Change
Hh3B1  7.71 
HhNET  2.62 
HhBac26  0.47 
LPS  5.66 
 
 
 
 
 
 
 
 
  206
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Macrophage cell line RAW264.7 infection assay.  The graph illustrates type 
H. hepaticus strain Hh3B1, possessing the HhPAI, and LPS induced a significantly 
increased response versus control for the cytokines exhibited.  The H. hepaticus strains 
are at an MOI=0.1 and exposure time of 24 hours.  The HhBac26 HhPAI isogenic mutant 
did not differ from controls for all cytokines measured. 
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Chapter 6 
 
Summary 
 
 
This thesis reported on studies of the molecular pathogenesis of Helicobacter hepaticus 
induced liver disease.  H. hepaticus is a model organism of the enterohepatic 
Helicobacter spp., and the cause of hepatocellular carcinoma (HCC) in A/JCr mice.  The 
experiments focused on 3 areas: (1) the gene signature of the A/JCr male mouse hepatic 
transcriptional response to infection by the H. hepaticus type strain ATCC 51448  
(Hh3B1) at 3, 6, and 12 months post-inoculation; (2) the A/JCr mouse hepatic 
histopathological response and corresponding hepatic colonization levels to infection by 
3 H. hepaticus wild type strains.   Two of the strains (HhNET and HhG) lacked a putative 
pathogenicity island (PAI) containing components of a type IV secretions system (T4SS) 
present in the third strain, Hh3B1; and (3) the in vitro cytokine response of the murine 
macrophage, the predominant inflammatory cell in lobular hepatitis, after 24 hour 
exposure to Hh3B1, HhNET, and HhBac26.  Hh3B1 contains the PAI, Hh NET lacks the 
PAI, and HhBac26 is an isogenic mutant with a partial deletion of the PAI, including 
components of the T4SS. 
 
The results of the experiments demonstrated: (1) a definitive gene expression signature of 
lesions induced by H. hepaticus infection at 3, 6, and 12 months post inoculation.  It also 
suggested a potential hepatic gene signature for H. hepaticus infection in male mice not 
exhibiting lesions.  This will require further study.  (2) a significant difference in 
virulence among the 3 wild type strains of H. hepaticus, providing additional evidence of 
the existence of a PAI in Hh3B1.  Hh3B1 hepatic colonization levels trended higher than 
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HhG and HhNET; and (3) the macrophage response of selected cytokines is significantly 
increased versus controls by exposure to Hh3B1, as compared to HhNET and HhBac26 
versus controls.  This again provides evidence of a PAI and T4SS in Hh3B1. 
 
The molecular mechanisms of H. hepaticus induced HCC remains unclear.  H. hepaticus 
possesses characteristics of both a tumor promoter and tumor initiator, and may indeed be 
a complete carcinogen.  The prototypical non-genotoxic carcinogen that promotes HCC 
in rodents is phenobarbital.  It activates the orphan nuclear receptor constitutive 
active/adrostane receptor (CAR) and results in differential expression in the liver of some 
cytochrome P450 genes in common with H. hepaticus infection.  CAR deficient mice do 
not exhibit HCC after diethylnitrosamine initiation and phenobarbital promotion.  Future 
H. hepaticus experimental infections of CAR deficient mice would test the hypothesis of 
shared pathways of H. hepaticus and phenobarbital in the molecular pathogenesis of 
HCC. 
 
The reasons for male predominance of H. hepaticus induced chronic, active inflammation 
progressing to HCC are also unknown.  Investigations are underway to determine the 
effect that H. hepaticus has on steroid hormones and cholesterol, biomolecules with many 
shared biochemical pathways.  Further investigation of enterohepatic Helicobacter 
species is important, because increasing evidence suggests a definitive role in human 
enterohepatic disease.  This would not be a surprising result, given the paradigm of H. 
pylori.  
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Abstract 
Transcriptional profiling of entire tumors has yielded considerable insight into the 
molecular mechanisms of heterogeneous cell populations within different types of 
neoplasms. The data thus acquired can be further refined by microdissection methods that 
enable the analyses of sub-populations of neoplastic cells.  Separation of the various 
components of a neoplasm- i.e., stromal cells, inflammatory infiltrates, and blood vessels- 
has been problematic, primarily because of a paucity of tools for accurate 
microdissection. The advent of laser-capture microdissection combined with powerful 
tools of linear amplification of RNA and high throughput microarray-based assays have 
allowed the transcriptional mapping of intricate and highly complex networks within pure 
populations of neoplastic cells. Using this approach, specific “molecular signatures” can 
be assigned to tumors of distinct or even similar histomorphology, thereby aiding the 
desired objective of pattern recognition, tumor classification, and prognostication. This 
review highlights the potential benefits of global gene expression profiling of tumor cells 
as a complement to conventional histopathologic analyses. 
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Introduction 
Although the virtual explosion in the development of new molecular biological tools 
during the past decade has greatly expanded our understanding of the genetics and 
pathophysiology of tumorigenesis, histopathology remains the most reliable tool (the 
'gold standard') for definitive diagnosis and classification of tumors. Classification of 
cancers has relied primarily upon morphological characteristics of the tumor, including 
tumor size, lymph node status, histology, and more recently, expression of specific 
markers associated with clinical course.26  Traditionally, pathologists build up a relational 
database correlating histopathology of tumors with available patient data, such as 
recurrence rates, infiltrative nature, metastatic or non-metastatic behavior, post-surgical 
survival, and treatment response. These subjective measurements of cell morphology and 
behavior are ultimately combined to provide the framework for diagnostic, prognostic, 
and therapeutic decisions.  However, our ability to predict tumor behavior based solely 
on histopathology remains elusive at best. 
 
In tumors that follow a multistage model of progression, such as cancers of the colon or 
breast, only a subset of precancerous lesions progress to malignancy.  For example, 
human colorectal cancer (CRC) is characterized by pathologically defined stages 
including the formation of preneoplastic aberrant crypt foci (ACF), pre-invasive 
adenomas, and carcinomas.34,53,72 However, a significant percentage of ACF and 
adenomas do not progress to metastatic tumors.49,53,92 In the case of CRC, TGF- type II 
receptor mutations and microsatellite instability are generally associated with a better 
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prognosis, whereas allelic losses of chromosomes 8q and 18q are often considered 
markers of poor prognosis.127,133  Unfortunately, there are no reliable markers that can 
unequivocally distinguish the malignant potential of such lesions.72  Therefore, it is of 
critical importance to develop robust methodology that may provide the means to stratify 
risk potential of specific precursor lesions. Such an approach can be extended to other 
forms of cancer. For example, human breast tumors typically progress through a pre-
malignant atypical ductal hyperplasia, followed by pre-invasive ductal carcinomas in situ, 
culminating in invasive ductal carcinoma.5,26,68 Although markers such as the estrogen 
receptor, her2/neu, PCNA, and VEGF have provided some utility in predicting the 
clinical course of the disease, they do not allow sufficient stratification of patients into 
groups that would benefit from a particular course of therapy.26 Gene expression profiling 
using microarray technology has greatly improved our ability to classify tumors by 
generating unique molecular fingerprints that have delineated tumor subtypes.29,54,95,97 
 
In this review, we discuss the potential benefits of global gene expression profiling of 
tumor cells as a complement to conventional histopathologic analyses. It is argued that 
such a combined approach will further enhance our understanding of the molecular 
pathogenesis of neoplasia. It should also be emphasized that the same 
principle/technology can be applied to the study of non-neoplastic diseases, including 
infectious and autoimmune diseases. 
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1) Gene expression profiling 
Genes under epigenetic and transcriptional regulation produce their various forms of 
coding and non-coding RNA molecules.  All of these RNA molecules with their 
differentially regulated synthesis, and degradation, form hierarchical systems, which 
function through topologically complex and interactive pathways that ultimately 
determine organ, tissue, and cell function.  An aggregate effect of the complex multitude 
of molecular aberrations that control gene transcription may ultimately contribute to 
tumor phenotype. Traditional techniques that focus on a single gene or a limited 
composite of genes may limit our view of these complex interactions.  Several global 
approaches, such as differential hybridization, subtractive hybridization, differential 
display, and serial analysis of gene expression have been developed with a goal towards 
identifying differentially expressed genes in normal and diseased tissues.61  
 
Each of these methods suffer from inherent limitations, such as requiring large amounts 
of RNA, and being labor intensive.61 Since its development in the mid-1990s, microarray 
technology has gained considerable interest in the scientific field. Microarray technology 
enables a snapshot of the entire cellular transcriptome on a single microarray chip, 
furnishing investigators with a global perspective of the complex interactions among 
thousands of genes simultaneously.25,100 Microarray technology conveys a gene 
expression “fingerprint” that potentially characterizes a specific physiologic or pathologic 
state of an organ, tissue, or cell, thereby allowing the establishment of new subtypes of 
previously recognized diseases with prognostic correlations.13,17,62,95 In fact, the RNA 
profile obtained from microarrays is a static representation of the biological state of the 
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sample, and yields the highest information and throughput of any classification assay.29 
Thus, microarray technology can be a powerful ancillary tool by allowing the 
identification of gene signature in tumor cells that in turn may provide important 
etiological and diagnostic clues.  Using this experimental approach, studies utilizing 
microarrays and other technologies are now focusing on the dynamic behavior of 
neoplasia as a consequence of therapeutic intervention.29,48  
2) Laser-capture microdissection (LCM) 
Data output from microarray experiments is a direct reflection of the input RNA, which is 
dependent on the cellular composition of the particular tumor. Solid tumors are generally 
comprised of a heterogeneous mixture of tumor cells, including stromal tissue, 
inflammatory cells, blood vessels, and necrotic tissue.  Therefore, if the goal of the 
microarray experiment is to analyze genetic changes within pure populations of cancer 
cells, isolation of RNA from complex tissues (i.e., grossly dissected tumors) may 
compromise the usefulness of the expression profiles thus generated. Furthermore, 
expression profiles from whole tumors may vary considerably between samples, a result 
of differences in the relative proportions of cell types present within each tumor 
specimen.  
 
The confounding influence of cell heterogeneity can be resolved by applying methods 
that achieve high-resolution separation of cells based on morphology or fluorescent 
markers. Techniques such as flow cytometry/cell sorting and the use of affinity-labeled 
magnetic beads allow separation of sub-populations of cells from a complex mixture of 
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cells. However, these approaches are not necessarily practical for solid tissues.  A 
relatively new technology, LCM directly addresses the issue of cell heterogeneity since it 
allows precise identification of cells by light microscopy followed by microdissection 
and harvesting of pure populations of cells.15,30 Microdissection was initially performed 
by manually scraping an area of interest from a glass slide using needles. Later, this 
process was mechanized by the use of micromanipulators.39,102,118 These techniques were 
fraught with errors and were labor-intensive. The first laser-assisted microdissection 
method was published in 1992104  following which there has been a tremendous 
advancement in this technology.  Several different types of LCM systems are available, 
providing the investigator with the ability to procure pure population of cells for further 
genetic analyses and global gene expression profiling.  
 
Thus, coupling LCM to microarray technology impart the investigator with a 
sophisticated tool for obtaining genetic information from individual populations of cells. 
By using these combined approaches, it is now possible to correlate variations in gene 
expression with specific histologic stages of disease, an approach that may ultimately 
shed new light on the etiopathogenesis of cancer.83,108 Most notably, the advent of LCM 
allows the rapid, reliable, and accurate procurement of pure populations of cells from 
specific putative, preneoplastic lesions. These technological advancements thus provide 
the opportunity to perform molecular genetic analysis at early time points during the 
tumorigenic process.15 
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(a)  LCM tissue preparation:    
Careful tissue preparation is critical to the successful outcome of subsequent molecular-
based applications. A robust method that consistently yields high quality RNA for 
microarray analysis is to freeze quickly the tissues in a cryoprotectant media such as 
OCT. Both RNA and DNA of good quality can be extracted from such specimens for 
most downstream molecular-based applications. The frozen tissue sections are fixed 
briefly in 75% ethanol and stained rapidly with a modified hematoxylin-eosin staining 
procedure (http://dir.nichd.nih.gov/lcm/LCMTAP.htm). It should be noted that 
conventional immunohistochemistry could also be performed on these tissue sections, 
thereby enabling the visualization and capture of immuno-stained cells. Similarly, 
fluorescently-labeled cells can be visualized and microdissected by fluorescence-
equipped LCM systems for downstream applications.35 
 
The final dehydration steps with ethanol and incubation with xylene are critically 
important for successful dissection. Samples with residual moisture will be subject to 
hydrostatic forces that make it difficult to separate the microdissected tissue from the 
glass slide. Furthermore, fixatives such as formalin extensively cross-link RNA, DNA 
and proteins, thereby limiting analysis of nucleic acids.76  However, DNA from formalin-
fixed tissues is amenable to downstream applications such as direct sequence analysis for 
mutations and loss of heterozygosity studies.  Alternatively, newer fixation protocols, 
such as ethanol fixation or the recently developed HOPE fixative, have been developed 
that allow preservation of tissue morphology and RNA quality.85  A comprehensive list of 
standard protocols for tissue preparation and staining of both frozen and formalin-fixed 
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tissues is provided elsewhere (http://dir.nichd.nih.gov/lcm/LCMTAP.htm). It should be 
cautioned that all of the solutions that are used for staining must be RNAse and DNAse 
free, and must be replaced periodically. For optimal microdissection and guarantee 
extraction of high quality RNA, the entire work area and reagents must be maintained 
within an “RNAse-free zone”.  
(b) LCM methodology:  
After the stained histologic section is visualized under a conventional light microscope, 
the region of interest is either transferred to a thermoplastic polymer film using a low 
energy infrared laser pulse, or cut with a high-energy ultraviolet laser and catapulted into 
a tube. Although, these two systems use slightly different technologies for procuring the 
cells, the end-result is the same. In this review, we will describe the thermoplastic film 
system as an example. In the thermoplastic film system, the area of film that absorbs the 
laser energy expands and adheres to the underlying cells (Fig.  1A).  The laser pulse 
typically lasts several hundred microseconds to two milliseconds, and the transient heat 
generated in the film is rapidly dissipated through the glass slide heat sink, leaving the 
biomolecules undamaged.75 When the device coated with the film is lifted off the tissue 
section, the tissue shears at the edges of its attachment to the polymer, leaving all of the 
untargeted area still attached to the glass slide (Fig. 1B).  The exact morphology of the 
transferred cells is maintained and held on the transfer film (Fig. 1B).  The device with 
the film is then mated to tubes with appropriate buffers to obtain DNA/RNA or proteins 
for subsequent experiments. Subsequent molecular analyses are not affected by the 
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microdissection process, as LCM typically creates only minimal chemical bonds with the 
targeted tissue.118    
 
Thus, LCM aids in the analysis of cellular function in complex organs by separation of 
morphologically or histochemically identifiable subunits that can be subsequently 
analyzed using array-based experiments.108 The inception of the Cancer Genome 
Anatomy Project (CGAP), sponsored by the National Center for Biotechnology 
Information, has been instrumental in the development and implementation of LCM 
technology.  The CGAP goal is to establish an exhaustive and high quality database of 
genes expressed by normal, preneoplastic, and neoplastic human tissues.  LCM has 
provided a particularly useful experimental tool for this project because of its fine 
resolution with respect to cellular dissection. At the CGAP website, an exhaustive library 
of partially sequenced clones has been generated using microdissected normal, 
preneoplastic, and neoplastic tissues.6,67,82,87,88,99,101,105,130  In fact, the ability to study 
global gene expression at the cellular level with LCM has been demonstrated through 
studies reported in the fields of breast cancer26,68  and colon cancer.77 
3) Linear amplification (LA)  of RNA  
The ability to study global gene expression at a cellular level using laser-capture 
microscopy (LCM) is often compromised by the limited yield of RNA extracted from the 
low numbers of captured cells. This is especially true in the study of focal preneoplastic 
lesions. The developments of experimental strategies to amplify RNA thus become 
imperative. Since the publication of the original method,123 several approaches have been 
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developed to amplify RNA in a linear fashion without creating an inherent bias in 
transcript levels.27,52,118,125 These methods are largely based on the T7 RNA polymerase 
system. Briefly, LA technology consists of three distinct phases: first strand synthesis, 
second strand synthesis, and in vitro transcription.  During first strand synthesis, mRNA 
within the total cellular RNA is converted to cDNA using a reverse transcriptase enzyme 
and a DNA primer that contains an oligo-dT and a T7 promoter sequence (Fig. 1C).  
Following first strand synthesis (conversion of mRNA to cDNA), the resultant single-
stranded cDNA is converted to double-stranded cDNA utilizing DNA polymerase and a 
second exogenous (degenerate) primer.  This double-stranded cDNA contains a T7 
promoter site that will be recognized by T7 RNA polymerase to generate thousands of 
copies of each transcript during the in vitro transcription phase.  The amplified RNA 
generated is in the antisense orientation and usually represents several hundred bases of 
the 3’ region of the parent mRNA.  The antisense RNA (aRNA) generated after one 
round of amplification can be used as template for another round of amplification as 
described above to yield a further 1,000 to 3,000 fold amplification (Fig. 1C). Thus, a 1 
to 9 million-fold amplification of the native mRNA population can be attained through 
two rounds of amplification. Successful amplification can be verified by ultraviolet 
spectrophotometry, gel electrophoresis, or commercially available lab-on-a-chip 
technology. 
 
Linear amplification of RNA enables the generation of 30 to 100 micrograms of aRNA 
from 500 picograms to 10 nanograms of total cellular RNA or 50 to 1000 cells.  Unlike 
other amplification techniques such as polymerase chain reaction (PCR), an advantage of 
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LA is its high fidelity.66,123,125 The relative proportions of rare as well as abundant 
transcripts within the native mRNA pool are maintained throughout the amplification 
process. Reproducibility and linearity of LA have been verified and well-documented in 
the literature and in commercial protocols.27,50,52,118  
 
Amplifying RNA from certain cell types (e.g., enterocytes) may pose a particular 
challenge because these cells contain only a very low proportion of mRNA within their 
total cellular RNA (less than 0.5 percent). These limitations can be further accentuated 
when analyzing preneoplastic lesions that contain only limited numbers of cells. One way 
to address this challenge is to prepare serial sections of a tissue specimen from which the 
same lesion is laser-captured, followed by pooling of extracted RNA before LA.  
 
Recently, non-uniform quality of the amplified aRNA as a result of inter-protocol 
variability of LA was described..52 These differences may potentially impair direct 
comparisons of results between research groups that use different amplification 
strategies. Therefore, to facilitate the comparison of expression data, it was recommended 
to use a “standard reverse transcription reaction” for small-sample-transcriptome 
profiling experiments as part of the Minimal Information about a Microarray Experiment 
(MIAME) set of standards that has been established for microarray-based experiments 
(see details in microarray section).52 Use of commercial kits for LA may address these 
issues of standardization. 
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4) Microarray  
In this section, we will describe the critical components of a successful microarray 
experiment, including microarray platforms, data collection, analysis, and visualization. 
The two most commonly used array-based platforms are oligonucleotide and cDNA 
(complimentary DNA) arrays. It is important to note that in the microarray literature, a 
“target” is usually defined as the synthesized oligonucleotide or cloned cDNA sequences 
anchored to the glass slide, while the “probe” is the labeled RNA or cDNA from the 
experimental sample. Oligonucleotide arrays have shorter target sequences (typically 
between 25-60 base pairs) and are manufactured commercially by several methods 
including photolithography, ink-jet printing, and spotting pens.12,36,46,118 Targets typically 
consist of a single long oligomer, or multiple shorter oligomers per gene.  Increasing the 
target density of oligomer arrays allows a greater density of genes per array. The 
advantages of oligonucleotide arrays are a higher target density and greater specificity 
relative to cDNA arrays.12,64 Cross platform comparisons of microarrays have revealed 
discrepancies in results necessitating buyer discretion.31,116,118  
 
In cDNA arrays, discrete DNA sequences (PCR products of 500-5000 base pairs) 
representing specific sets of genes are spotted on a chemically coated glass microscope 
slide using spotting pens.28 The large size of the target cDNA sequences provides 
extensive complementarity for hybridization, generally producing positive signals under 
most experimental conditions. However, there are several disadvantages to the cDNA 
platform. The large size of the targets may result in cross-hybridization between genes 
that share varying degrees of homology, raising the possibility of generating spurious 
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results.  This may be especially problematic for high throughput studies that involve the 
analyses of hundreds, or even thousands of samples.  Furthermore, denatured target 
sequences may re-anneal, potentially affecting the interaction of the probe and its target 
sequence.66   
 
Oligonucleotide and cDNA arrays can be hybridized with either the test and reference 
samples simultaneously on the same array, or separately on different arrays, depending 
on the manufacturer’s specifications.  The mRNA isolated from test and control samples 
are processed to yield cDNA molecules that are labeled with fluorescent dyes.  Oligomer 
arrays utilize one or two fluorescent dyes of a specific wavelength allowing their signals 
to be clearly distinguished.  The one dye method allows array-to-array comparisons, with 
one array usually serving as the reference/control array.  The two-dye method allows 
comparisons within arrays, and typically compares expression profiles of two samples on 
the same array.  The most popular fluorescent dyes used to label, test and reference 
samples are Cyanine-3 (green) and Cyanine-5 (red).    After hybridization, slides are 
scanned using a confocal scanner that illuminates every spot and measures fluorescence 
intensity for each dye.  These signal intensity measurements determine the relative 
abundance of the mRNA species within the test sample relative to the control/reference. 
Fig. 2 depicts the flow chart of the microarray schema for the two-dye/channel or one-
dye/channel microarray scenarios. Briefly, cyanine-5 (red) labeled cDNA/aRNA from the 
test sample is mixed with cyanine-3 (green) labeled cDNA/ aRNA from the reference 
(control) sample, and is hybridized to a microarray (Fig.  2A). The hybridized microarray 
is scanned under two channels and the raw fluorescence intensity under each channel is 
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calculated. Because two-color microarrays are based on the principle of competitive 
hybridization between two samples, the expression level of a particular gene (spot) in a 
test sample relative to the reference sample (red versus green) is measured by evaluating 
the relative fluorescent intensities in each channel. Higher magnification of a hybridized 
microarray slide (Fig. 2A) demonstrates a wide array of colors (between the red and 
green spectrum) that correspond to multiple genes (spots).  For example, a yellow spot 
indicates comparable expression level for a particular gene in both test and reference 
samples (i.e., red + green = yellow), while a redder or greener spot indicates greater 
number of mRNA transcripts for that gene in the sample labeled with cyanine-5 and 
cyanine-3, respectively. Lack of color (black) at a specific gene spot indicated lack of that 
specific mRNA transcript in both test and control samples (Fig.  2A). In one-color 
hybridization, test and reference samples are labeled with the same fluorophore and 
hybridized to separate arrays; scanned under the appropriate channel and the ratios of 
fluorescent intensity in the test and reference arrays are computed to generate the relative 
gene expression level (Fig.  2B). 
 
After the array hybridization phase of the study is completed, image acquisition, analysis, 
normalization, modeling, and identification of differentially expressed genes are required.  
An integral component to microarray-based experiments is the increasingly sophisticated 
software tools that provide relatively robust image visualization and analysis.  
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(a) Image analysis:  
Image analysis software facilitates acquisition of raw signal data from each spot.  A high 
quality image is critical as it enhances the efficacy of the microarray experiment and 
decreases the need for manipulation of the acquired data. A final signal value is 
ultimately dependent upon several important variables including spot features (location, 
orientation, size, and shape), uniformity of composition of the oligomer/cDNA, dye 
biases, resolution of the scanner, and chip alignment. Algorithms taking into account the 
spatial distribution, cumulative signal, and number of pixels that collectively represent 
each oligomer/cDNA determine the ultimate signal intensity level.  If there are multiple 
oligomers representing an individual gene in a microarray, further processing is done, and 
signal to noise thresholds are utilized to determine the presence or absence of expression 
for that particular gene. For example, an algorithm could determine the presence or 
absence of gene expression based on the average signal level of a number of oligomer 
probes representing a gene versus the background signal level of the chip surface. The 
smallest copy number of sample cDNA that can be detected determines sensitivity, while 
specificity is decided by the amount of cross-hybridization between oligomers. Thus, 
image analysis entails identification of internal standards and removal of ambiguous and 
poor quality spots. The remaining high quality, signal level data is stored permanently for 
further analysis or for comparison in other experiments.   This is especially important for 
reference controls in experiments.58,109 Details of image acquisition and data pre-
processing have been extensively reviewed elsewhere.58,109  
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(b) Data normalization: 
The next step in data analysis is normalization of the signal data acquired from multiple 
array experiments. The normalization process is inherent to a successful microarray 
analysis because the amount of RNA initially processed or the cDNA/aRNA applied to 
the array(s) is often unequal.  Furthermore, differences in hybridization kinetics and 
labeling/detection efficiencies are important issues inherent to replicate or multiple 
microarray experiments. The ultimate aim of data normalization is to efficiently remove 
bias between each individual microarray experiment.129  Less sophisticated normalization 
strategies using house-keeping genes are being replaced by more complex approaches. 
The currently used normalization strategies are often dependent on the microarray 
technology utilized, and have been reviewed elsewhere.14,59,91,109,129 Commonly used 
normalization approaches include non-linear smoothing, data transformation for altering 
the signal distribution, non-parametric, parametric and mixed methods.14,59,91,109,129  
(c) Data Analysis: 
Further processing of normalized data allows reduction of additive and multiplicative 
error in microarray comparisons, as illustrated by the “model based expression index.” 
This is a statistical model that is generated to allow probe level analysis on multiple 
arrays.59 The microarray data obtained with a small number of experimental cases and a 
large number of genes do not conform to “classical biostatistics,” which is usually 
characterized by large number of experimental cases and a small number of variables.  
Conventional statistical analyses provide the probability (p) that a difference in gene 
expression occurred by chance.121  For example, a significant p-value of 0.01 is 
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significant in the context of small number of test genes. However, during expression 
analysis of 10,000 genes, a p-value of 0.01 indicates that 1% (100 genes) of the genes 
will show a difference between test and control samples by chance and not because of 
actual biological differences (type I statistical error). Therefore, there is a need to 
eliminate as many false positive and false negative results as possible.  To address this 
issue of “false discovery rate” (FDR), Tusher et al.121 developed a novel statistical 
method specifically for microarray analysis, referred to as significance analysis of 
microarrays (SAM). They were successful in using FDR to identify non-significant genes 
by analyzing permutations of the measurements. SAM also allows filtering of genes that 
are above or below a user-defined fold-change (delta value). This is especially important, 
as there is a constant danger in microarray analysis of not including genes that are 
minimally altered, but highly relevant.  
 
The next important step in the analysis of the voluminous data set is pattern recognition.  
Pattern recognition algorithms are loosely classified into two categories: “unsupervised or 
clustering” (implying no a priori classification of data) and “supervised or classification” 
(using data from known a priori classifications and applying predictors from these data to 
new data). A hybrid of these two approaches is also commonly utilized.109 These 
algorithms may recognize a pattern in the data that correlates with a disease or a 
previously unrecognized subtype of a disease, thus complementing histopathologic 
classification. A cornucopia of algorithmic terms exists, including hierarchical and non-
hierarchical clustering, K-means clustering, self-organizing maps, principal component 
analysis, one and two dimensional dendrograms, heat-maps, linear discriminant analysis, 
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support vector machines, decision trees, and neural networks.  In summary, although 
statistical tools are constantly evolving to analyze microarray data, the ultimate aim is to 
develop a specific and universally accepted analytic approach for disease diagnosis and 
prognosis. 
 (d) Data presentation:  
The final step in microarray experiments is presentation of data. This is extremely 
important because of the voluminous nature of the data set.  Most commonly, expression 
data from microarray experiments can be pictorially summarized within a two-
dimensional table, in which each row represents a single gene, and each column 
represents the expression levels of the entire set of genes within a single sample. A color 
scale correlates color intensity to gene expression. This approach allows easy 
visualization of the gene expression data in an intuitive manner, thereby allowing a global 
perspective on the transcriptome for multiple samples (see example in section 7).  
 
Although microarray technology has the potential to analyze the entire transcriptome, the 
only limiting factor is the number of target elements present on the array. However, with 
the genome sequences of human, mouse, rat, and dog now completed, construction of 
arrays that represent the entire genome is now feasible. Thus, expression profiles of the 
entire genome (transcriptome) can be probed on a single array and the acquired data can 
be then superimposed on the genome sequence of the species that is being studied, 
thereby providing a new kind of genomic map. For example, if a subset of genes is 
deregulated (upregulated/downregulated) in a test sample, and a subset of these genes can 
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be localized within a specific chromosomal locus, chromosomal segment aberration 
(duplication/deletion) can be suspected. This can be verified by comparative gene 
hybridization (CGH) analysis or array CGH. Similarly, based on the knowledge of known 
transcriptional targets, deregulation of a subset of genes may also suggest a defect within 
a particular control element (transcription factor, tumor suppressor genes, 
protooncogenes, etc.). Thus, by carefully examining patterns of global gene expression, it 
may be possible to identify potential genetic aberrations. Such bioinformatics approaches 
are now feasible because of the efforts of the Gene Ontology (GO) Consortium.  The GO 
Consortium (http://www.geneontology.org) is a work-in-progress for obtaining consistent 
descriptions of gene products, lists of protein domains, pathways, and respective 
chromosomes.  The GO consortium also provides a standardized vocabulary for gene 
product attributes, including biological processes, cellular components, and molecular 
function. 
 
One major criticism of microarray technology is the lack of uniformity of microarray data 
between experiments and across platforms.12,43,118 In an attempt to standardize microarray 
data acquired from different academic and commercial platforms, the Microarray Gene 
Expression Data (MGED) Society has advocated the use of a set of minimum standards 
for each microarray experiment.7,16,58  The standards are available at the Minimal 
Information about a Microarray Experiment (MIAME) website 
(http://www.mged.org/Workgroups/MIAME/miame.html). While lack of standardization 
may be less of an issue with experiments using commercial microarrays, documentation 
of experimental parameters and software analysis is essential for experimental 
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replication.  For customized arrays, compliance with MIAME is now a prerequisite for 
publication of microarray data in many peer-reviewed journals.  
5) Post-array experiments 
 An important requirement of microarray technology is the careful validation of test 
results using complementary quantitative methods. The expression changes observed in 
multiple gene sets are usually validated by reverse transcriptase PCR (RT-PCR), 
quantitative real time PCR (QRT-PCR), Northern analysis, or in situ hybridization.20,21  
 
The relationship between the expressed levels of mRNA and protein is non-linear in 
many cases, especially because protein levels are often affected by post-translational 
modifications.57,74 Therefore, data acquired from gene expression studies should be used 
cautiously in formulation of hypotheses and drawing conclusions pertaining to gene 
function.  For these reasons, the field of proteomics is gaining significant traction as an 
important adjunct to transcriptome profiling. Direct mass spectrometric and two-
dimensional PAGE analyses are widely used techniques that can be used in parallel with 
expression profiling.57,74 In addition, immunohistochemistry (IHC) can also be used to 
independently confirm cell-type specific expression of proteins in tissues.  In fact, the 
gaining of popularity of tissue microarrays for IHC allows a high throughput validation 
of microarray targets at the protein level.113,120,122   
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6) Special considerations for overcoming inherent limitations 
A drawback of the technology described above that combines laser-capture 
microdissection-linear amplification (LCM-LA) and microarray is the absolute 
requirement for frozen tissue sections. This limitation is especially problematic from a 
clinical perspective, where the availability of fresh-frozen specimens may be limiting.  
However, recent technical advances in LCM-LA have enabled the extension of this 
approach to formalin-fixed, paraffin embedded tissue sections.69 
 
The potential for RNA degradation is another important issue that must be considered. 
RNA degradation is important in LCM-LA experiments because the microdissected cells 
(few hundreds to thousands) are much fewer in comparison to conventional tissue/cell 
culture samples. However, this complication can be addressed by keeping the time 
required for tissue harvesting and tissue preservation (i.e., snap freezing) minimum. This 
is especially important while studying tissues with high levels of endogenous RNAses, 
such as the pancreas and gastrointestinal tract. Fortunately, one can minimize RNA 
degradation with the use of RNAse inhibitors and denaturants during the extraction 
procedures and subsequent amplification reactions, while taking extreme care to control 
for contamination in the work area. Another disadvantage of this technology is the cost. 
Technical advances will hopefully bring down the cost and provide the possibility of 
retrospective analyses of tumor tissues. This will greatly expand the utility of this 
approach within the clinical setting.   
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7) Molecular profiling of cancerous and precancerous lesions in humans and 
laboratory animals 
During the past decade, numerous microarray-based studies have attempted to identify 
unique patterns of gene expression that can be used to assist in patient classification, 
treatment, and prognosis. For example, among patients with diffuse large B-cell 
lymphoma, therapeutic response is typically non-uniform.3,4,29 However, it was not 
possible to distinguish between these two populations of patients.3,4 Microarray-based 
experiments were able to identify unique gene expression signatures among ‘responders’ 
and ‘non-responders’, thereby aiding the classification of these patient subgroups with 
distinct prognosis.3,4 A similar approach was successful in distinguishing acute myeloid 
leukemia (AML) from acute lymphoblastic leukemia (ALL) in humans.40  In this study, 
unique gene expression profiles (class predictor sets) were established by microarray 
analysis for known cases of AML and ALL. These class predictor sets were then used to 
successfully classify unknown leukemic blood samples.40 Similarly, microarray studies in 
human melanoma cell lines have successfully identified subsets of genes  that play an 
important role in growth rate, contact inhibition, and metastasis.25 Microarray 
experiments on primary solid tumors (for example, breast cancer) have also reinforced 
the use of genetic signatures to classify tumor subtypes.37,87,96,111 Advances in gene 
expression-based tumor classification have also been documented in  lung,38 liver,55,84,106 
prostate,19,130 ovaries,126 colon,132,134 skin (melanoma),22 and brain.65,94,96   
 
Alterations in the gene expression profiles of human colon tumors using oligonucleotide 
and customized cDNA microarrays were recently reported.6,82 Molecular changes that 
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occur concurrently with the adenoma-carcinoma progression sequence in human 
colorectal cancer were monitored by expression profiling of early colonic adenomas and 
late adenocarcinomas.62  The resultant set of unique discriminatory genes that were 
differentially expressed in adenomas and carcinomas of the colon were used as an 
objective, highly sensitive and specific diagnostic scoring system (“molecular diagnosis 
score”). Using this molecular diagnosis score, the authors correctly predicted whether the 
unknown samples were adenomas or adenocarcinomas. Similarly, in another study, 
primary non-metastatic and metastatic (to liver) human colon adenocarcinomas were 
compared by microarray analysis.60 Several putative metastasis genes (PRDX4, CKS2, 
MAGED2, and EST BF696304) were subsequently identified. Distinct gene expression 
profiles within areas of dysplasia in colonic adenomas that were likely to be involved in 
progression from the adenoma to carcinoma stage were reported using LCM-microarray 
approach.56  Recently, differences in global expression profiles between cancers arising 
from the left and right colon were established, followed by near perfect molecular 
classification of human colonic adenocarcinomas that were positive or negative for 
lymph node metastasis.133 Interestingly, this classification was derived without previous 
pathological information, and based entirely on gene expression data.    
 
In early microarray studies utilizing heterogeneous cell populations of tumors, the need to 
identify gene expression in pure population of cells was complicated by several technical 
issues. These included  the issue of total RNA quantity needed for microarray assays, 
lack of linear amplification (LA) schemes to obtain the necessary amount of RNA, and a 
method to capture the cells of interest with intact  RNA.  Significant technical advances 
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in microdissection of complex tissues, particularly with the development of laser-capture 
microdissection-linear amplification (LCM-LA), provide the investigator with the ability 
to undertake array-based expression analysis using in vivo-derived genetic material 
originating from histologically complex tissue.  The LCM-LA approach has been used 
successfully to analyze gene expression profiles in several different cancers, including 
carcinomas of the cervix, colon, breast, ovary, prostate, and esophagus.67,82,88,105,107  
 
The combination of LCM-LA and microarray technologies has allowed the generation of 
epithelial-specific, in situ gene expression profiles of premalignant, preinvasive, and 
invasive stages of breast cancer.68 Results demonstrated significant gene alterations at the 
earliest phenotypically recognized stage of progression of breast cancer (atypical ductal 
hyperplasia). However, these changes were maintained throughout the later stages of 
progression (ductal carcinoma in situ and invasive ductal carcinoma) without any unique 
discriminatory signature profiles segregating the precancerous lesions. Their results 
implied that different stages of progression are most likely clonal in origin and confirmed 
the putative malignant nature of these lesions. The authors were thus able to study the 
molecular relationship between morphologically distinct stages of breast cancer 
progression within an individual patient and between multiple patients.68  Evaluation of 
estrogen receptor (ER)-positive invasive breast cancers from patients treated with 
adjuvant tamoxifen by LCM-LA, allowed the identification of a simple two-gene 
expression ratio of HOXB13:Il17BR from the entire microarray data set.69 This ratio was 
utilized to accurately predict tumor recurrence in the setting of tamoxifen therapy and 
identify individuals at risk for tumor recurrence. This finding was especially important 
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because approximately 40% of patients with ER-positive breast cancers do not respond to 
therapy and can even become resistant to tamoxifen resulting in disease progression. This 
ratio proved more powerful than the currently used clinicopathological features, such as 
tumor stage, grade, ERBB2, and EGFR protein expression.  
 
Using a similar approach, our laboratory recently demonstrated the ability to segregate 
preneoplastic colon lesions of similar histology, but divergent risk potential from two 
mouse strains that are differentially susceptible to the colonotropic carcinogen, 
azoxymethane (AOM).80 AOM-induced preneoplastic aberrant crypt foci (ACF) from 
two strains of mice (A/J and AKR/J) were subjected to LCM-LA. Colonic epithelia from 
saline treated animals were similarly processed for use as reference controls. The 
amplified RNA was subsequently labeled with fluorescent dyes and hybridized to a 15K 
microarray slide with 4,992 gene elements represented in triplicate. The array slides were 
scanned and the raw fluorescence intensities were calculated. The data was processed and 
subjected to normalization and the ratios of the lesion to the normal saline-treated colons 
were determined for each strain for subsequent comparisons across the strains. The 
similarity in expression profiles between the control colons from A/J and AKR/J strains 
allowed comparison of lesions to each other. The scatter-plot of fluorescent gene 
intensities shown in Fig.3 demonstrates a simple way of inter-sample comparisons. For 
example, the expression profiles of two histologically similar microadenomas from A/J 
mouse colon, were highly correlated (Fig. 3A).  As expected, the expression profile 
between histologically dissimilar samples remained skewed (Fig.  3B). Furthermore, 
using the unsupervised method of clustering (centroid algorithm), we identified several 
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subsets of genes that were distinct between ACF of similar histomorphology across the 
two strains with variable risk. The dendrogram (relationship tree) in Fig. 4 shows a subset 
of genes that were mostly up-regulated (red) in A/J and down-regulated (green) or 
unchanged (black) in AKR/J dysplastic ACF. The mathematical relationships between 
lesions are computed on the basis of the overall gene expression patterns, and the length 
of the branches of the dendrogram is inversely proportional to the similarities in the 
samples with respect to gene expression level. Thus, the dendrogram in Fig. 4 shows 
clear segregation of dysplastic ACF from the two mouse strains, and this was exclusively 
based on the unique gene expression profiles. These data imply that lesions of similar 
morphologies may have distinct molecular signatures that ultimately determine their 
biological outcome.80 In the same model, microarray approach was used to study the 
functionality of two important tumor-suppressor pathways, p53 and TGF-β.41,77 We 
demonstrated that despite high levels of p53 protein in AOM-induced colon tumors in 
A/J mice, microarray analysis of a panel of transcriptional targets of p53 gene were found 
to be non-regulated, providing further evidence for inactivation of the p53 pathway, 
independent of mutational inactivation.77 Similarly, lack of activation of the TGF-β 
pathway was demonstrated in AOM-induced murine colonic tumors.41   
 
In summary, LCM-LA technology in human and rodent tissues has begun to yield 
significant benefits. Studies that focus on identification of unique gene expression 
signatures in tumors may now complement the subjective, histomorphologic phenotype. 
Expression profiles can be of prognostic significance when specific signatures are 
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compared to available patient data such as rate of recurrence, metastasis, patient survival, 
response to therapy, etc.  
 
8) Gene expression analysis in veterinary medicine 
High throughput expression analysis has great potential in the field of veterinary 
oncology to advance our knowledge of tumor biology and enhance the quality of life of 
affected animals. Unfortunately, the use of microarrays in the veterinary field has been 
limited by two main factors: lack of availability of species-specific microarrays and the 
high cost of analysis. The availability of human, mouse, and rat genomes allow 
manufacture of microarrays specific for these species.  Fortunately, the sequencing of the 
genomes of other domestic animals such as the pig, sheep, cat, and cow is on-going 
(http://www.ncbi.nlm.nih.gov/Genomes/index.html).81,115 For example, the Canis 
familiaris genome (based on the boxer dog) was recently sequenced at high resolution, 
and is publicly available (http://www.ncbi.nlm.nih.gov/genome/guide/dog).  The entire 
genomes of the beagle and the standard poodle were sequenced privately, and a canine 
microarray is commercially available based on the privately licensed sequence.  As a 
result, there has been an increase in the use of microarray-based technology in the 
veterinary field, most of which has been in the study of non-neoplastic diseases.  
 
Canine specific cDNA microarray comprised of 60-cardiovascular related genes was 
developed to study expression profiles of myocytes during myocardial ischemia and 
necrosis.8 Approximately 50% of the genes including Ecto-5’-nucleotidase, Endothelin-1, 
PAI-1, and AT receptors were found to have an altered expression under conditions of 
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ischemia.8 The ability of microarray analysis to evaluate simultaneously the expression 
patterns of the entire transcriptome has resulted in several attempts to increase the 
number of probe sets represented on these custom-built canine microarrays. A larger 
canine cDNA array consisting of 12,473 genes was recently designed to identify subsets 
of genes that are transcriptionally regulated by hepatocyte growth factor in a commonly 
used canine renal epithelial cell line.10  
 
a) Cross-species hybridization studies: 
Because currently available microarrays for domestic animals are capable of probing 
relatively few genes, cross-species hybridization strategies have been used to increase the 
number of represented genes. One group designed a custom canine array consisting of 
13,729 canine genes and 9,045 human-derived probe sets.45 This array was employed to 
identify biomarkers of acute phase response in the liver following administration of 
lipopolysaccharide to dogs. To maximize cross-species hybridization efficiency, the 
human-derived probes were designed for the more homologous terminal end of the 
coding region relative to the canine probes that were designed for the non-homologous 3’ 
UTR region.  
 
A similar cross-hybridization microarray experiment was performed using a high-density 
human oligonucleotide microarray to evaluate  gene expression patterns of bovine 
monocyte-derived macrophages incubated with Mycobacterium avium subsp. 
paratuberculosis.128 In another study, specific gene expression profiles in mitogen 
stimulated and unstimulated bovine peripheral blood mononuclear cells (PBMC) were 
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evaluated using a bovine specific cDNA array comprised of genes involved in immune, 
endocrine, and inflammatory responses.117  Using this experimental system, the authors 
demonstrated similar gene expression patterns in ovine and porcine PBMC, thereby 
advocating the use of the cross-species hybridization strategy.  
 
Although cross-species hybridization has merit in the veterinary field, especially with 
only limited availability of species-specific microarrays, a serious limitation is that only 
homologous genes across species will produce positive signals. Interpretation of negative 
results may thus be complicated and may be due to the absence of cross-species 
hybridization to non-homologous probe sets.  
 
To overcome the disadvantages associated with these cross-species hybridization 
experiments, several investigators have custom designed bovine microarrays comprised 
of few hundred to several thousand bovine-specific probe sets to study multiple aspects 
of mammary gland development, pregnancy associated changes in multiple organs, and 
immune-endocrine axis.11,44,71,114,131  
 
(b) Current and future applications in veterinary oncology: 
Despite recent articles describing the use of microarray in bovine and canine species, 
high throughput microarray technology has only rarely been applied to the study 
domestic animal neoplasms. Recently, an array comparative genome hybridization 
(CGH) approach was utilized to evaluate gene copy number changes in canine 
lymphoma.119 The array CGH is a powerful technique that allows high resolution 
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molecular karyotyping and has encouraged further development in veterinary oncology. 
However, array CGH based technology cannot be used to perform gene expression 
analyses. Interestingly, the converse has been demonstrated in humans by using cDNA 
gene arrays for CGH analysis.47,63,110,122 Such an approach allowed direct correlation 
between mRNA transcripts and amplification/deletion of genes at the genomic DNA 
level.47,63,110 For example, CGH using cDNA microarrays identified several novel genes, 
whose over-expression was attributable to gene amplification in human breast cancer.47 
Such approaches allowing simultaneous evaluation of both the transcriptome and the 
genome, are critical in gaining insights to multiple diseases.  
  
In the veterinary oncology literature, techniques such as immunohistochemistry (IHC) 
and in situ hybridization (ISH) are typically used to complement traditional 
histomorphologic analysis. Commonly used markers include cell surface molecules (for 
immunophenotyping), intermediate filaments (to ascertain histogenesis), proteins 
involved in cell proliferation (PCNA, Ki-67, and AgNOR), cell cycle (cyclin D1, p21, 
and p27), growth stimuli (c-Myc, K-ras, and β-catenin), growth inhibition (p53 and Rb), 
apoptosis (caspase-3 and Bcl2), and vascularization (VEGF and bFGF).93 Although IHC 
and ISH have been useful in prognostication to some extent, their reductionist nature 
precludes a global perspective on the neoplastic cell state.   
 
As clearly described above, the application of high throughput, microarray technology 
may allow for evaluation of complex multidimensional cell circuits and greatly hasten the 
discovery of potential biomarkers of prognostic significance. There are numerous 
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examples of neoplasia in the veterinary field that are potential candidates for such high 
throughput analysis.  Although it is beyond the scope of this review article to present an 
exhaustive set of examples, there are several key examples of tumors where grade or 
histologic features correlate with survival, metastatic rate, disease-free interval, and/or 
speed of local recurrence.  These examples include canine cutaneous mast cell tumors 
(MCT), lymphoid tumors, canine histiocytic diseases, hemangiosarcomas, mammary 
gland carcinomas, and vaccine site-sarcoma (VSS).   
 
The long term tumor behavior of MCT is dependent upon the subjective 
histomorphologic classification scheme.86,112 Grade II and III tumors have worse 
prognosis than grade I.  However, there is approximately 50-60% discordance in the 
tumor grade between experienced pathologists, resulting in reproducibility issues.112 
Using molecular markers such as AgNOR, PCNA, Ki-67, c-kit, and p53 have been 
attempted to predict biological behavior of MCT in terms of recurrence, metastasis, and 
survival.1,112 Similarly, in the example of canine histiocytic diseases (cutaneous 
histiocytosis, systemic histiocytosis, splenic histiocytosis, and malignant histiocytosis), 
there are marked differences in prognosis and outcome. Diagnosis is often based on organ 
involvement and microscopic features.2,70 The use of microarray-generated profiles in 
these examples may provide clues for ascertaining histogenesis of the tumors, yield 
multiple biomarkers that might be useful in predicting risk, response to treatment, and 
remission rates. This might prove to be a valuable supplement to histology that may 
provide additional objectivity to the current histomorphologic classification scheme. 
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Using an immunophenotyping approach (by IHC), differentiation of feline lymphoid 
tumors that were non-responsive and responsive to chemotherapy was unsuccessful.24 
Application of microarray technology to such neoplasms may enable identification of the 
inherent genetic difference between the non-responders and responders. In canine 
lymphosarcoma, identification of cell lineages (immunophenotyping) has prognostic 
significance; dogs with B cell lymphosarcoma have a better prognosis than those with T 
cell neoplasms.103 Significant differences in prognosis between B- and T-cell subtypes of 
canine lymphomas were demonstrated in a recent study.89 Definitive diagnoses and 
predictive outcome in such cases are dependent upon histomorphology and/or 
cytochemical stains. However, these are often limited by the availability of antibodies 
and can yield equivocal results. Similarly, differentiation of hemangioma and 
hemangiosarcoma in any species can be difficult, especially when based on biopsy or 
cytologic examination, as these can be confounded by excessive hemorrhage, 
inflammation and inadequate sampling.23 Canine mammary tumors are challenging for 
clinicians and pathologists because of complex histologic classification, low specificity 
of cytologic diagnosis, and unpredictable biologic behavior.135  Several studies in canine 
mammary tumors have attempted to investigate the correlation between histologic 
invasiveness (stage) and proliferation markers such as AgNOR and Ki-67 with some 
success.98 In all of the above examples, use of microarray-based technology may allow 
identification of unique signature profiles that aid in molecular classification of these 
neoplasms with an ultimate aim of accurate diagnosis and/or prognosis. 
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Feline VSS has been an important neoplasm of cats that has been epidemiologically 
linked to feline leukemia virus and feline rabies vaccines.78,79 Despite extensive research 
in the field in the last decade, etiopathogenesis of VSS is largely speculative and 
circumstantial. Application of microarray technology may allow comparison of VSS to 
non-vaccine site sarcomas and thereby allow valuable insights into the pathogenesis of 
VSS.  
 
In summary, there does not seem to be a paucity of appropriate diseases in veterinary 
medicine to which this technology can be successfully applied. The microarray approach 
has the potential to yield robust panel of markers for specific conditions; and such newly 
discovered markers can be tested in tissues by the more practical and inexpensive tools 
(such as IHC or PCR-based assays) to assist the veterinary clinician. Despite these 
apparent applications, it is important to highlight that the use of microarrays in diagnostic 
human oncology is still in its infancy, and microarrays are even further away from 
practical application in veterinary oncology.  
 
(c) Comparative oncology: 
Application of microarray to study animal neoplasms has gained impetus with recent 
establishment of the comparative oncology program at the National Institutes of Health 
(http://ccr.nci.nih.gov/resources/cop/).  The primary goal of this program is to 
characterize and validate comparative models for use in pre-clinical trials, including 
companion animals to obtain a broader understanding of the etiopathogenesis and 
treatment of cancer. Companion animals are being used as animal models because they 
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share similar environmental risk factors as their human owners and in some cases, have 
similar tumor histology.42  For these reasons, it is important to know how similar or 
dissimilar many of these companion animal tumors are to their histological counterparts 
in humans. Apart from the detailed histomorphologic, IHC analysis of these 
“comparative animal tumors”, microarray-based platforms add another dimension to the 
comparative oncology initiative. With a similar initiative taken by the American College 
of Veterinary Pathologists on lymphoid neoplasms and myeloproliferative disorders, 
application of microarray analysis can greatly benefit comparative veterinary oncology. 
 
9) Application in non-neoplastic diseases 
Despite the extensive application of laser-capture microdissection linear amplification 
(LCM-LA) technology to neoplasms, it must be emphasized that microarray studies are 
not necessarily restricted to the study of neoplastic diseases. A number of recent 
microarray studies have focused on infectious and autoimmune diseases, pharmacologic 
applications, and parasitology.9,73,90 Microarray technology has been used to understand 
the complex genetic processes underlying the interaction between microorganisms and 
the host.18  DNA microarray platforms have been utilized in the study of emerging 
infectious diseases to rapidly identify and characterize novel viruses.124 Microarrays have 
been utilized to study various aspects of microbial pathogenesis, and have been especially 
useful in the identification and discovery of “pathogenicity genes.”32,33,51  Furthermore, 
microarrays have been tremendously useful in the testing of the “molecular Koch’s 
postulates” for various virulence- and pathogenic trait-associated genes.33 Microarrays 
have also been extremely useful in investigating the mechanisms of drug action and to 
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identify unique gene expression fingerprints that can predict adverse drug-associated 
reaction in patients.32,33,51  
 
10) Conclusions 
Pathology has been the cornerstone of diagnostic practice for more than a century. 
Subjective evaluation of cell morphology and behavior by pathologists is ultimately 
combined to provide the framework for diagnostic, prognostic and therapeutic decisions. 
Can rapidly developing molecular technology render pathologists obsolete? In our 
opinion, this is a highly unlikely scenario, at least in the near future. As the field 
continues to mature, microarray-based applications are likely to refine and tune the 
current tumor classifications, rendering further objectivity to the current subjective 
criteria of disease evaluation.  Information that is being accumulated from thousands of 
microarray experiments will continue to provide a powerful and expanding database that 
will ultimately be compiled within a public repository, annotated and stored in 
accordance with Microarray Gene Expression Data (MGED) recommendations.  
Furthermore, laser-capture technology provides investigators with a superb dissection 
tool that can be used to procure samples for subsequent array-based genomic, 
transcriptional, and ultimately proteomic analyses, which can be combined to generate a 
unique tumor fingerprint. The compilation of such an exhaustive multi-dimensional and 
universally available database, combined with morphologic and clinical data will 
ultimately provide the research community with valuable new insights into infectious, 
autoimmune, and neoplastic diseases. Thus, it is of paramount importance for the 
veterinary field to remain at the forefront of this revolutionary approach and start by 
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creating appropriate tumor repositories to facilitate future multi-group and multi-
disciplinary studies. 
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Figures 
Fig. 1. Microdissection and linear amplification process. (A) The laser-capture 
microdissection process. An optical grade cap sits on top of a tissue section mounted on a 
conventional glass slide without a cover slip. The thin polymer film at the bottom of the 
cap is kept 12 microns above the tissue using concentric rails.  The area of interest is then 
visualized through the microscope and the laser beam (red) is activated to dissect the 
cells. The thin polymer on the cap expands locally upon activation by the laser, contacts 
and subsequently adheres to the underlying tissue. On removal of the cap from the glass 
slide, the adherent tissue is detached from the adjoining section. The microdissected 
tissue attached to the cap is subjected to extraction buffers to harvest biomolecules. (B) 
Focal dysplastic aberrant crypt foci (ACF) from an azoxymethane treated A/J mouse 
colon before laser-capture, after capture, and within a cap after dissection. (C) Schematic 
representation of T7-polymerase-based linear amplification of RNA. Reproduced with 
permission from Arcturus Bioscience Inc., Mountain View, CA.  Briefly, the mRNA 
undergoes 1st strand synthesis using an oligo-dT primer with a T7 promoter site (1st 
primer) which is then converted to a double stranded (ds) cDNA molecule using random 
hexamers (2nd primer).  The purified ds cDNA is used as a template for an in vitro 
transcription reaction to generate multiple copies of antisense RNA (aRNA) which are 
complementary to the sequence of the original mRNA species. For a second round of 
amplification, the process is repeated using aRNA produced from the first round.  
 
Fig. 2. Schematic representation of a microarray experiment.  One- or two-color 
microarray procedures start with test and reference mRNA that undergo reverse 
transcription (RT) or linearly amplification to generate complimentary DNA (cDNA) or 
antisense RNA (aRNA), respectively. (A) For two-color microarray hybridization, 
samples are labeled with fluorescent dyes of two different excitation/emission 
wavelengths. The differentially labeled cDNA or aRNA are pooled and hybridized to a 
microarray. The relative fluorescence intensities for each spot (gene) from the test and 
reference samples are measured as a ratio using a dual channel confocal laser scanner. 
Higher magnification of a grid in a scanned hybridized array shows multiple gene spots 
with varying degree of hybridization, as depicted by colors between the red and green 
spectrum. (B) A single fluorescent dye is used in one-color microarray hybridization.   
The labeled cDNA or aRNA from each sample is separately hybridized to microarrays. 
Detection of the hybridization is made by a separate scan of each array using a confocal 
laser scanner.  The relative abundance of mRNA for each gene between the two samples 
is measured by comparison of the absolute intensities for that gene between the two 
different normalized arrays.  
 
Fig. 3. Graphical representation of differential gene expression between two samples 
by scatter-plot analysis. (A) Comparison of logarithm-transformed raw fluorescent gene 
intensities between two histologically similar, azoxymethane (AOM)-induced 
microadenomas microdissected from an A/J mouse colon, linearly amplified and 
hybridized onto a 15,000-element mouse cDNA array shows high correlation (r=0.93). 
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(B) Comparison of raw fluorescent intensities of genes between a microadenoma and 
normal appearing, adjacent crypts from an AOM-treated A/J mouse. Cells were 
microdissected, linearly amplified, and hybridized onto a 15,000-element cDNA array.  
The reduction in correlation coefficient (r=0.83) is consistent with samples that are 
histologically dissimilar.  
 
Fig. 4. Dendrogram and heat map of gene expression. Levels of a subset of genes from 
three laser-captured, dysplastic aberrant crypt foci (ACF) from azoxymethane-treated A/J 
and AKR/J mouse strains, each, using Genesite software (BioDiscovery) are shown. The 
RNA from A/J and AKR/J strains were labeled with cyanine-5 and cyanine-3-labeled 
dUTP, respectively, during reverse transcription and hybridized to a cDNA array. Each 
row and column represents a gene and a lesion, respectively.  Dendrograms or 
relationship trees are generated with software that evaluates the Pearson’s correlation 
coefficient between same genes across different samples. The expression level of most of 
the genes in the A/J ACF are similar to each other (red=highly expressed) and distinct 
from the low (green) levels or no change (black) in AKR/J ACF. The generated 
dendrograms (note branches), based on this distinct expression profile, allow clear 
segregation of ACF in the two mouse strains. Color bar at the bottom correlates color-
intensity to gene expression.  
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